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Abstract 
Bowel symptoms (constipation and/or faecal incontinence) affect the vast majority 
of patients with multiple sclerosis (MS), but the pathophysiology is unclear and 
treatment remains empirical. 
The primary hypothesis of this thesis is that involvement of the spinal cord by the 
disease is central to the development of bowel symptoms, and this is tested in the 
first two studies: 
1. A study of the overlap in prevalence of bladder symptoms in patients with 
MS and bowel symptoms. 
2. A study of rectal compliance, as an important reflection of both the gut’s 
neural tone and its ability to hold content, in comparison to patients with 
supraconal spinal cord injury and normal controls.  
The secondary hypothesis is that residual spinal cord function can represent a 
potential target of treatment, and this is tested in studies 3 and 4: 
3. A prospective observational study of bowel biofeedback in symptomatic MS 
patients. 
4. A prospective observational study of transanal irrigation in symptomatic MS 
patients. 
Study 1 shows that the prevalence of bladder symptoms – determined by spinal 
cord disease - is higher in patients with bowel symptoms than in the general 
population of MS sufferers. 
The second study shows that rectal compliance - as an index of the spinal reflex 
activity regulating autonomic rectal function – is altered in patients with MS 
according to the clinical degree of spinal cord involvement by the disease. A similar 
pattern is followed for symptoms of constipation, but not faecal incontinence. 
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The two treatment studies showed that: 
 Biofeedback improves bowel symptoms and 5-seconds-endurance squeeze 
pressure. Improvement of sphincter pressure could be the result of 
behavioural changes, inducing physiological changes through residual 
efferent pathways in the spinal cord.  
 Transanal irrigation is effective to treat bowel symptoms in patients who fail 
biofeedback.  
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Synopsis 
The thesis is structured in a logical manner: 
 
 
Treatment for patients with a higher degree of spinal cord diesease (Chapter 6) 
Study 4: Transanal irrigation 
Testing  secondary hypothesis: Residual spinal cord function can be a target 
fortreatment (Chapter 5) 
Study 3: Biofeedback  
 
Testing the primary hypothesis: Spinal cord disease is central to developing bowel 
dysfunction (Chapters 3 and 4) 
Study  1: Prevalence of bladder symptoms in 
patients with multiple sclerosis and bowel 
symptoms 
Study 2: Study of rectal compliance comparing 
patients with multiple sclerosis, spinal cord 
injury and normal controls 
Current management strategies for Neurogenic Bowel Dysfunction  
(Chapter 2) 
Need for the study and formulation of the hypotheses (Chapter 1) 
The disease 
Anatomical 
considerations 
Bowel dysfunction in 
multiple sclerosis 
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CHAPTER 1: INTRODUCTION 
Chapter overview: 
 The disease 
 Relevant anatomical considerations 
 Bowel dysfunction in multiple sclerosis, detailing alteration of physiological 
process of defecation 
 Possible mechanism of constipation in multiple sclerosis  
 Possible mechanism of faecal incontinence in multiple sclerosis 
  Primary and secondary hypotheses 
1.1 The Disease 
Multiple Sclerosis (MS) is the most common neurological disorder in young adults, 
and affects around 100,000 people in the UK (Sara L Thomas, 2009; World Health 
Organization, 2008), with a worldwide peak of recorded prevalence in Scotland of 
193 per 100,000 inhabitants (Pugliatti et al, 2002) and an average of 1 per 1000 in 
the Western world (Williams et al, 1995).  
The disease is characterised by an autoimmune response that results in the 
disruption of the myelin sheath in the central nervous system (CNS), 
(demyelination), and the subsequent gliosis leads to the widespread occurrence of 
plaques in the white matter of the CNS (Figure 1.1). These plaques affect signal 
transmission in the CNS, and the wide spectrum of symptoms reflects the variety of 
neurological pathways affected. The aetiology is unknown and currently there is no 
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treatment that can affect the natural history of the disease, which is of a 
progressive accumulation of neurological symptoms leading to severe disability. 
Eighty per cent of patients present with relapsing remitting symptoms and only in a 
minority (5-37%) of cases is the disease progressive from the beginning (Compston, 
2006). Based on clinical course MS is classified as: relapsing remitting, secondary 
progressive, primary progressive and progressive relapsing. Although most present 
with relapsing remitting disease, the median time to secondary progression using 
survival techniques is 11 years (Confavreux et al, 1980).  
There are significant pathological differences between relapsing remitting MS and 
progressive MS, with more new and active focal inflammatory demyelinating 
lesions in the white matter of patients with relapsing disease. In contrast, diffuse 
injuries of the normal appearing white matter were observed in primary and 
secondary progressive multiple sclerosis (Kutzelnigg et al, 2005). Axonal loss 
resulting in atrophy of both the brain and spinal cord is of critical importance in 
determining permanent clinical disability, particularly in patients with progressive 
disease (Furby et al, 2008). Recent studies have suggested that inflammation is the 
driving force for brain injury in progressive MS, but anti-inflammatory and 
immunomodulatory therapies do not have a significant effect (Bradl & Lassmann, 
2009). 
  Chapter 1: Introduction 
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Figure 1.1: Sagittal MRI brain scan demonstrating sclerotic plaques in the white 
matter in a patient with MS. 
1.2 Anatomical Considerations 
The voluntary voiding of faeces, faecal continence and the ability to delay 
defecation rely on the integrity of several neuro-muscular structures, the influx of 
hormones and luminal content, stool consistency as well as psychological factors 
and the ability to access the toilet. 
Schematically normal colonic transit will allow stools to reach the rectum; in the 
presence of a normal rectal reservoir and preserved rectal sensation, an urge to 
defecate will arise, and the recto-anal inhibitory reflex (RAIR, also called the 
sampling reflex, Figure 1.2) will allow rectal content to come in contact with the 
anal epithelium. This event has the dual function of both distinguishing the nature 
of the rectal content (solid, liquid or gas) to allow selective voiding and also to 
signal to the brain to take a conscious decision if defecation has to be delayed.  
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Figure 1.2: The various components of RAIR wave on a manometry trace  
 Excitation peak: initial increase in the resting pressure associated with the 
sudden rectal distension.  
 Excitation Latency: duration from the point of excitation peak back to the 
baseline pressure.  
 Point of maximum relaxation: lowest point of resting pressure secondary to 
reflex IAS relaxation.  
 Recovery time: the duration between maximum relaxation and the point at 
which the resting pressure recovers to two-thirds its baseline.  
 Total reflex duration: calculated as the duration from the point of the 
Excitation Peak to the point two thirds' the recovery. 
 
In the presence of normal anal sensation voluntary contraction of the external anal 
sphincter will allow deferment to a time that is deemed appropriate. The tonic 
contraction of the internal anal sphincter (with the contribution of the external anal 
sphincter and vascular haemorrhoidal cushions) stops seepage of rectal content 
(Figure 1.3). 
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Figure 1.3: The anal sphincter complex 
Defecation is initiated by assuming an appropriate toileting position, and increasing 
abdominal pressure by the action of the abdominal muscles, in synchrony with the 
coordinated relaxation of the pelvic floor muscles (Figure 1.4). 
 
 
Figure 1.4: The male pelvic floor 
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1.2.1 Extrinsic Innervation of the Gut 
Somatic and visceral sensation from the ano-rectum is conveyed through afferent 
fibres to the cortex via the sacral segments. The pudendal nerve is responsible for 
the anal sensation, whilst parasympathetic fibres from the sacral segments S2-S4 
cover sensation from the rectum. Proximal colonic innervation is from the vagus 
nerve for the parasympathetic stimulating and sensorial component, whilst the 
inhibitory sympathetic fibres arise from the thoracic spinal cord (T5-L2) to the colon 
and rectum (Figure 1.5). 
 
Figure 1.5: Autonomic innervation of the bowel 
CG, coeliac ganglion; SMG, superior mesenteric ganglion; IMG, inferior mesenteric 
ganglion; HP, hypogastric plexus; SP, sacral plexus 
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The internal anal sphincter is a continuation of the circular muscle layer of the 
bowel, and its slow-twitch, fatigue-resistant smooth muscle is responsible for 80% 
of resting anal pressure (Schweiger, 1979). This is maintained by tonic sympathetic 
discharge (Frenckner & Ihre, 1976). The external anal sphincter is a striated muscle 
under voluntary control from Onuf´s nucleus in the ventral horn of the sacral spinal 
cord via the pudendal nerve (S2-S3). 
1.2.2 Intrinsic Innervation of the Gut 
As I will discuss in Chapter 4, the bowel and the bladder share many similar 
anatomical and functional features. However, their specialisation is related to 
crucial structural differences. One of these is the presence in the bowel wall of the 
enteric nervous system (ENS), which is represented by two ganglionated plexuses, 
the myenteric and submucosal plexus, located within the bowel wall. The ENS, 
through a variety of neuropeptides, coordinates peristalsis as well as the secretive 
and absorptive function of the colo-rectum that is only modulated by the extrinsic 
innervation (Goyal & Hirano, 1996). 
The myenteric plexus is primarily concerned with the control of the smooth muscles 
in the longitudinal and circular layers of the bowel wall, whilst the submucosal 
plexus is mainly secretomotor and has a sensory component. 
1.2.3 Cerebral Control of Defecation 
The higher defecation centres are not well anatomically defined, but sensorial 
information are integrated at cortical level to generate appropriate responses. The 
sensation from the gut is conveyed via the spinal cord to the periaqueductal grey 
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matter and thalamus. The cortex is then reached through the insula and limbic 
system (Mayer et al, 2006). It has been suggested that a defecation centre exists 
within the brainstem (Weber et al, 1985). 
In the last two decades, functional brain imaging – notably positron emission 
tomography (PET) and functional magnetic resonance imaging (fMRI) – has allowed 
us to gain more insight in our knowledge of the brain control of defecation.  
Sensory pathways are clearly crucial to brain-gut interactions, and maintaining 
anorectal function. Visceral sensation is conveyed via spinal and vagal afferents. 
The latter projects to the brainstem nucleus of the solitary tract (Andrews, 1986), at 
which level reflex control of gut function is integrated (Sawchenko, 1983). Spinal 
afferents are mainly through the spinothalamic tract and the dorsal columns. 
A sequence of PET, fMRI (Aziz et al, 1997), electro-encephalography (EEG) and 
magneto-encephalography studies have allowed us to identify cortical activation 
with visceral stimulation.  
Most of these studies have focused on oesophageal sensation, because of the 
feature of this organ of both a somatic (upper third) and visceral (lower part) 
innervation. Nevertheless, cortical activation patterns of the anorectum appear to 
be similar to that of the oesophagus (Mertz et al, 2000; Silverman et al, 1997). A 
consistent finding seems to be activation of the cingulate cortex, the insula, the 
prefrontal cortex, the primary and secondary somatosensory cortex and the 
thalamus (Rapps et al, 2008). In the primary somatosensitive cortex representation 
of visceral sensation is less defined. The involvement of limbic and para-lymbic 
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structures, such as the cingulate, the insula and the prefrontal cortices (Bittorf et al, 
2006) might explain how psychological factors also can play an important role in the 
elaboration of rectal visceral sensation, as demonstrated in patients with Irritable 
Bowel syndrome (IBS) (Mertz et al, 2000).  
The importance of the cerebral control of anorectal function is also demonstrated 
in patients with stroke of the frontal lobes, who develop fecal incontinence 
(Nakayama et al, 1997; Weber et al, 1990). This has raised the possibility of a 
frontal lobe “defecation center” analogous to the micturition control locus in the 
midline frontal lobe. 
Trans-cranial magnetic stimulation offers the possibility of evaluating brain-gut 
efferent signals. In this technique, a “figure-of-8-shape” coil is placed on the scalp, 
and a magnetic stimulator discharges a high-current magnetic pulse that focally 
stimulates the underlying motor cortex. Gut electromyographic (EMG) activity is 
then measured in response to direct stimulation of the cerebral cortex (Rothwell et 
al, 1991). Using this technique, it has been shown that there is bilateral cortical 
representation of the anal, and pelvic floor muscles within the primary motor 
cortex (Turnbull et al, 1999). Trans cranial magnetic stimulation has also been used 
to induce changes in anorectal functions that may be important in maintaining 
continence (Hendermann J, 1995), demonstrating the cortical influences on the gut. 
This has confirmed that although autonomic nervous reflexes primarily control gut 
motor activity, it can also be influenced by cortical activity, and autonomic colonic 
motility is modulated by cortical influxes.  
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Essentially, from the neural point of view, the act of defecation is a reflex arch 
controlled and modulated by cortical efferents, and MS can disrupt this at several 
levels of the neural hierarchy, sometimes at different levels at the same time; 
damage can fluctuate according to disease progression. 
1.3 Bowel Dysfunction in Multiple Sclerosis 
Faecal incontinence occurs in 1-2% of the general adult population (Nelson et al, 
1995), while the prevalence of constipation varies between 2% to 20% (Heaton et 
al, 1992). Bowel dysfunction, manifest as constipation and/or incontinence, often 
co-existing and alternating, affects between 39 and 73% of patients with MS (Bakke 
et al, 1996; Hinds et al, 1990; Hinds & Wald, 1989; Munteis et al, 2006; Nordenbo 
et al, 1996). 
The pattern of bowel dysfunction is variable, with constipation being the more 
prevalent symptom. Around half of MS patients experience some degree of faecal 
incontinence during the course of the disease and for 25% of the patients it 
represent a permanent feature (Hinds & Wald, 1989). Quality of life is greatly 
reduced because of these symptoms (Norton & Chelvanayagam, 2010) which limit 
patients’ ability to work – the third cause of inability to work after spasticity and 
incoordination- (Bauer et al, 1965) and cause them great psychosocial disability 
(Hornby, 1978). Furthermore, these symptoms are frequently under-reported and 
underestimated (Trezza et al, 1999).  
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1.4 Multiple Sclerosis and Bowel Physiology 
The genesis of bowel symptoms as a consequence of MS can be attributed to 
disturbances of neurological pathways, disability and behavioural alterations. There 
are also factors with a high impact on the gastrointestinal tract, which are not 
directly related to the disease, but rather are a consequence, such as the effect of 
certain drugs and diet-modifications induced symptoms (restriction of fluid or food 
intake). Very little evidence is available on the pathophysiology of bowel 
dysfunction. I will discuss both potential mechanisms and what evidence is 
available in the literature, considering the different level of neural hierarchy and 
the effect of MS on the end organ. 
1.4.1 Cortex 
It can be speculated that at the cortical level the voluntary control of bowel 
function could be lost as the result of the involvement of the frontal lobe; this can 
cause psychosocial behavioural disturbances, resulting in the loss of voluntary 
control of stools or failure of relaxation of the pelvic floor and obstructed 
defecation. Emotional factors and behavioural changes may influence toileting 
habits directly, or via altered autonomic control of gut function (i.e. loss of 
supraspinal modulation of spinal reflexes) (Wiesel et al, 2001). 
1.4.2 The Spinal Cord 
The spinal cord seems to have a crucial causative role in bowel dysfunction. 
Disturbances in the spinal cord control of colonic motility are a relevant factor in 
determining bowel dysfunction and this has been widely demonstrated in patients 
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with spinal cord injury (SCI) (Aaronson et al, 1985; Glick et al, 1984; Gore et al, 
1981; Sun et al, 1990a). In MS, the role of the spinal cord is based only on indirect 
and inconclusive evidence. Conduction in the central motor pathways to the 
sphincteric sacral neurons is delayed in MS (Snooks & Swash, 1985). 
Patients with MS and bowel dysfunction have showed delayed somato-sensory 
evoked potentials from the spinal cord to the brain, with normal potentials 
recorded at the lumbar spine (Haldeman et al, 1982). There is also evidence for the 
involvement of motor spinal pathways, as conduction times between cortex to 
lumbar spine and cortex to pelvic floor striated muscle conduct were prolonged in 
some patients with MS and bowel symptoms (Mathers et al, 1990).  
1.4.3 Pelvic Floor Dyssynergia 
Another phenomenon described is pelvic floor incoordination, resulting from the 
loss of cortical modulation of spinal reflexes that causes the pelvic organs to 
function automatically, and this is the explanation of the bladder detrusor 
dyssynergia (Betts et al, 1993). A similar mechanism might occur with MS patients, 
with the generation of uncoordinated pelvic floor contractions responsible for the 
genesis of outlet obstruction (pelvic floor dyssynergia) (Chia et al, 1996). These 
abnormalities have been well documented with proctography in patients with MS 
and intractable constipation (Gill et al, 1994) and paradoxical contraction of 
puborectalis on straining have been found on electro-myography (Mathers et al, 
1990). 
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1.4.4 Colonic Transit 
Another shared feature between SCI and MS patients is delayed colonic transit 
time, particularly in the left colon (Chia et al, 1996; Nicoletti et al, 1992; Waldron et 
al, 1993; Weber et al, 1987). This could be the result of reduced parasympathetic 
outflow or be secondary to obstructed defecation (Chia et al, 1996), but it has also 
been suggested that slow transit could be secondary to a dampened gastro-colic 
reflex (Glick et al, 1982). On the other hand, increased motility through the 
generation of intracolonic pressures has been observed and can be related to the 
interruption of the normal cortical inhibition of colonic motor activity (Glick et al, 
1982).  
1.4.5 Ano-Rectal Unit Alterations 
Rectal hyposensitivity is another of the features of MS and sensory thresholds have 
been found to be altered, with reduced sensitivity of rectal fullness (Glick et al, 
1982; Nordenbo et al, 1996). Associated attenuated anal sensation has also been 
associated with the onset of bowel symptoms (Munteis et al, 2006; Nordenbo et al, 
1996). 
Studies looking at the rectal properties in patients with MS have shown that the 
basal tone of the rectal wall is increased (Glick et al, 1982; Haldeman et al, 1982; 
Weber et al, 1987), and compliance reduced (Nordenbo et al, 1996). I will discuss 
rectal compliance in more detail in Chapter 5. 
Finally, another possible and recurrent finding is weakness of the external sphincter 
(Chia et al, 1996; Jameson et al, 1994b; Nordenbo et al, 1996; Swash et al, 1987; 
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Weber et al, 1987). This could be the result of impaired function of the striated 
muscle that is ubiquitous in MS or as the result of alterations in motor pathways as 
discussed above (Mathers et al, 1990; Snooks & Swash, 1985). The hypothetical 
mechanism underlying it could therefore be a reduction in conduction of the motor 
pathways extending from the motor cortex to synapse with neurons in Onuf’s 
nucleus in the anterior horn of the sacral spinal cord segments. Sphincter weakness 
could also be due to coexisting pathologies (parity, diabetes, lumbar disc prolapse) 
(Swash et al, 1987). 
1.5 Symptoms and Physiological Correlation 
In the evaluation of patients with MS and bowel symptoms, both pre-existing and 
co-existing factors should be considered and this will be discussed in more detail in 
Chapter 2. I will now describe the physiological alteration within the context of the 
symptoms. 
1.5.1 Constipation 
Overall it appears that constipation is related to disability, disease duration, 
presence of bladder dysfunction and the use of medications (Hinds & Wald, 1989). 
A recurrent finding is increased colonic transit, which can result in a loss of 
supraspinal modulation of the spinal reflex activity, and unopposed the sacral 
sympathetic outflow to the large bowel. Other factors might be represented by 
reduced mobility, dampened gastro-colic reflex and the retrograde effect of pelvic 
floor dyssynergia. In fact spastic contraction of the external anal sphincter might 
generate an increase in transit time in subjects with idiopathic constipation (Klauser 
et al, 1990). 
  Chapter 1: Introduction 
33 
Pelvic floor incoordination has a definite role in the genesis of obstructed 
defecation, resulting from the lack of relaxation of the puborectalis muscle and of 
the anal sphincter, or from the generation of inadequate expulsive forces (rectal 
contraction and increase in intra-abdominal pressure). This has been shown to 
determine constipation in the general female population (Read et al, 1986) and has 
been documented with radiological evidence (Halligan et al, 1995). 
This phenomenon of incoordination of pelvic floor muscles could be parallel to 
bladder detrusor dyssynergia and be manifested by a pelvic level of spasticity and 
incoordination, a result of the loss of modulation of the spinal activity. However, 
the recto-anal incoordination seen in some MS patients may be a behavioural 
phenomenon, as in non-neurologically impaired patients (Halligan et al, 1995), 
particularly those who have experienced incontinence or have difficulty accessing 
the toilet through disability.  
Blunting of rectal sensation can be the cause of constipation by reducing the urge 
to defecate, but could also contribute to the genesis of outlet obstruction with two 
possible mechanisms. In fact reduced sensation could result in a sensory-motor 
alteration of the rectum and in the genesis of inadequate rectal contraction. Also, 
blunting in the urge to defecate in patients with reduced rectal sensation could 
result in a failure of relaxation of the pelvic floor on straining (Gladman et al, 2006). 
A further possible cause of failure of relaxation of the external anal sphincter could 
be a disturbance of the RAIR (Thiruppathy et al, 2012). Fatigue and weakness of the 
abdominal wall are a contributing factor to a functionally altered defecation, 
through the production of inadequate expulsive forces. 
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It has been observed that constipation in MS patients is associated with decreased 
rectal compliance, accompanied by reduced rectal and anal sensation (Nordenbo et 
al, 1996). This could result in reduced awareness of rectal content due to a lack of 
rectal wall distension, and is reflected in the reduction or loss of normal desire to 
defecate; at the same time this explains the associated urgency and urge 
incontinence, with the sudden generation of contraction of the rectal wall, and late 
awareness of the initiation of defecation due to reduced anal sensation. 
The co-existence of bladder dysfunction and the distress resulting from urinary 
urgency and incontinence induces patients to reduce fluid intake, which in turn 
dehydrates the stools, making their progress and expulsion difficult. In parallel, 
patients with faecal urgency and incontinence drastically reduce their food intake in 
an attempt to constipate themselves. Sometimes the quality of diet might be poor 
as a consequence of unemployment, where patients tend to prefer cheap high 
calorie-low fibre food. 
Drugs are certainly relevant, in particular medication for spasticity (gabapentin) and 
antidepressants (tryciclic and amytriptiline), as well as anti-cholinergic drugs used 
for bladder dysfunction.  
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Figure 1.6: Potential mechanisms underlying constipation in MS patients 
 
1.5.2 Incontinence 
Faecal incontinence is an on-going complaint in about 25 % of patients, whilst 50% 
of patients will have been affected at some point (Hinds et al, 1990). The 
involuntary loss of stools is critically related to the lack of ano-rectal sensation and 
anal sphincter weakness (Speakman & Kamm, 1993). Hyposensitivity is a potential 
cause of incontinence on its own, even in the presence of a normal sphincter. The 
reduced rectal sensation is responsible for a delay or absence of the perception of 
rectal fullness; this afferent component is essential to trigger voluntary contraction 
of the anal sphincter once the RAIR has been activated by rectal distension, 
particularly as this occurs at a lower threshold in patients with reduced rectal 
sensation (Sun et al, 1990b).  
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Rectal compliance and sensation interact as crucial elements of the reservoir 
function of the rectum, and their alteration is frequently combined in MS. Rectal 
compliance was found to be reduced in a small study that employed an out-dated 
technique of measurement (Nordenbo et al, 1996). Still it can be speculated that 
this has the dual effect of making the patient constipated, and with the build-up of 
faeces, can generate a sudden uncontrollable rectal contraction. The mechanisms 
described above are also the basis of faecal urgency.  
Sphincter weakness is also a potential feature in MS as discussed earlier, and 
childbirth could be an aggravating factor contributing by direct sphincter damage, 
or by damaging the pudendal nerve (Swash et al, 1987). 
Often the presence of loose or liquid stool will be the cause of incontinence, and 
the underlying dysfunction might be the generation of high intracolonic pressures 
and uncontrolled peristalsis, a phenomenon that has been observed in patients 
with a SCI (Glick et al, 1984). As the external sphincter contributes to the resting 
anal pressure, its weakness, in the presence of loose stools, might cause seepage of 
rectal content. A prolonged recovery phase of the RAIR has been found to be 
correlated to faecal incontinence (Thiruppathy et al, 2012).  
Rectal impaction of faeces and overflow should also be considered as a cause of 
incontinence. Dietary irritants such as caffeine and alcohol should be considered as 
contributing factors, and eliminated when present. In addition, medications that 
reduce spasticity in striated muscle may be contributing to the problem. These 
primarily include baclofen and tizanidine, both frequently used in MS, and their 
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dose or scheduling may need to be adjusted. In Figure 1.7 I relate the potential 
mechanisms for faecal incontinence. 
 Rectal compliance, ano-rectal sensation, sphincter control, RAIR and colonic 
motility are factors involved in a coordinated process, and along with voluntary 
control of bowel function allow the normal process of defecation. These have been 
considered separately but they can reciprocally affect one another, contributing to 
the onset of bowel symptoms in MS.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7: Mechanisms underlying faecal incontinence in patients with MS. 
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1.6 Hypothesis 
It appears evident that there is a lack of systematic and hypothesis-driven studies. 
Most of the literature available is old and either based on retrospective series, 
small prospective studies without a control group or physiological studies 
performed with out-dated modalities. 
In fact this study is the first that aims to define the pathophysiology of bowel 
symptoms on the basis of a hypothesis and to lay the foundation for future 
systematic studies and randomised controlled trials in the area of neurogenic bowel 
dysfunction secondary to MS. 
1.6.1 Primary Hypothesis 
I hypothesise that bowel dysfunction in MS is secondary to extent of spinal cord 
involvement by the disease, assessed clinically with the Expanded Disability Status 
Scale (which I will describe in chapter 3.5). From this hypothesis we developed 2 
studies: 
Study 1: Relationship between bowel and bladder dysfunction 
Study 2: The role of the spinal cord in bowel dysfunction secondary to MS: a 
comparison with SCI 
1.6.2 Secondary Hypothesis 
My secondary hypothesis is that the treatment strategies should target residual 
spinal cord function. This hypothesis was tested in a prospective observational 
study: 
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Study 3: Bowel biofeedback treatment in patients with MS and bowel symptoms 
(pilot study) 
For patients that do respond to biofeedback or are too disabled for this treatment, 
mechanical bowel emptying should be considered as an option. We therefore 
carried out the fourth study: 
Study 4: Transanal Irrigation for bowel symptoms in patients with MS  
I will next discuss neurogenic bowel dysfunction in the most common neurological 
diseases, and available treatment strategies. 
The Ethics Committee of University College of London granted ethical approval (REC 
reference number: 08/h07164/7) for the study. 
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CHAPTER 2: NEUROGENIC BOWEL DYSFUNCTION: 
PATHOPHYSIOLOGY, CLINICAL MANIFESTATIONS AND 
TREATMENT 
Neurogenic bowel dysfunction: pathophysiology, clinical manifestations and 
treatment.  
Preziosi G., Emmanuel A.V.  
Expert Review in Gastroeneterology and Hepatology 2009 Aug;3(4):417-23. 
Chapter overview: 
 Neurogenic bowel dysfunction, introduction 
 Neurophysiology of bowel dysfunction in SCI and MS  
 Neurophysiology of bowel dysfunction in Parkinson’s Disease  
 Management 
2.1 Introduction  
Bowel symptoms (faecal incontinence, infrequent or difficult defecation) are both 
common and severely troubling problems for patients with SCI, MS and Parkinson´s 
Disease (PD). The aetiology of these symptoms is complex: there may be autonomic 
and pelvic nerve dysfunction (with attenuation of voluntary motor function, and 
impaired ano-rectal sensation and ano-rectal reflexes), or generalised systemic 
factors (altered diet and behaviour, impaired mobility, psychological disturbance or 
drug adverse effects). The mainstay of current treatment is adapting a conservative 
approach towards reversing the systemic effects and optimising the mechanics of 
defecation through the use of laxatives and irrigation approaches. When successful, 
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this approach improves both evacuation and incontinence symptoms, with 
associated improvements in quality of life and independence. Future therapies may 
be directed at modulating pelvic innervation through electrical stimulation. Stoma 
formation remains an option for patients refractory to other approaches. 
2.1.1 Overview 
Disorders of the CNS are common, with worldwide estimates of the prevalence of 
SCI at over 2.5 million, MS considerably greater than 1.5 million and PD 
approximately 3 million (Lang & Lozano, 1998a; Lang & Lozano, 1998b; Saunders et 
al, 2009; Williams et al, 1995). Whilst mobility, pain and bladder dysfunction has 
been relatively well studied, bowel and pelvic floor dysfunction has been 
comparatively, something of a Cinderella subject. This is doubly unfortunate, as a 
large proportion of patients with CNS dysfunction experience frequent bowel 
symptoms, and these symptoms are amongst the most physically, socially and 
emotionally disabling (Edwards et al, 1992; Glickman & Kamm, 1996; Hinds et al, 
1990). In this chapter I will deal primarily with the bowel dysfunction associated 
with three common CNS diseases – SCI, MS and PD. The literature on the most 
common of all CNS diseases – stroke – is patchier and is often directed towards 
acute post-stroke problems as opposed to chronic neurogenic bowel dysfunction. 
With rapid advances in rehabilitation medicine resulting in increased survival of 
patients, these individuals are experiencing bowel symptoms for ever longer 
periods. 
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2.1.2 The Scale of the Problem 
Spinal cord injuries are common, with an estimated 50 people per million sustaining 
a traumatic spinal injury every year in the Western world (De Vivo, 2002). Non-
traumatic injury (vascular, infection, tumour) is even more common, and cancer 
alone is estimated to cause more SCI than trauma (Avery & Avery, 2008). Traumatic 
injuries mostly affect young men, and advances in rehabilitation medicine mean 
that the longevity of paraplegics is similar to the general population, while that of 
tetraplegics is 10 years shorter (Biering-Sorensen et al, 1990). Bowel dysfunction 
affects almost all patients with a chronic SCI – up to 95% report constipation, faecal 
incontinence is experienced at least once per year by 75% and daily by 5%, with 
33% experiencing regular abdominal pain (Finnerup et al, 2008; Glickman & Kamm, 
1996; Krogh et al, 1997). Inevitably, given the nature and chronicity of the bowel 
symptoms, this represents a significant contributor to reduced quality of life in SCI 
individuals (Glickman & Kamm, 1996). Patients with SCI reported bowel dysfunction 
as more problematic than bladder dysfunction, pain, fatigue and body image 
(Glickman & Kamm, 1996). 
Bowel dysfunction in MS is less well studied, but almost as prevalent as in other 
neurological conditions. The prevalence of MS is approximately 1 per 1 000 
(Williams et al, 1995). As discussed in Chapter 1, about one-third of MS patients 
suffer from constipation and one-quarter are incontinent at least once per week 
(Bakke et al, 1996; Hinds et al, 1990). In patients with PD, constipation, in particular 
difficulty with defecation occurs in 37% (Krogh et al, 2008). One quarter of stroke 
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survivors experience constipation, and 15% suffer with faecal incontinence (Doshi 
et al, 2003). 
2.2 Neurophysiology of Bowel Dysfunction in Spinal Cord Injury 
and Multiple Sclerosis 
The pathophysiology of pelvic floor and colorectal dysfunction is broadly similar in 
patients with both SCI and MS. The extent of injury is the most important factor in 
determining bowel symptoms in both SCI and MS. However, whereas in chronic SCI 
patients the lesion is usually sharply defined and unchanging, in patients with MS 
the lesions typically occur at multiple levels within the CNS and tend to vary with 
time. Pathophysiology of MS-related bowel dysfunction has already been discussed 
in detail, so I will now focus on alterations observed in SCI, highlighting any 
similarity. 
Standard clinical classification of SCI relates to the level of injury and completeness. 
The International Standards for Neurologic and functional classification of SCI 
classifies it according to neurologic level (the most caudal segment of the spinal 
cord with minimal sensory or motor function in both sides of the body). The 
severity of damaged is assessed by the American Spinal Injury Association (ASIA) 
Impairment Scale (Marino et al, 2003). 
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Table 2.1: American Spinal Injury Association impairment scale 
A complete No sensory or motor function preserved in sacral segments 
S4 to S5  
B incomplete Sensory but no motor function preserved below the 
neurologic level, including S4 to S5 sacral segments  
C incomplete Motor function preserved below the neurologic level and 
more than half of key muscles below the neurologic level 
have a muscle grade below 3 (useless)  
D incomplete Motor function preserved below the neurologic level and 
more than half of key muscles below the neurologic level 
have a muscle grade of 3 or higher (useful) (incomplete) 
 
Depending on the level involved in the spinal cord they are divided in: 
  Supraconal or suprasacral (lesion above the conus medullaris – T5, 
conventionally termed upper motoneuron lesions) interrupting modulatory 
pathways that normally coordinate bowel and sphincter function. 
 Lesions of the sacral cord or nerve roots (cauda equina type injury -lumbar–
sacral nerve roots damage or disease) conventionally termed lower motor 
neuron lesions as they disconnect part of the bowel and sphincters from 
their source of innervation in the spinal cord. 
In supraconal SCI, an ‘upper motor neurone’ type injury of the bowel results in 
slowed whole gut transit (Lynch et al, 2000; Sun et al, 1995) and hypertonia and 
hyperreflexia of the hindgut (i.e. distal to the splenic flexure) (Krogh et al, 2000; 
Lynch et al, 2000). The slowing of transit is autonomic-mediated, but also 
contributed to by reduced mobility and attenuation of the gastro-colic response 
(Aaronson et al, 1985). The rectal hypertonia results in reduced rectal compliance 
and predisposes to reflex defecation and incontinence. In cauda equina lesions the 
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efferent limb of the reflex arc to the hindgut is interrupted, resulting in a ‘lower 
motor neurone’ type bowel dysfunction with hypotonia and hyporeflexia (Krogh et 
al, 2003).  
Supraconal injury tends not to alter anal tone, whilst the reduced tone of cauda 
equina lesions may relate to faecal bilus impaction as much as loss of 
parasympatehtic input. Thus, in motor complete SCI the voluntary control of the 
external anal sphincter is lost (Craggs et al, 2006). Completeness of the SCI 
according to the ASIA criteria can be confounded when looking at function of the 
ano-rectum. For example, in clinical practice a patient with a motor incomplete SCI 
might not have voluntary contraction of the external anal sphincter. It appears in 
fact that both patients with complete and incomplete SCI have similar symptoms, 
and that the level of injury might be more relevant (Valles & Mearin, 2009).  
Rectal hyposensitivity occurs in both supraconal and cauda equina lesions, and 
predisposes to faecal impaction (especially in the flaccid rectum of patients with 
cauda equina lesions) (Krogh et al, 2003). 
2.3 Neurophysiology of Bowel Dysfunction in Parkinson’s 
Disease 
The pathophysiology of bowel dysfunction in patients with PD is quite different 
from that of SCI or MS. Dystonia of the striated muscles of the pelvic floor and 
external anal sphincter explains the defecatory dysfunction (Ashraf et al, 1995); this 
aetiological factor is supported by the observation that pelvic floor dysfunction is 
alleviated with l-Dopa (Singaram et al, 1995).  
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In addition to the pelvic dysfunction, colonic transit time is usually prolonged in 
patients with idiopathic PD (Ashraf et al, 1995). Two important pathopysiological 
factors contribute to this: firstly, the number of dopamine producing cells in the 
colonic wall is reduced in idiopathic PD (Edwards et al, 1994); and secondly, Lewy 
bodies, typical of PD, form in the enteric ganglia (Kupsky et al, 1987). Recent 
observations have identified that men with a bowel opening frequency less than 
every 24 hours have an almost threefold risk of developing PD in later life 
compared to men with a daily or more often bowel frequency (Abbott et al, 2001), 
suggesting that PD is not just a degenerative disorder of the CNS but also of the 
ENS. It has been proposed that bowel symptoms may permit early identification of 
PD. 
2.4 Management 
2.4.1 Assessment 
The critical first step in managing most patients with neurogenic bowel dysfunction 
is to define the patient’s prior bowel pattern. Current bowel symptomatology is 
next assessed, and this is in relation to bowel frequency, stool consistency, faecal 
incontinence and manoeuvres needed to achieve bowel management. This 
information is usually gathered from standard patient and carer history, but scoring 
systems exist which may supplement this. There are standard instruments (St 
Mark’s incontinence score (Maeda et al, 2007), Wexner-Constipation (Agachan et 
al, 1996) and Wexner-Incontinence score (Jorge & Wexner, 1993), and recently a 
condition specific score has been developed for neurologic patients (Krogh et al, 
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2006b). This Neurogenic Bowel Dysfunction (NBD) Score is validated in SCI, but not 
PD. I will assess the NBD in patients with MS in Chapter 4. 
Digital rectal examination is an essential component, allowing assessment of rectal 
filling, resting anal tone, ability to generate a voluntary contraction and it also gives 
a crude assessment of anal sensitivity. The place of more interventional 
physiological or radiological transit investigations is not established, but may be 
appropriate if there is any co-morbidity (prior anal surgery, obstetric history, pelvic 
organ prolapse). Plainly, patients with alarm symptoms should have the necessary 
colonic imaging performed. Other causes of bowel symptoms should be ruled-out 
in individual cases by means of laboratory tests (thyroid function, electrolytes 
imbalance, coeliac disease, etc.), radiological or endoscopical investigations (i.e. 
inflammatory bowel disease). 
2.4.2 Basic Management 
Treatment is usually empirical, with an escalating step-wise approach usually being 
adopted. There is little formal clinical trial evidence for this, and no consensus on 
the basic data set required, the decision-making strategy or the components of the 
management algorithm. 
The basic management intention for all patients is to establish a pattern of 
scheduled defecation in a comfortable position, exploiting any easily 
implementable manipulations of diet and lifestyle before considering laxatives, 
suppositories or constipating agents (1998). Despite the absence of a strong 
evidence base, these conservative interventions are helpful in the vast majority of 
neurogenic bowel patients (Krogh et al, 1997). In the absence of any consensus, this 
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needs to be empirical and flexible to accommodate the patient’s realistic ability to 
comply, recognising that there is huge individual variation both in bowel pattern 
and in response to modifications. Components of this aspect of care may include 
the following: 
 simplifying drug regime to minimise use of any constipating medication 
(anti-cholinergics, muscle relaxants, diuretics, etc) 
 rationalising fibre intake (recognising that patients may be taking too much 
dietary fibre which is both unhelpful and exacerbates abdominal bloating) 
 optimising fluid intake to ideally more than 1.5l per day (within the balance 
of what is practical given the bladder regime) 
 avoiding excess caffeine, sorbitol or artificial sweetener intake (which can 
promote stool looseness and soiling) 
 timing regular mealtimes 
 attempting the bowel evacuation regime in the mornings after a warm drink 
and small meal in order to optimise the gastro-colic response 
 abdominal massage may accelerate gut transit and ease bowel management 
(Ayas et al, 2006). 
The patient or carer often needs to undertake digital examination to check that 
there is rectal content. If there is no spontaneous defecation, rotatory digital 
stimulation of the ano-rectum will provoke reflex rectal contraction and may allow 
bowel emptying. If such digital stimulation is insufficient, stimulation of these same 
rectal contractions with suppositories (glycerine or bisacodyl) is preferred to 
manual extraction of stool. A recent study has suggested that docusate mini-
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enemas and PEG-base bisacodyl suppositories are more effective than standard oil-
base bisacodyl suppositories (Ayas et al, 2006). If there is no response to 
suppositories, a mini-enema may be required (Ayas et al, 2006). Commercially 
sponsored trials of the macrogol osmotic agents have established a place for these 
compounds (Movicol®) in patients with PD (Zangaglia et al, 2007) and faecal 
impaction (Chen et al, 2005), but it is likely that other osmotic agents would be 
equally effective. Fibre supplements are generally unhelpful (as discussed above), 
but stimulant laxatives are sometimes helpful when taken in the evening to 
optimise the opportunity for a morning bowel action (1998).  
Recently, an innovative prokinetic agent, Prucalopride, has been introduced onto 
the market. Prucalopride is a highly selective, high-affinity 5-HT4 receptor agonist 
with prokinetic properties (Emmanuel et al, 1998). The 5-HT4 receptor has a 
particularly important role, both physiologically and pathophysiologically, in the 
regulation of gut function (Kim & Camilleri, 2000). Activation of neuronal 5-HT4 
receptors results in prokinetic activity throughout the GI tract, and triggers the 
release of neurotransmitters from the enteric nerves resulting in increased 
contractility and stimulation of the peristaltic reflex (Gershon, 2005). In vivo studies 
have shown that prucalopride increases the velocity of coordinated colonic 
propulsion (Jin et al, 1999) and enhances colonic motility and transit (Emmanuel et 
al, 2002). 
There are no studies of prucalopride in neurological patients, but three large clinical 
trials of prucalopride have been undertaken in patients with laxative refractory 
constipation (Camilleri et al, 2008; Quigley et al, 2009; Tack et al, 2009). All three 
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studies showed that prucalopride increased the number of bowel movements and 
reduced the severity of symptoms. These three studies enrolled almost 2000 
patients. The most frequently reported adverse events of prucalopride were 
headache, nausea, abdominal pain and diarrhoea, which were mainly reported on 
the first day of treatment. There were no clinically relevant adverse events 
reported on prucalopride. The majority of patients recruited to these studies (85%) 
were female, but the magnitude of effect was similar in both men and women. 
Prucalopride is particularly promising for patients with MS and SCI, particularly in 
the acute phase of symptoms where there are no primary abnormalities in the 
bowel wall, which can sometimes be observed in chronic idiopathic constipation 
(Lyford et al, 2002). In a study of patients with a chronic SCI prucalopride was both 
effective and safe, with only 2 out 11 patients discontinuing the drug because of 
abdominal pain (Krogh et al, 2002a). 
Loperamide (rather than codeine or lomotil) is the first line treatment for patients 
with faecal incontinence (Norton et al, 2007). The alternative, or additional, 
strategy to reduce faecal incontinence in this group is to optimise rectal clearance 
with suppositories or small volume enemas, on the principle that an empty rectum 
cannot cause incontinence. 
Bowel biofeedback treatment has a well-established role in the treatment of 
functional constipation and faecal incontinence (Enck et al, 2009), and has been 
proposed for MS patients with lower disability and lesser alterations in standard 
ano-rectal physiology (ARP) tests (anal sphincter manometry and ano-rectal 
sensation) (Munteis et al, 2008; Wiesel et al, 2000). These studies though had the 
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limitation of having a small number of patients (Wiesel et al, 2000) and of being 
retrospective (Munteis et al, 2008). I will discuss biofeedback further in Chapter 6. 
2.5 Mechanical Bowel Emptying 
2.5.1 Retrograde Irrigation 
When lifestyle and laxative approaches cannot achieve satisfactory bowel 
management, the next step is to attempt irrigation of the colon. The least invasive 
method of undertaking this is with transanal irrigation (TAI), which will be discussed 
in more depth in Chapter 7. This has been shown to successfully empty the rectum 
and often the left colon too, thus helping neurogenic patients with both 
constipation and faecal incontinence (Christensen et al, 2003). A major 
improvement in this technique came from the commercial development of 
Peristeen®, which replaced earlier ad hoc (frequently uncomfortable) devices 
(Shandling & Gilmour, 1987). This system, consists of a reservoir, hand control and 
single-use catheter, and allows variable volumes of liquid to be instilled, up to 4000 
ml. 
An important randomised trial among SCI subjects with bowel dysfunction showed 
that TAI reduced constipation symptoms and episodes of faecal incontinence 
compared to standard bowel management without irrigation (39). There were 
associated improvements in symptom-related quality of life, and subsequent 
studies have shown that the system is cost effective compared to standard 
supportive bowel management (40). These observations complemented the 
classical findings in children with NBD that demonstrated the efficacy of TAI 
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(Christensen et al, 2006). With careful patient selection (those able to tolerate 
rectal instillation, potentially independent of carers, able to transfer to a toilet or 
commode), this technique represents an important addition to the therapeutic 
options for this patient group. Whilst MS patient were included in studies on TAI, 
and the largest contained 25 (Faaborg et al, 2009a), no study has evaluated its 
efficacy in a selected group of MS patients.  
2.5.2 Antegrade Irrigation 
Following the initial reports of TAI, Malone and colleagues undertook a novel 
procedure of antegrade irrigation via an appendicostomy (as the conduit for 
instillation of tap water or osmotic agent) (Malone et al, 1990). Commonly known 
as the antegrade continence enema (ACE) procedure it has been especially used in 
children with constipation and faecal incontinence due to NBD, especially 
myelomeningocoele (Koyle et al, 1995). In adults, long-term satisfaction with ACE is 
reported in over 80% of patients (Worsoe et al, 2008). ACE achieves near total 
colonic clearance, the chief drawback being that the appendicostomy may stenose 
with time (Gerharz et al, 1997). In fact, a recent decision analysis model (which did 
not include TAI) suggested that ACE is the optimal long-term option for NBD (Furlan 
et al, 2007). An alternative to the surgical creation of an irrigation port is the 
formation of a percutaneous endoscopic colostomy (PEC), whereby an enterostomy 
tube is endoscopically located in (usually) the left colon. A single retrospective 
publication of PEC showed that over 80% of adults with NBD reported symptom 
improvement with such management (Cowlam et al, 2007). It must be remembered 
that the technique is not without complications (sepsis, tube displacement, 
  Chapter 2: Neurogenic Bowel Dysfunction 
53 
haemorrhage, pain) that can ultimately be fatal, and the technique needs a greater 
evidence base before its potential role is identified.  
2.6 Surgical Intervention 
2.6.1 Neuromodulation 
Sacral nerve stimulation, or sacral neuromodulation (SNM), is an emerging 
minimally invasive technique for patients with idiopathic faecal incontinence and 
constipation refractory to standard treatments (Furlan et al, 2007). In brief, the 
technique involves the insertion of a stimulating electrode via the sacral foramina 
onto the anterior (efferent) roots of the S2 or S3 roots (Kenefick & Christiansen, 
2004). A temporary electrode connected to an external battery is inserted for a two 
to three week trial period. If there is a satisfactory response, then a permanent 
electrode and implantable pulse generator is placed, although there is a question 
about whether this trial period is actually an accurate predictor of response to a 
permanent electrode (Mowatt et al, 2007). Overall, 41-75% of patients achieved 
complete faecal continence, and smaller studies in patients with constipation 
suggest similar rates of response for this too (Thomas et al, 2013). The mechanism 
of action is unknown, but is thought to involve afferent neuromodulation as much 
as efferent neurostimulation (Kenefick et al, 2003). Two recent small studies on 
patients with spinal and cauda equina injury have suggested that the technique 
may help in selected patients with incomplete neurological lesions (Gstaltner et al, 
2008; Jarrett et al, 2005). Nevertheless, anxieties remain about the durability of 
effect in this group, and especially about the potential risks of autonomic 
dysreflexia.  
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A non-invasive option of nerve stimulation is offered by Posterior tibial nerve 
stimulation (PTNS). Originally used in chronic pelvic pain and sexual dysfunction, it 
is a relatively newer neuromodulation modality to treat faecal incontinence, first 
employed for (Shafik et al, 2003). There have since been eight studies, with a total 
of 129 patients, including two prospective controlled studies, with a success rate of 
between 30% to 83.3% and without major complications (Findlay & Maxwell-
Armstrong, 2011).  
The mechanisms by which PTNS improves faecal incontinence is not clear, but may 
be similar to sacral nerve stimulation. What is known is that it improves anal 
squeeze pressure (Findlay & Maxwell-Armstrong, 2011). There is an ongoing 
multicentre randomised-controlled trial to define its role in idopathic faecal 
incontinence. This modality of treatment will also merit further evaluation for the 
treatment of NBD. 
2.6.2 Formation of a Stoma 
An option for patients with NBD is the formation of a colostomy or ileostomy. 
However, this should not be considered a last ditch option of desperation, as the 
procedure reduces time spent with bowel care and can provide independence, 
improving quality of life for patients (Randell et al, 2001; Safadi et al, 2003; Stone et 
al, 1990). A questionnaire study on patients with a colostomy for neurogenic bowel 
revealed that the overwhelming majority of patients would undergo the procedure 
again and wished they had been operated on earlier (Norton et al, 2005). However, 
the caveat is that patients with neurological diseases experience greater 
complications with their stoma than neurologically intact patients (Randell et al, 
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2001; Stone et al, 1990), relating in part, at least, to body habitus and wheelchair 
use. Furthermore, whilst incontinence and independence of bowel management 
are often greatly enhanced by stoma formation, impairment of colonic transit is not 
altered by the procedure, so stoma irrigation or laxative use may continue to be 
required. In this regard, some surgeons prefer the formation of a laporoscopic loop 
ileostomy. 
2.7 Summary 
Patients with CNS diseases frequently experience socially restricting bowel 
dysfunction. The causation of these symptoms is multifactorial, and our 
understanding of bowel transit and the pelvic reflexes in these patients has 
increased in recent years.  
A logical step-wise approach can improve bowel symptoms and includes: 
 Conservative interventions (position of toileting, meal timing, minimising 
constipating medication, use of suppositories), which can improve function 
in many patients. 
 Antegrade irrigation via an appendicostomy may benefit some patients with 
NBD; it is especially effective in children. 
 An alternative for antegrade colorectal irrigation is via an endoscopically 
placed colostomy; however this is limited by a high incidence of adverse 
affects. 
 TAI using a novel system of single use rectal catheters offers a well tolerated 
approach for patients with NBD. 
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 Formation of a colostomy or ileostomy is the last option – but a reasonably 
successful one – for some refractory patients. 
Three-quarters of these patients can be managed conservatively, but these simple 
steps need to be applied systematically. Only a minority of patients need to 
undergo more complex procedures (irrigation, electrical stimulation or surgical).  
It appears clear that there is almost a complete lack of evidence on the efficacy of 
treatment for bowel symptoms in MS, and that most of our experience in managing 
NBD is based on evidence accumulated in patients with SCI. 
As MS, like SCI, is at present incurable and a sizable social issue, greater emphasis 
should be given to the management of symptoms. 
The aim of my study is to lay the foundations to a rationalised – targeted approach 
to bowel symptoms in MS, in order to develop a treatment algorithm and identify 
new treatment strategies. 
As stated in section 1.6.1, my primary hypothesis is that bowel dysfunction in 
patients with MS is secondary to the extent of spinal cord involvement by the 
disease. A key element in the development of my hypothesis is that patients with 
MS show similar end organ alteration to patients with a supraconal-SCI, and the 
degree of measurable dysfunction could also follow a pattern. I will develop this 
further in Chapter 5. 
I have so far discussed NBD in MS and other common neurological disorders, 
outlining the rationale of my studies. In the next chapter I will illustrate the 
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assessment tools I have employed in my studies, including questionnaires, disability 
scales and tests of ARP. 
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CHAPTER 3: METHODS 
Chapter overview: 
 Assessment of ano-rectal physiology 
 Measurement of rectal compliance 
 Assessment of bowel symptoms and general health status 
 Assessment of disability and MS impact 
3.1 Introduction 
The experimental part of this thesis is composed of four studies.  
1. A study of prevalence of bladder symptoms in patients with MS and bowel 
symptoms involving 71 patients. 
2. A study of rectal compliance through the comparison of patients with 
supraconal SCI and normal controls, involving 46 patients with MS, 23 
patients with a supraconal-SCI (SCI, above T-5 level) and 25 healthy 
individuals without bowel symptoms. 
3. A prospective observational study of bowel biofeedback involving 39 
patients. 
4. A prospective observational study of TAI involving 29 patients. 
Whilst the thesis is conducted on the basis of a unified hypothesis, each individual 
study has its own specific hypothesis and aims. Therefore the study design is 
described in each individual chapter. Patients in study 1 (correlation of bowel and 
bladder symptoms, chapter 4) and 3 (biofeedback study, chapter 6) are 
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independent cohorts, whilst all the patients in the transanal irrigation study 
(chapter 7) had been also included in the rectal compliance study (chapter 5). 
In this chapter the tests and questionnaire employed are described, highlighting in 
which study they have been used. 
3.2 Ano-Rectal Physiology Tests 
In all studies except study 1 all patients underwent baseline standard ARP tests 
(measurement of anal sphincters pressure and ano-rectal sensation). In the 
biofeedback study (study 3) these tests were repeated after treatment. In studies 2 
and 4 patients also had measurements of baseline rectal compliance. I performed 
all the measurements according to standardised criteria (Diamant et al, 1999) 
(Diamant et al, 1999).  
Given that our cohort was predominately female patients, normal values for this 
gender, currently used at our Unit, are reported (Jameson et al, 1994a). In brief, 
resting anal pressure (internal anal sphincter function), squeeze and endurance 
squeeze pressure (external sphincter function) were measured using an 8-channel 
water-perfused catheter (Ardmore Healthcare Limited, External Diameter 3.9mm 
with Mui pump, using Medical Measurement System software) and a ‘station pull-
through’ method.  
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Figure 3.1: The manometry stack 
 
Figure 3.2: Manometry catheter 
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Figure 3.3: Manometry sensors 
 
Figure 3.4: Manometry trace 
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The lower limit for normal anal resting and squeeze pressures at our unit is 60 
cmH2O. Rectal sensitivity to balloon distension was measured by continuous 
inflation of a latex balloon placed in the rectum, 6 cm above the anal verge: 
threshold volume of first sensation (normal range 20–60 ml), urge volume at which 
urge to defecate is first perceived (normal range 35-120 ml) and maximum 
tolerated volume (normal range 100-260 ml) were recorded.  
 
Figure 3.5: Tip of the manometry catheter demonstrating the mounted balloon. 
This was used to elicit the RAIR. 
Finally, anal and rectal electro-sensitivity was measured with a bipolar electrode 
catheter (Gaeltec Ltd., using Medical Measurement System software) placed in the 
anal canal and then in the rectum.  
Anal electric-stimulation was applied at 1cm from the anal verge at 5Hz with a pulse 
width of 0.1msec; the current was then incrementally increased up to 20mA until 
the patient reported their first sensation (normal range 2-9 mA). In the rectum, at 
6cm from the anal verge, electrical stimulation was applied at 10 Hz with a width of 
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0.5msec and increased up to 50mA until the patient reported their first sensation 
(normal range 14-38 mA). 
3.3 Measurement of Rectal Compliance 
3.3.1 Rectal Compliance 
In the normal subject the colon propels the stools in the rectum, and subsequent 
rectal distension has the dual effect of generating a sense of rectal fullness and of 
activating the RAIR. Their transmission to the cortex clearly depends on an intact 
spinal cord. The integration of these two physiological mechanisms at the 
supraspinal level generates a desire to defecate and a decision of whether it is an 
appropriate time to void the rectum. This simplistic and schematic view makes 
evident the importance of the distensibility of the rectum in response to pressure, 
rectal compliance. 
Measurement of rectal compliance is calculated as the average changes in volume 
determined by changes in pressure. The distensibility of the rectum depends on the 
various structures composing its wall, namely the mucosa, connective tissue and 
the smooth muscle. As expected, physical alteration of the rectal wall can alter 
rectal compliance, like for example in ulcerative colitis and radiation proctitis 
(Bajwa A., 2009; Farthing & Lennard-jones, 1978; Rao et al, 1987; Varma et al, 
1985). Alteration of rectal compliance in neurological diseases suggests instead that 
changes in rectal stiffness and tone can be secondary to modification of the 
autonomic outflow and its effect on smooth muscle in the rectal wall. 
  Chapter 3: Methods 
64 
3.3.2 Measurement of Rectal Compliance – Instruments 
The measurement of rectal compliance has been the subject of debate, but 
minimum standards have been agreed (Whitehead & Delvaux, 1997).  
Rectal compliance was measured with a mechanical barostat (Distender II, G & J 
Electronics, On, Canada, Figure 3.6) and a 20cm x 15cm polyethylene, over-sized, 
non-compliant bag (maximum volume 600ml) tied to ridges 10cm apart to a dual 
lumen silicon catheter (Mui Scientific Inc., Ontario, Canada, Figure 3.7), and placed 
into the rectum at 6 cm from the anal verge. 
The barostat bag has to have specific properties so that whilst it is distended and in 
contact with the rectal wall, the pressure measured within the bag equates to the 
pressure exerted on the bag by the rectum. For this to occur, the bag itself had to 
be infinitely compliant exerting no force of its own.  
This means that polyethylene rather than latex (which has the problem of requiring 
a large initial pressure to stretch but then stretches very easily) had to be used. 
There are two ways of designing an infinitely compliant bag. Either a balloon that is 
infinitely compliant up to its maximum volume, or a fixed, large-volume non-
compliant bag which has a maximum volume greater than the maximum volume of 
the rectum. Krogh et al demonstrated that results using the 'oversized bag' are 
more reproducible (Krogh et al, 2001a), so for this study a 20 x 15 cm polyethylene, 
over-sized, non-compliant bag with a maximum volume of 600ml (CT-BP500R bag, 
Mui Scientific, Ontario, Canada) was used to measure compliance (Figure 3.7).  
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Figure 3.6: The barostat machine 
 
Figure 3.7: The barostat catheter 
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3.3.3 Measurement of Rectal Compliance - Distension Protocol  
We employed a distension protocol (Fox et al, 2006), which reduces variability of 
measurement due to variation in rectal capacity. Initially a minimal distending 
pressure (MDP) is calculated as the pressure at which respiratory excursions are 
regularly recorded as changes in barostat volume. This is the minimal level of 
pressure required for the barostat bag to be adherent to the rectal wall without 
distending it. (Bell et al, 1991). The basal operating pressure (BOP) was set at MDP 
+ 2mmHg (Bharucha et al, 1997). In order to make measurement reproducible it is 
required that the rectal wall basal tone is stabilised though repeated and 
equilibrated distensions, a phenomenon called tissue pre-conditioning (Bharucha et 
al, 2004; Hammer et al, 1998), and this also has the function of familiarising the 
individual to the barostat assembly. So by using the BOP as a baseline, the 
conditioning distension sequence was performed; this consisted of sequential 
4mmHg staircase distensions up to 20mmHg. Each step was maintained for 15 
seconds. Subsequently, the index distension was performed and sequential 4mmHg 
stepwise distensions were attained up to a maximum of BOP + 40mmHg or a 
patient’s tolerance. Each distension step was maintained for 1 minute.  
3.3.4 Calculation of Compliance: Analysis of the Pressure-Volume 
Data 
Special software (Protocol Plus) provided by the barostat manufacturer (G&J 
Electronics, Ontario, Canada) was used to analyse the raw data recorded during 
distension sequences (Figure 3.8).  
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The software was utilised to average the volume of air within the bag over the last 
10 seconds of the each distension step. This usually reflected the volume of the bag 
in a stable stage of the corresponding pressure increment phase (Figure 3.8). This 
volume was then plotted against the pressure of correspondent distension, to 
produce a pressure-volume curve. 
 
Figure 3.8: The software used for analysis of volume-pressure data 
The pressure-volume values were entered into Prism 4.0 (GraphPad Software Inc, 
CA, USA) to create a graphical representation of the values.  
a) Sigmoidal relationship observed: 
If a sigmoidal relationship was observed, a best-fit curve was computed and a 
tangent was then drawn to the steepest part of the curve. The gradient of this line 
was considered as the compliance of the rectum (measured in ml/mmHg) (Figure 
3.9)(Varma & Smith, 1986). 
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Figure 3.9: Typical sigmoidal pressure-volume curve 
b) Sigmoidal relationship not observed: 
A linear relationship was sometimes identified between the pressure-volume 
values. On these occasions, a best-fit line was computed and its gradient was taken 
to be the compliance value (Figure 3.10) (Bharucha et al, 2004).  
 
Figure 3.10: Linear pressure-volume relationship curve 
Normal values for rectal compliance were obtained by applying this protocol in 
normal controls and the normal range at our Unit is 11-15 ml/mmHg. 
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3.4 Symptoms Assessment  
No bowel questionnaire has been validated to measure bowel symptoms in 
patients with MS. We employed different questionnaires depending on the type of 
study, and the reasons for specific choices are given in the individual chapters. 
In study 1 we used the NBD questionnaire and patient-reported symptoms of bowel 
and bladder dysfunction. In the other studies we employed the Wexner-
Constipation and Wexner-Incontinence questionnaires. 
3.4.1 Neurogenic Bowel Dysfunction Questionnaire  
This questionnaire was employed in Study 1. The NBD questionnaire has been 
designed and validated in patients with SCI (Krogh et al, 2006a), and includes 
questions about background parameters (n=8), faecal incontinence (n=10), 
constipation (n=10), obstructed defecation (n=8), and impact on quality of life 
(QOL) (n=3). The NBD score weights each symptom of bowel dysfunction in relation 
to its impact on quality of life, and scores are categorised as follows: 0-6 very minor 
dysfunction, 7-9 minor dysfunction, 10-13 moderate dysfunction and 14-47 severe 
dysfunction. The use of this questionnaire in study 1 was dictated by the need to 
have an instrument that quantifies constipation and faecal incontinence as well as 
impact on quality of life. 
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Figure 3.11: The NBD score 
3.4.2 Patient-Reported Symptoms of Bowel and Bladder Dysfunction 
This modality of symptoms assessment was employed in Study 1. Patient-reported 
outcome measures are increasingly used in medical studies (Ang et al, 2011; 
Paterson, 1996; Rahimi et al, 2010) and were assessed within a structured 
interview, conducted in the outpatient clinic. The alternating and fluctuating 
pattern of bowel habit in MS patients is similar to that of irritable bowel syndrome. 
In patients with this condition, the product of frequency and severity of symptoms 
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has been employed to quantify bowel function (Talley et al, 1989; Talley et al, 
1990). So each patient was asked what proportion of time of his or her life was 
affected by constipation and/or faecal incontinence, with five possible answers (0%, 
25%, 50%, 75% or 100% of the time). We then assessed severity by asking patients 
to use a visual analogue scale (VAS) from 0 to 100, with 0 representing absence of 
symptoms, and 100 if the patient thought that bowel symptoms were the worst 
possible.  
The presence of bladder symptoms and on-going treatment (anti-muscarinic 
agents, use of intermittent self-catheterisation, permanent catheter) was 
ascertained from the patient’s history and clinical notes. Urgency was defined as a 
sudden compelling desire to pass urine that is difficult to defer (Abrams et al, 
2002); urge urinary incontinence was defined as incontinence accompanied by or 
immediately preceded by urgency. The patient was also asked about difficulty of 
initiating bladder voiding (hesitancy), interruption of flow, sense of incomplete 
bladder emptying and use of pads. 
We wished to quantify bladder and bowel dysfunction uniformly. Therefore we 
asked the proportion of time a patient perceived bladder symptoms affected his or 
her life, with five possible answers (0%, 25%, 50%, 75% or 100% of the time). 
Severity was assessed on a VAS from 0 to 100, similarly to bowel symptoms. 
This modality of assessment is not validated, and their limitations are 
acknowledged in the discussion. 
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3.4.3 Wexner Constipation and Incontinence Scores 
The Wexner-Constipation (Agachan et al, 1996) and Wexner-Incontinence (Jorge & 
Wexner, 1993) questionnaires provide a validated and reproducible quantitative 
assessment of bowel symptoms (Holzer et al, 2008; Vaizey et al, 1999). The 
incontinence score ranges between 0-20, and the constipation score between 0-30, 
with 0 representing absence of symptoms, and 20 or 30 the most burdensome level 
of symptoms.  
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Wexner Constipation Score 
Please answer the following questions that relate to the emptying of your bowels. Circle 
the most appropriate number that applies to you. 
1). Typically how often do you empty your bowels? Score 
1-2 Times per 1-2 days 0 
2 times per week 1 
Once per week 2 
Less than once per week 3 
Less than once per month 4 
2). How often do you have to strain to empty your bowels?  
Never 0 
Rarely 1 
Sometimes 2 
Usually 3 
Always 4 
3). How often do you feel you have not fully evacuated your 
rectum when you empty your bowels? 
 
Never (always feel empty) 0 
Rarely 1 
Sometimes 2 
Usually 3 
Always (never feel empty) 4 
4). How often do you suffer with abdominal pains due to your 
bowel evacuation problem? 
 
Never 0 
Rarely 1 
Sometimes 2 
Usually 3 
Always 4 
5). Typically how long do you spend in the lavatory per 
attempt? 
 
Less than 5 minutes 0 
5 – 10 minutes 1 
10 – 20 minutes 2 
20 – 30 minutes 3 
More than 30 minutes 4 
6). Which of the following do you need, to help with the 
emptying of your bowel? 
 
No help 0 
Laxatives 1 
Digital assistance, suppositories, or enema 2 
7). Typically how often do you attempt to empty your bowels 
WITHOUT a result in a 24hr period? 
 
Never 0 
1-3 1 
3-6 2 
6-9 3 
More than 9 4 
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8). How long have you had these bowel symptoms?  
0 Years 0 
1-5 Years 1 
5-10 Years 2 
10-20 Years 3 
More than 20 Years 4 
Total score   
Figure 3.12: Wexner Constipation questionnaire 
 
 
 
Figure 3.13: Wexner faecal incontinence questionnaire 
3.4.4 Assessment of Anxiety and Depression 
Anxiety and depression were evaluated in study 3 before and after treatment with 
the Hospital Anxiety and Depression Scale (HADS)22. This is a widely used 
instrument of self-assessment of psychological state in non-psychiatric patients, 
both in the hospital and primary care setting.23 It is composed of 7 questions for 
each domain, and scores of 0-7 in respective sub-scales are considered normal, with 
8-10 borderline, and 11 or over suggesting the presence of a clinical syndrome.  
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I feel tense or wound up:    I feel as if I am slowed down:  
Most of the time      Nearly all the time    
A lot of the time      Very often    
Occasionally      Sometimes    
Not at all      Not at all    
I still enjoy the things I used to enjoy:  I get a sort of frightened feeling like 
“butterflies” in the stomach:  
Definitely as much      Not at all    
Not quite as much      Occasionally    
Only a little      Quite often    
Hardly at all      Very often    
I get a sort of frightened feeling as if 
something awful is going to happen: 
 I have lost interest in my appearance:  
Very definitely and quite badly     Definitely    
Yes, but not badly      I don’t take as much care as I should    
A little, but it doesn’t worry me      I may not take quite as much care    
Not at all      I take as much care as ever    
I can laugh and see the funny side of 
things:  
 I feel restless as if I have to be on the 
move:  
As much as I always could     Very much indeed 
 
  
Not quite as much now      Quite a lot   
Definitely not so much now      Not very much    
Not at all      Not at all    
Worrying thoughts go through my 
mind: 
 I look forward with enjoyment to 
things:  
A great deal of the time     As much as I ever did    
A lot of the time      Rather less than I used to    
From time to time, but not too often      Definitely less than I used to    
Only occasionally      Hardly at all    
I feel cheerful:  I get sudden feelings of panic: 
Not at all     Very often indeed    
Not often      Quite often    
Sometimes      Not very often    
Most of the time      Not at all    
I can sit at ease and feel relaxed:   I can enjoy a good book or television 
programme: 
Definitely    
 
Often    
Usually    
 
Sometimes    
Not often     Not often    
Not at all      Very seldom    
 
Figure 3.14: Hospital anxiety and depression questionnaire 
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3.4.5 Assessment of General Health Status 
General health status was measured in study 4 with the widely used 36-item short 
form health survey (SF-36) (McHorney et al, 1993). The modified version including 
specific MS items did not show any advantage in comparison with the shorter 
original SF-36 (Freeman et al, 2001), which was therefore used for this study. The 
values range between 36 and 149 which are then converted into a scale of 0-100 so 
that each domain has the same impact on the final score; the higher the score the 
better the health status. 
 
SF-36 HEALTH SURVEY 
 
 
INSTRUCTIONS: This survey asks for your views about your health. This information will help 
keep track of how you feel and how well you are able to do your usual activities. Answer every 
question by marking the answer as indicated. If you are unsure about how to answer a 
question, please give the best answer you can. 
 
1. In general, would you say your health is:  
                                                                                                     (circle one number only) 
Excellent ………………………………………………………………………………………….1 
Very good…………………………………………………………………………………………2 
Good……………………………………………………………………………………………….3 
Fair…………………………………………………………………………………………………4 
Poor………………………………………………………………………………………………..5 
 
 
2. Compared to one week ago, how would you rate your health in general now? 
                                                                                                     (circle one number only) 
Much better now than one week ago                                                                                    1 
Somewhat better now than one week ago                                                                            2 
About the same as one week ago                                                                                         3 
Somewhat worse now than one week ago                                                                            4 
Much worse now than one week ago                                                                                    5 
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3. The following questions are about activities you might do during a typical day.  Does 
your health now limit you in these activities?  If so, how much? 
                                                                                                     (circle one number on each line) 
 
ACTIVITIES 
Yes, 
Limited 
A Lot 
Yes, 
Limited 
A Little 
No, Not 
Limited
At All 
Vigorous activities, such as running, lifting heavy 
objects, participating in strenuous sports 
1 2 3 
Moderate activities, such as moving a table, pushing a 
vacuum cleaner, bowling, or playing golf 
1 2 3 
Lifting or carrying groceries 1 2 3 
Climbing several flights of stairs 1 2 3 
Climbing one flight of stairs 1 2 3 
Bending, kneeling, or stooping 1 2 3 
Walking more than a mile 1 2 3 
Walking half a mile 1 2 3 
Walking one hundred yards 1 2 3 
Bathing or dressing yourself 1 2 3 
 
4. During the past week, have you had any of the following problems with your work or other 
regular daily activities as a result of your physical health? 
                                                                                                       circle one number on each 
line) 
 YES NO 
Cut down on the amount of time you spent on work or 
other activities 
1 
 
2 
Accomplished less than you would like 1 2 
Were limited in the kind of work or other activities 1 2 
Had difficulty performing the work or other activities (for 
example, it took extra effort) 
1 2 
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5. During the past week, have you had any of the following problems with your work or other 
regular daily activities as a result of any emotional problems (such as feeling depressed 
or anxious)? 
                                                                                                     (circle one number on each 
line) 
 YES NO 
Cut down on the amount of time you spent on work or other activities 1 2 
Accomplished less than you would like 1 2 
Didn't do work or other activities as carefully as usual 1 2 
 
 
6. During the past week, to what extent has your physical health or emotional problems 
interfered with your normal social activities with family, friends, neighbours, or groups? 
                                                                                                                (circle one number only) 
Not at all                  
…………………………………………………………………………….1 
Slightly                     
…………………………………………………………………………….2 
Moderately               
…………………………………………………………………………….3 
Quite a bit                
…………………………………………………………………………….4 
Extremely                
…………………………………………………………………………….5 
 
 
7. How much bodily pain have you had during the past week? 
                                                                                                               (circle one number only) 
None                        …………………………………………………………………………….1 
Very mild                 ……………………………………………………………………………..2 
Mild                         .…………………………………………………………………………….3 
Moderate                ……………………………………………………………………………..4  
Severe                    ……………………………………………………………………………..5 
Very severe            ……………………………………………………………………………..6 
 
 
8. During the past week, how much did pain interfere with your normal work (including both 
work outside the home and housework)? 
                                                                                                             (circle one number only) 
Not at all                   …………………………………………………………………………….1 
A little bit                  …………………………………………………………………………….2 
Moderately               ……………………………………………………………………………3 
Quite a bit                …………………………………………………………………………….4 
Extremely                …………………………………………………………………………….5 
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9. These questions are about how you feel and how things have been with you during the 
past week.  For each question, please give the one answer that comes closest to the way 
you have been feeling.  How much of the time during the past week. 
                                            (circle one number on each line) 
 
 All of 
the 
Time 
Most of 
the Time 
A Good 
Bit of the 
Time 
Some 
of the 
Time 
A 
Little 
of the 
Time 
None 
of the 
Time 
Did you feel full of life? 1 2 3 4 5 6 
Have you been a very 
nervous person? 
1 2 3 4 5 6 
Have you felt so down in 
the dumps that nothing 
could cheer you up? 
1 2 3 4 5 6 
Have you felt calm and 
peaceful? 
1 2 3 4 5 6 
Did you have a lot of 
energy? 
1 2 3 4 5 6 
Have you felt 
downhearted and low? 
1 2 3 4 5 6 
Did you feel worn out? 1 2 3 4 5 6 
Have you been a happy 
person? 
1 2 3 4 5 6 
Did you feel tired? 1 2 3 4 5 6 
 
 
10. During the past week, how much of the time has your physical health or emotional 
problems interfered with your social activities (like visiting with friends, relatives, etc.)? 
 (circle one) 
All of the time  …………………………………………………………………………….1 
Most of the time       …………………………………………………………………………….2 
Some of the time     …………………………………………………………………………….3 
A little of the time     …………………………………………………………………………….4 
None of the time      …………………………………………………………………………….5 
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11. How TRUE or FALSE is each of the following statements for you? 
                                                                                                (circle one number on each line) 
 Definit
ely 
True 
Mostly 
True 
Don't 
Know 
Mostl
y 
False 
Definitely 
False 
I seem to get ill a little 
easier than other 
people 
1 2 3 4 5 
I am as healthy as 
anybody I know 
1 2 3 4 5 
I expect my health to 
get worse 
1 2 3 4 5 
My health is excellent 1 2 3 4 5 
 
Thank you 
 
Figure 3.15: SF-36 questionnaire 
3.5 Assessment of Specific Aspects of MS 
3.5.1 Disability 
Disability was measured with the Expanded Disability Status Scale (EDSS) (Kurtzke, 
1983), which is commonly used in patients with MS both in research and clinical 
practice. The EDSS scale ranges from 0 to 10 in 0.5 unit increments that represent 
higher levels of disability and is principally based on ambulatory ability of the 
patient. For scores between 1 and 4.5 the patient is able to walk, and the score is 
mainly based on evaluation of 8 functional system: pyramidal, cerebellar, brain 
stem, sensory, bowel and bladder, visual function, cerebral and mental function 
and lastly any other system. 
With an EDSS above 5 mobility is impaired, at 7 the patient is wheelchair-bound, 
and for scores above 8 the patient is bed-bound.  
 
  Chapter 3: Methods 
81 
 
Figure 3.16: Rating neurologic impairment in MS: an expanded disability status 
scale (EDSS).  
Disability is thought to be dependent on spinal cord involvement by MS, a common 
site of demyelinating lesions (Oppenheimer, 1978). About 90% of patients with MS 
have spinal cord lesions, and most will have them at presentation, whether diffuse 
or localized. The use of MRI using multi-array coils and fast spin echo has allowed to 
study in vivo the load, site and characteristics of lesions, and to correlate these 
factors with clinical features. In a seminal study, scans of the brain and the spinal 
cord of 80 MS patients, and it was observed that whilst there is no correlation 
between load of cord lesions on imaging and MS symptoms, it appears that spinal 
cord atrophy (signifying axonal loss) is a good radiological marker that correlates 
with clinical disability as measured with EDSS (Kidd et al, 1996; Kidd et al, 1993). In 
this study patients with MS who had cord atrophy at one or more of four spinal 
cord levels (C5, T2, T7 and T11), had significantly higher scores on the EDSS than 
those who did not have atrophy. The lack of correlation between symptoms and 
spinal cord load might be the consequence of limitations in MRI resolution, and this 
aspect was further highlighted in a study of serial MRIs, where in the presence of 
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increased disability there was no evidence of new appearing active lesions (Kidd et 
al, 1996). This could be the result the inability of MRI to detect new small but 
clinically relevant lesions or the result of axonal loss within pre-existing lesions. In 
fact pathological heterogeneity of the lesions cannot be differentiated with 
conventional T2-weighted MRI. This study further confirmed that the most reliable 
marker that is detectable on MRI is cord atrophy, which correlates with EDSS (Kidd 
et al, 1996; Kidd et al, 1993; Losseff et al, 1996) and is a reflection of diffusion of 
spinal cord disease (Lycklama a Nijeholt et al, 2000). 
Spinal cord atrophy is measured as Mean Upper Cervical Cord Area (MUCCA) on 
magnetic resonance imaging (MRI). Usually the area imaged is at the level of C1-C2 
(13,14) and measurements in this region are thought to be more accurate. 
Moreover, lower regions are commonly affected by movement artifacts due to 
breathing and swallowing. 
A very recent, study measured MUCCA in 196 MS patients and 55 healthy controls, 
and confirmed that cervical cord atrophy is independently associated with clinical 
disability, as well as reduced mobility. The authors concluded that MUCCA is a 
relevant marker for clinical disability in long-standing disease, independent of other 
MRI measures. Finally MUCCA is also associated with the number of spinal cord 
lesions (Daams et al, 2014). This in line with a previous multicenter study (Losseff et 
al, 1996) that employed different image acquisition protocol. Losef et al. measured 
normalized cross-sectional area at the C2-C5 level in 212 MS patients in 3 European 
centers. 
From appraisal of this evidence it appears that EDSS is a good surrogate marker of 
spinal cord atrophy at cervical level. This is in relation with extent of spinal cord 
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disease and therefore we elected to employ EDSS to clinically quantify spinal cord 
disease in our cohort.  
On the basis of these considerations we judged that employing a clinical surrogate 
of spinal cord disease we could avoid costly, time-consuming and possibly 
inaccurate imaging. 
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Table 3.1: Expanded disability status scale (EDSS) 
EDSS score 
CHAPTER 4: Description 
0 No disability, minimal signs in one FS 
1.5 No disability, minimal signs in more than one FS 
2 Minimal disability in one FS 
2.5 Mild disability in one FS or minimal disability in two FS 
3 Moderate disability in one FS, or mild disability in three or four FS. No 
impairment to walking 
3.5 Moderate disability in one FS and more than minimal disability in 
several others. No impairment to walking 
4 Significant disability but self-sufficient and up and about some 12 
hours a day. Able to walk without aid or rest for 500m 
4.5 Significant disability but up and about much of the day, able to work 
a full day, may otherwise have some limitation of full activity or 
require minimal assistance. Able to walk without aid or rest for 300m 
5 Disability severe enough to impair full daily activities and ability to 
work a full day without special provisions. Able to walk without aid or 
rest for 200m 
5.5 Disability severe enough to preclude full daily activities. Able to walk 
without aid or rest for 100m 
6 Requires a walking aid - cane, crutch, etc - to walk about 100m with 
or without resting 
6.5 Requires two walking aids - pair of canes, crutches, etc - to walk 
about 20m without resting 
7 Unable to walk beyond approximately 5m even with aid. Essentially 
restricted to wheelchair; though wheels self in standard wheelchair 
and transfers alone. Up and about in wheelchair some 12 hours a day 
7.5 Unable to take more than a few steps. Restricted to wheelchair and 
may need aid in transferring. Can wheel self but cannot carry on in 
standard wheelchair for a full day and may require a motorised 
wheelchair 
8 Essentially restricted to bed or chair or pushed in wheelchair. May be 
out of bed itself much of the day. Retains many self-care functions. 
Generally has effective use of arms 
8.5 Essentially restricted to bed much of day. Has some effective use of 
arms retains some self-care functions 
9 Confined to bed. Can still communicate and eat 
9.5 Confined to bed and totally dependent. Unable to communicate 
effectively or eat/swallow 
10 Death due to MS 
FS = functional system 
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3.5.2 MS impact 
The impact of MS on patients’ lives was recorded in study 4 with the MSIS-29 
questionnaire (Hobart et al, 2001), which is a validated instrument to evaluate both 
the physical and psychological impact of the disease (Hobart et al, 2005; 
Hoogervorst et al, 2004). The MSIS-29 scores range between 29 and 145 and 
indicating respectively ‘no impact at all’ and life ‘extremely affected’ by MS. 
Multiple Sclerosis Impact Scale (MSIS-29) 
 
 The following questions ask for your views about the impact of MS on your day-to-
day life during the past two weeks
 
 
 
 For each statement, please circle the one number that best describes your situation  
 
 Please answer all questions  
 
In the past two weeks, how 
much has your MS limited 
your ability to... 
Not 
at all 
A 
little 
Moderately Quite 
a bit 
Extremely 
 
1. Do physically demanding 
tasks? 
 
1 2 3 4 5 
2. Grip things tightly (e.g. 
turning on taps)? 
1 2 3 4 5 
3. Carry things? 
 
1 2 3 4 5 
 
In the past two weeks, how 
much have you been bothered 
by... 
Not 
at all 
A 
little 
Moderately Quite 
a bit 
Extremely 
 
4. Problems with your 
balance? 
 
1 2 3 4 5 
5. Difficulties moving 
about indoors? 
1 2 3 4 5 
6. Being clumsy? 
 
1 2 3 4 5 
7. Stiffness? 
 
1 2 3 4 5 
8. Heavy arms and/or 
legs? 
1 2 3 4 5 
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9. Tremor of your arms or 
legs? 
 
1 2 3 4 5 
10. Spasms in your limbs? 
 
1 2 3 4 5 
11. Your body not doing 
what you want it to do? 
1 2 3 4 5 
12. Having to depend on 
others to do things for 
you? 
1 2 3 4 5 
  
In the past two weeks, how 
much have you been bothered 
by... 
Not 
at 
all 
A 
little 
Moderately Quite 
a bit 
Extremely 
 
13. Limitations in your social 
and leisure activities at 
home? 
1 2 3 4 5 
14. Being stuck at home more 
than you would like to be? 
1 2 3 4 5 
15. Difficulties using your 
hands in everyday tasks? 
1 2 3 4 5 
16. Having to cut down the 
amount of time you spent 
on work or other daily 
activities? 
1 2 3 4 5 
17. Problems using transport 
(e.g. car, bus, train, taxi, 
etc.)? 
1 2 3 4 5 
18. Taking longer to do 
things? 
 
1 2 3 4 5 
19. Difficulty doing things 
spontaneously (e.g. going 
out on the spur of the 
moment)? 
1 2 3 4 5 
20. Needing to go to the toilet 
urgently? 
1 2 3 4 5 
21. Feeling unwell? 
 
1 2 3 4 5 
22. Problems sleeping? 
 
1 2 3 4 5 
23. Feeling mentally fatigued? 
 
1 2 3 4 5 
24. Worries related to your 
MS? 
 
1 2 3 4 5 
25. Feeling anxious or tense? 1 2 3 4 5 
26. Feeling irritable, 1 2 3 4 5 
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impatient, or short 
tempered? 
27. Problems concentrating? 
 
1 2 3 4 5 
28 Lack of confidence? 
 
1 2 3 4 5 
29. Feeling depressed 1 2 3 4 5 
  
 
Figure 3.17: Multiple Sclerosis Impact Scale (MSIS-29) 
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CHAPTER 4: PREVALENCE OF BLADDER AND BOWEL 
SYMPTOMS IN PATIENTS WITH MULTIPLE SCLEROSIS  
Gut dysfunction in patients with Multiple Sclerosis and the role of spinal cord 
involvement by the disease 
G. Preziosi, D. Raptis, A.Raeburn, K. Thirrupathy, J. Panicker, P. Boulos, A.V. 
Emmanuel.  
Eur J Gastroenterol Hepatol. 2013 Sep;25(9):1044-50 
4.1 Chapter Layout 
Having discussed the rationale for this thesis, and the background of cortical and 
spinal involvement, I will describe my first study. Since bladder dysfunction has 
been studied for longer and in more detail, it has become clear that selective 
plaque involvement in the spinal cord can predict symptom pattern with bladder 
dysfunction. To understand the landscape better, I undertook this initial study to 
look at the overlap prevalence of bladder and bowel symptoms in MS. 
4.2 Abstract 
Background: Bowel and bladder symptoms are both highly prevalent in patients 
with MS. Bladder dysfunction (affecting 75% of these patients) is caused by disease 
in the spinal cord, whilst the neural alteration causing bowel dysfunction is 
unknown.  
Hypothesis: My primary hypothesis is that bowel dysfunction in MS is secondary to 
extent of spinal cord involvement by the disease, assessed clinically with the 
Expanded Disability Status Scale. Pathways regulating bowel and bladder lie in close 
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proximity within the spinal cord, and co-existence of their dysfunction might be the 
result of common pathophysiology, and prevalence of bladder symptoms should be 
greater in patients with MS and bowel symptoms. 
Objective: To evaluate prevalence of bladder symptoms in patients with MS and 
bowel symptoms. We also evaluated how patient-reported symptoms quantify 
bowel dysfunction, and any correlation between patient-reported bowel and 
bladder symptoms.  
Design: The NBD questionnaire results and the presence of bladder symptoms were 
recorded. Both bowel and bladder symptoms were quantified by patient-reported 
frequency, expressed as a time percentage (0%, 25%, 50%, 75%, 100% of the time 
the symptom was perceived), and patient-reported severity on a VAS between 0-
100. Correlation analysis was performed. 
Settings: Specialist neurogastroenterology clinic, tertiary referrals centre. 
Patients: Seventy-one patients with MS and bowel symptoms (55 female, age 43±9, 
median disease duration 78±43 months) 
Results: Prevalence of bladder symptoms was 85%. The NBD score was significantly 
correlated with both patient-reported frequency (r=0.860, p<0.0001) and severity 
of bowel symptoms (r=0.659, p=<0.0001). Patient-reported frequency and severity 
of bowel and bladder symptoms were also correlated (r=0.367, p=0.002 and 
r=0.463, p<0.0001 respectively).  
Conclusions: Prevalence of bladder symptoms is higher than expected in patients 
with MS and bowel symptoms, suggesting a common pathophysiology of bowel and 
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bladder dysfunction. Patient-reported bowel symptoms quantified well bowel 
dysfunction, and are correlated with patient-reported bladder symptoms.  
4.3 Introduction 
The primary hypothesis of my thesis is that spinal cord disease in patients with MS 
is central to developing bowel symptoms. In this study I attempt to demonstrate 
this through a prevalence study. I also analysed how well bowel dysfunction is 
assessed by patient-reported bowel symptoms, and any correlations between 
patient-reported bowel and bladder symptoms. 
4.4 Formulation of the Hypothesis for a Prevalence Study 
Bladder dysfunction, affecting around 75% of MS patients (DasGupta & Fowler, 
2003), has been well characterised. It is established that MS plaques in the spinal 
cord are central in causing urinary symptoms (Betts et al, 1993), and their 
treatment has been rationalised and standardised (Gilman et al, 1998). 
Neurological pathways regulating pelvic organs are in close proximity within the 
spinal cord. The spinal pathway for defecation, operating through the sacral roots 
S2-S4, lies in the lateral column of the cord, in close proximity to the pathways 
important for bladder control (Nathan & Smith, 1951; Nathan & Smith, 1953; 
Nathan & Smith, 1958).  
The neural pathways concerned with physiological bladder control operate through 
complex bulbo-spinal-bulbar pathways, in close proximity to the lateral pyramidal 
tracts, and are mediated peripherally through the sacral roots S2 to S4 (Bradley et 
al, 1974; De Groat, 1979). Cortical voluntary control of micturition is established by 
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connection of the frontal cortex to the micturition centre in the pons (McLellan, 
1939).  
So it is unsurprising bowel and bladder symptoms often co-exist in MS patients 
(Hinds et al, 1990; Munteis et al, 2006; Nordenbo et al, 1996). When this is the 
case, it could be that demyelinating lesions in the spinal cord simultaneously affect 
bladder and bowel function. However in a study of MS patients with bladder 
dysfunction (Chia et al, 1995), the prevalence of bowel symptoms was only around 
50%. This apparent discrepancy could be explained by the presence of the gut’s 
ENS, which would allow preservation of some bowel function in the presence of 
altered extrinsic hindgut modulation; this compensatory mechanism is not available 
to the bladder. My primary hypothesis is that bowel dysfunction in MS is secondary 
to extent of spinal cord involvement by the disease, assessed clinically with the 
Expanded Disability Status Scale. To test this in a prevalence study, I hypothesised 
that if bowel and bladder dysfunction can be caused by the same MS-related 
neurological alteration, in a selected population of MS patients with bowel 
symptoms a higher prevalence of bladder symptoms should be observed than in 
the general MS population. The aim of this study is to test this hypothesis. I also 
analysed how well bowel dysfunction is assessed by patient-reported bowel 
symptoms, and any correlations between patient-reported bowel and bladder 
symptoms. 
4.5 Patients and Methods 
Entry criteria were a definite diagnosis of MS and normal bowel function prior to 
onset of MS. Exclusion criteria included: concomitant primary bowel pathology, co-
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morbidities (i.e. diabetes, thyroid dysfunction, coeliac disease, prostate 
hypertrophy, etc.) and sphincter injury. These were ruled out in all patients by 
means of a negative investigation (colonoscopy, radiological or laboratory test) as 
appropriate. We recruited to the study 71 consecutive patients with MS referred 
for bowel symptoms to a specialist neuro-gastroenterology clinic, in a tertiary 
referrals unit. None of the patients met any of the exclusion criteria. Disability was 
measured with the EDSS (Kurtzke, 1983).     
4.6 Symptoms Assessments 
In this study I adopted the NBD questionnaire and patient-reported symptoms of 
bowel and bladder dysfunction, which were described in Chapter 3. 
4.7 Study Design and Statistical Analysis 
Scores from questionnaires and outcome of outpatient interviews were 
prospectively collected. Prevalence of bladder dysfunction was established as the 
presence of at least one urinary symptom at least 25% of the time. Data were 
either ordinal or not normally distributed (according to Kolmogorov-Smirnov test), 
so are expressed as median and inter-quartile ranges and non-parametric tests 
were employed. Correlations between our parameters (EDSS, MS type and 
duration, NBD and patient-reported bowel and bladder symptoms) were evaluated 
with the Spearman’s Rank test.  
To evaluate how patient-reported symptoms quantified bowel dysfunction, we 
analysed correlations between NBD scores and patient-reported bowel symptoms 
with the Spearman’s rank test (r= correlation coefficient). The values of the NBD 
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score for each of the four different categories of patient-reported frequency of 
bowel symptoms (25%, 50%, 75%, 100%) were compared with the Kruskal-Wallis 
test. Statistical significance was two-sided, and declared for p values ≤ 0.05.  
4.8 RESULTS 
Patient’s characteristics are reported in Table 4.1. Of the interviewed patients, 85% 
had some degree of urinary symptoms. 
 
Table 4.1: Patients’ baseline characteristics 
 
All cohort 
(n=71, 
55 female) 
Primary 
progressive MS 
(n=16,  
13 female) 
Secondary 
progressive MS 
(n=30 
23 female) 
Relapsing 
remittimg MS 
(n=25,  
19 female) 
Age 43±9 39±10 44±8 45±8 
Disease 
duration 
(months) 
78±43 58 (33.5 – 107.5) 84.5 (55-104) 67 (45-89) 
EDSS 3 (1-4) 1.5 (0.5-3) 3.5 (1-4.5) 3.5 (1.75-4) 
NBD score 8 (6-13) 5.5 (4-8) 10.5 (6-14) 8 (7-18) 
 
4.8.1 Correlation Analysis  
Correlation of EDSS, MS type and duration, NBD and patient-reported bowel 
symptoms is summarised in Table 4.2. Figure 4.1 shows graphically the correlation 
between EDSS and NBD.  
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Table 4.2: Correlation analysis of bowel symptoms and patients’ characteristics 
 Relapsing 
Remitting  
MS (25) 
Primary 
Progressive 
MS (16) 
Secondary 
Progressive 
MS (20) 
Disease 
Duration 
(70, 47-
100) 
EDSS 
(3, 1-4) 
NBD 
score 
r= 0.168 
p= 0.161 
r= -0.355 
p= 0.002 
r= 0.137 
p= 0.253 
r= 0.125 
P= 0.297 
r= 0.526 
p<0.0001 
Bowel 
symptoms 
patient-
reported 
frequency 
r= 0.168 
p= 0.161 
r= -351 
p= 0.003 
r= 0.153 
p= 0.203 
r= 0.169 
p= 0.160 
r= 
0.645 
p<0.0001 
Bowel 
symptoms 
patient-
reported 
severity 
r= 0.21 
p= 0.873 
r= -0.120 
p= 0.318 
r= 0.81 
p= 0.500 
r= 0.79 
p= 0.512 
r= 
0.112 
p= 0.352 
Data are reported with median and range; Spearman’s Rank correlation coefficients (r) 
are given along with p value. Disease duration is in months. Statistically significant 
correlations are showed in bold.  
 
Figure 4.1: Correlation between EDSS and NBD (Spearman’s rank test) 
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The correlation between bowel and bladder patient-reported symptoms is 
summarised in Table 4.3 and shown graphically in Figure 4.2. 
Table 4.3: Correlation analysis of bowel and bladder symptoms 
 
Bladder symptoms 
Patient- reported 
frequency 
(50%, 0-100%) 
 
Patient-reported 
severity  
(41, 0-93) 
 
Bowel 
symptoms 
NBD 
(median 8, range 1-30) 
r=0.342 
p= 0.003 
r= 0.659 
p<0.001 
Patient reported frequency 
(50%, 25-100%) 
r= 0.367 
p= 0.002 
r= 0.300 
p= 0.011 
Patient -reported severity  
(median 58, range 11-96) 
r= 0.300 
p= 0.011 
r=0.463 
p<0.0001 
Spearman’s Rank correlation coefficient and p values are given for correlation analysis 
of variable of bowel and urinary dysfunction. All correlations were statistically 
significant.  
 
Figure 4.2: Scatter plot showing correlation between patient-reported bowel and 
bladder patient-reported severity of symptoms. 
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4.8.2 Evaluation of Patient-Reported Symptoms 
NBD scores were correlated with patient-reported frequency (r=0.860, p<0.0001) 
and severity (r=0.659, p<0.0001) of bowel symptoms. There was a significant 
difference between the values of NBD scores in the four categories of patient-
reported frequency of bowel symptoms (Table 4.4 and Figure 4.3). EDSS was 
positively correlated with patient-reported frequency (r=0.645, p<0.0001) but not 
with patient-reported severity (r=0.112, p=0.352) (figures 4.4 and 4.5) 
 
Table 4.4: Comparison of NBD scores between the four categories of bowel 
symptoms patient reported frequency 
Bowel symptoms 
patient-reported 
frequency 
Neurogenic Bowel 
Dysfunction score 
Kruskal-Wallis 
test 
25% 4 (3-5.5) 
p <0.001 
50% 8 (6-9.5) 
75% 17 (11-20) 
100% 26.5 (21-29.5) 
 
In this table values of NBD scores for each group of bowel symptoms patient-reported 
frequency are shown. 
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Figure 4.3: Comparison of NBD scores between the four categories of patient-
reported frequency of bowel symptoms.  
P value of Kruskal-Wallis test was <0.001 for all comparisons.  
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Figure 4.4: Scatter plot showing correlation between EDSS and patient-reported 
severity of bowel symptoms. 
 
4.9 Discussion 
In this study I have showed that the NBD score was strongly correlated with 
disability (EDSS). As discussed in section 3.5.1, EDSS is a clinical indicator of spinal 
cord involvement by MS. Also the prevalence of bladder dysfunction in our cohort 
was very high. 
These findings suggests that gut dysfunction in patients with MS is secondary to 
spinal cord involvement by the disease. 
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In patients with primary progressive disease there was an inverse relationship with 
bowel symptoms (i.e. the higher the EDSS the lower the level of symptoms). The 
lower level of disability of this sub-group might explain this, but it might just 
indicate that patients with other MS types have more bowel symptoms. 
 Patient-reported frequency and severity of bowel and bladder symptoms 
were correlated. 
 With regards to bowel symptoms evaluation, simple questioning of patient-
reported frequency and severity of bowel symptoms is as accurate as a 
validated questionnaire.  
Therefore physicians in the clinical setting would be able to assess the impact of 
bowel dysfunction by asking the percentage of time these symptoms are perceived. 
On the other hand, the NBD score could be employed to improve quality of bowel 
studies in patients with MS. 
4.9.1 Strengths 
The main strength of this study is the methodology used to evaluate our 
hypothesis, which is supported by anatomical considerations and supportive 
evidence (Section 1.4.2). Also the low level of disability in this cohort reduced the 
effect of confounders such as reduced mobility and polypharmacy. 
4.9.2 Limitations 
 A relevant limitation is the lack of a control group without bowel symptoms. 
Unfortunately, bowel symptoms are so prevalent that it is very difficult to 
recruit into a study such a reference population.  
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 It is well know that anti-muscarinic drugs used for urological symptoms can 
cause constipation, and this could be a confounding factor affecting our 
findings. Still in one study (Chia et al, 1995), where patients were receiving 
pharmacological treatment for bladder dysfunction, no higher occurrence of 
bowel symptoms was observed. Unfortunately we did not record drugs 
taken at the time. Antimuscarinic could hypothetically mask symptoms of 
faecal incontinence, ultimately making patients overall more constipated. 
Nevertheless patients with higher disability had high scores in both 
constipation and incontinence, suggesting that the confounder effect of 
drugs, if present was minimal. In some of our male patients the presence of 
undetected prostate hypertrophy might also have contributed to bladder 
symptoms.  
 A high prevalence of bladder symptoms in our cohort could have been 
related to small sample size. 
 Another limitation of this study is that bladder symptoms were not 
quantified using a standard questionnaire. The correlation of patient-
reported bowel and bladder symptoms merits further evaluation, employing 
a validated urological questionnaire. 
 An element that requires further discussion is the low level of disability in 
our cohort. In fact for an EDSS of less than 5, other functional systems other 
than the spinal cord are relevant. 
  Chapter 4: Prevalence 
101 
 Our correlation analysis does not constitute a formal validation of the NBD 
in MS patients; however it shows a good correlation between a formal 
questionnaire and simple questioning of patient symptoms. 
 
I have so far discussed the anatomical basis for my hypothesis and the indirect 
evidence that is available in the literature. This study of prevalence is a step further 
to proving the role of the spinal cord in determining bowel dysfunction in MS 
patients. I will describe next the physiology study. 
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CHAPTER 5: STUDY OF AUTONOMIC RECTAL 
ALTERATIONS IN PATIENTS WITH MULTIPLE 
SCLEROSIS AND BOWEL SYMPTOMS: A COMPARISON 
WITH SPINAL CORD INJURY AND NORMAL CONTROLS  
Autonomic rectal dysfunction in patients with multiple sclerosis and bowel 
symptoms is secondary to spinal cord disease 
G.Preziosi, D. Raptis, A. Raeburn, J. Panicker, A.V. Emmanuel. 
Disease of Colon and Rectum, April 2014 - Volume 57 - Issue 4 - pp 514-521 
 
5.1 Chapter Overview 
The content of this chapter represents the key physiological study of this thesis. 
Below I summarise the hypothesis, methods and the results in an abstract format, 
and then I will discuss the study in details. 
5.2 Abstract 
Background: Most patients with MS complain of bowel symptoms, but the 
underlying pathophysiology is unclear.  
Hypothesis: My primary hypothesis is that bowel dysfunction in MS is secondary to 
extent of spinal cord involvement by the disease, assessed clinically with the 
Expanded Disability Status Scale. So a similar disturbance to the one described for a 
SCI above T5 should observed in patients with MS and extensive spinal cord 
disease. 
Objective: To evaluate autonomic rectal dysfunction in patients with MS 
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Design: case-control study 
Settings: Neurogastroenetrology clinic, tertiary referrals centre 
Patients: 45 patients with MS, 19 with a SCI above T5 and 25 normal controls. 
Patients with MS were sub-divided into two groups according to an EDSS below 5 
(MS-minor-disability, n=25) or above 5 (MS-major-disability, n=20), as a reflection 
of spinal cord involvement. 
Main Outcome Measures: Rectal compliance, Wexner-constipation and Wexner-
incontinence scores. 
Results: Data are presented as means and standard deviation. EDSS (4 ± 2) 
correlated with rectal compliance (12.7±5.4mls/mmHg, r=0.410, p=0.005) but not 
with Wexner-Constipation (11±4.7, r=0.075, p=0.626) or Wexner-Incontinence 
scores (8±5.8, r=0.185, p=0.223). 
Rectal compliance (mls/mmHg): Normal controls (11±3.1) vs. MS-minor-disability 
(10.5±4.3) vs. MS-major-disability (15.4±5.6) vs. SCI (18 ± 5.8), p<0.0001. Post-hoc 
analysis: MS-major-disability = SCI > MS-minor-disability = normal controls 
Wexner-constipation: MS-minor-disability (10.8±5.3) vs. MS-major-disability 
(11.3±4.3) vs SCI (15.4±5.8) p=0.037.  
Wexner-incontinence: MS-minor-disability (6.12±4.72) vs. MS-major-disability 
(9.8±6.4) vs SCI (18±5.8) p=0.031.  
Post-hoc analysis showed no significant difference in Wexner-Constipation and 
Wexner-Incontience between the two MS groups.  
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Limitations: Lack of an asymptomatic group with MS and small sample size to 
evaluate bowel symptoms. 
Conclusions: Rectal compliance correlates with disability and observed alterations 
in the rectal properties are secondary to spinal cord involvement. Therefore, in 
neurological patients, rectal compliance is a surrogate of reflex activity of the spinal 
cord regulating rectal function, and both a potential predictor of outcome and 
target for treatment. MS patient sub-groups had similar symptom burden, arguing 
that bowel dysfunction is multifactorial. 
5.3 Introduction 
5.3.1 Background 
I discussed in Chapter 1 how previous studies of hindgut physiology in patients with 
MS have focused on motor and sensitive alterations of the colon and ano-rectum, 
showing delayed bowel transit, anal sphincter weakness and reduced ano-rectal 
sensation. (Wiesel et al, 2001). These alterations though are non-specific and do 
not correlate to a specific neuro-pathophysiological alteration. The demyelinating 
plaques of MS, are ubiquitous in the CNS but plaques in the spinal cord appear to 
be crucial to developing bladder symptoms, and in the previous chapter I discussed 
the evidence that this might also be the case for bowel symptoms (Preziosi et al, 
2013). Furthermore our group have shown that specific symptom patterns 
correlate with alteration of the RAIR (Thiruppathy et al, 2012), suggesting a primary 
role of spinal cord alteration. 
I wished to test my primary hypothesis, that NBD in MS is secondary to extent of 
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spinal cord disease as assessed clinically by EDSS, with a physiological study.  
Existing evidence in SCI research suggests that rectal compliance can be regarded as 
a marker of autonomic dysfunction, and that its changes can be correlated to the 
level of injury (Trivedi P, 2009). In this study patients with a supraconal SCI were 
found to have a higher rectal compliance than those with a lower motoneurone 
injury and normal controls. SCI patients represent an ideal control group, as the 
neurological damage is well defined, and therefore it is clear that in the absence of 
other factors (parity, drugs or co-morbidities) the observed ano-rectal physiological 
alteration can be attributed to a primary spinal cord damage. 
5.3.2 Anatomical Considerations 
The sympathetic supply to the large bowel arises from the T5-L3 nerve roots. The 
vagus nerve supplies parasympathetic fibres up to the splenic flexure. The 
parasympathetic supply to the left colon and rectum arises from the sacral nerve 
roots S2-4 synapsing in the pelvic plexus. As discussed in section 2.4 the 
pathophysiology of bowel dysfunction in a SCI is essentially related to the loss of 
the supraspinal modulation of sympathetic and/or parasympathetic efferents. 
NBD in SCI can be related precisely to the injury level, and so if the alteration is 
above the T5 level, the supra-spinal modulation of the autonomic outflow to the 
large bowel and rectum is lost and rectal compliance is increased, regardless of 
completeness of injury (Trivedi P, 2009).  
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5.3.3 Rectal Compliance 
I have discussed in detail the determinant of rectal compliance and its 
measurement in section 3.3. I will now discuss why I think it can represent a marker 
of autonomic dysfunction of the rectum in MS patients. In the colon the loss of 
supraspinal modulation of autonomic efferents can result in an alteration of transit 
times (Krogh et al, 2000; Krogh et al, 1997; Krogh et al, 2003). Similar alterations of 
motility can occur in the rectum, and are measured as altered rectal compliance 
(Craggs et al, 2006; Trivedi P, 2009), though with conflicting results. Inconsistencies 
might be related to sample size, heterogeneous patient’s cohort or methodology of 
measurement. 
Rectal compliance has been studied in MS patients before and was found to be 
reduced (Nordenbo et al, 1996). That study though had a small sample formed of a 
heterogeneous group of MS-patients, and compliance was measured with a 
surpassed technique. 
5.3.4 Hypothesis and Aims 
My primary hypothesis is that bowel dysfunction in MS is secondary to extent of 
spinal cord involvement by the disease, assessed clinically with the Expanded 
Disability Status Scale. So a similar disturbance to the one described for a SCI above 
T5 should observed in patients with MS and extensive spinal cord disease. The 
resultant autonomic dysfunction of the rectum should be measurable as increased 
rectal compliance. We therefore analysed rectal compliance and its relationship 
with disability (as a surrogate of spinal cord disease) and bowel symptoms in MS 
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and in comparison with patients with a supraconal-SCI and normal controls. We 
also compared symptoms burden and standard ARP tests between MS patients. 
5.4 Patients and Methods 
Patients were recruited at a neuro-gastroenterology clinic at a tertiary referral 
centre, and both verbal and written information were given prior to the patient 
agreeing to sign a consent form. Patients included were aged 18 or over and had 
bowel symptoms for at least 6 months, post-dating a diagnosis of MS or supraconal-
SCI. 
Exclusion criteria were:  
 Concomitant primary bowel pathology  
 Previous colorectal surgery (including haemorrhoidectomy and fistulotomy) 
 Previous sphincter injury, perianal sepsis, rectal prolapse 
 Diabetes  
These were ruled out in all patients by means of a negative investigation 
(colonoscopy, radiological or laboratory test) as appropriate and as part of their 
clinical assessment.  
Normal controls were enrolled by advertisement within the institution. No 
reimbursement was offered for participation. All controls underwent clinical 
assessment to exclude use of any medication or presence of any intestinal or 
chronic illness. 
Between February 2008 and Sept 2010 we recruited to the study 45 patients with 
MS (age 48±10.5 years, 21 females, mean parity 0.8±1) and 23 patients with a 
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supraconal-SCI. We also recruited 25 healthy individuals (14 females, age 54±18) 
without bowel symptoms. 
5.4.1 Disability 
Disability was measured with EDSS. As stated before, the EDSS is an established 
clinical measure of the degree of spinal cord involvement by MS (Kidd et al, 1996; 
Kidd et al, 1993; Losseff et al, 1996). In summary, for values between 1 and 4.5 the 
patient is fully ambulant, between 5 and 7.5 the patient is wheelchair-bound and 
for scores above the patient bed-bound. The first category (1 to 4.5) has less spinal 
cord involvement than those with a score of 5 and above, as manifested by 
impaired mobility. 
5.4.2 Measurement of Rectal Compliance 
Patients were asked to discontinue anti-muscarinic medications for at least one 
week before their appointment. Rectal compliance was measured with the 
methodology described in section 3.3. 
Normal values for rectal compliance varies widely amongst different GI physiology 
units, and ours were obtained by applying this protocol in normal controls where 
the range was 11-15ml/mmHg (Bajwa et al, 2011). 
5.4.3 Bowel Symptoms 
To assess bowel symptoms we adopted the Wexner-constipation (Agachan et al, 
1996) and incontinence (Jorge & Wexner, 1993) questionnaires (Section 3.4.3). The 
incontinence score ranges between 0-20, and the constipation score between 0-30, 
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with 0 representing an absence of symptoms, and 20 or 30 the most burdensome 
level of symptoms. 
5.4.4 Standard Tests of Ano-Rectal Physiology  
Standards test for ARP were performed according to the standardised criteria 
described earlier. 
In summary I measured in all patients with MS: 
 Anal manometry (resting and squeeze pressure) 
 Rectal sensation to balloon distension (threshold, urge and maximum 
tolerated volume) 
 Anal and rectal electro-sensitivity 
5.4.5 Study design 
I firstly evaluated if there was any relationship between disability (EDSS) and rectal 
compliance. 
Patients with MS were divided into two subgroups according to the clinical extent 
of spinal cord disease as evaluated with EDSS. So MS patients with a clinically low 
degree of involvement (EDSS<5) formed the MS-minor disability group (n=25), and 
those with clinically significant spinal cord disease (EDSS≥5) formed the MS-major 
disability group (n=20).  
Rectal compliance (primary outcome measure) was compared amongst the four 
groups. Wexner-constipation and Wexner-incontinence scores (secondary outcome 
measures) were compared between the MS-minor, MS-major disability and SCI 
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groups. Standard ARP parameters (anal manometry and ano-rectal sensation 
measurements) were compared between MS-minor and MS-major disability 
groups. 
5.4.6 Sample Size Calculation 
Rectal compliance in normal controls was normally distributed, and mean and 
standard deviation (RC: 11 ± 3 mls/mmHg), was similar to the values found in other 
studies employing the same distension protocol (Fox et al, 2006). Sample size 
calculation were performed to have 5% overall two-sided significance and 80% 
power to detect a difference of 3 ml/mmHg or greater between any two of the four 
groups. The Bonferroni correction was applied to allow for multiple testing. There 
are six possible comparisons between any two of the four groups so the sample size 
was calculated at the 0.83% significance level in order to retain overall 5% two-
sided significance. In total, 17 individuals were required in each group for the equal 
size group comparisons with 25 healthy controls, and 13 patients for each of the 
comparisons with healthy controls. Thus the study required 25 healthy controls, 
and 17 in each of the patient groups. Dropouts were not considered as only 
patients with completed tests and questionnaires were included in the study. 
5.4.7 Statistical Analysis 
As distributions of the physiological parameters were approximately bell-shaped, 
results are expressed as means and standard deviations, and the t-test and one-way 
analysis of variance with the Bonferroni correction were used for comparisons 
between groups. The Pearson correlation coefficient was used to assess 
correlations between EDSS, rectal compliance and Wexner scores. Comparability 
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between groups with respect to gender was assessed with the chi-squared test. 
Significance tests were two-tailed and the level of significance was set at less than 
or equal to 0.05. 
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5.5 Results 
Baseline characteristics of study participants are shown in Table 5.1.  
Table 5.1: Participants’ baseline characteristics 
 
MS  
(whole 
cohort) 
MS-Minor 
disability 
group 
MS-Major 
disability 
group 
Supraconal-
SCI 
(9 complete – 
10 
incomplete) 
Normal 
Controls 
Age (years) 48±10 45±11 51±9 46±12 54±18 
Gender 
(male/female) 
24/31 8/17 6/14 6/13 11/14 
Disease duration 
(years) 
13±8 12±8 14±9 9±6  
EDSS 4 ± 2 2.6 ± 1.3 6 ± 1 / / 
 
Of the SCI group, nine had a cervical injury, and ten a thoracic injury level above T5. 
In terms of aetiology, 14 had a traumatic injury, two a vascular accident and three a 
cord tumour. The four study groups were checked for comparability with respect to 
age, parity (one-way Anova) and sex (chi-squared test), and no statistical difference 
was identified. 
5.5.1 Correlation between EDSS and Rectal Compliance 
There was a positive and statistically significant correlation between EDSS (4 ± 2) 
and rectal compliance (12.7 ± 5.4 mls/mmHg, r=0.410, p=0.005) (Figure 5.1), but no 
such correlation with Wexner-constipation (11 ± 4.7, r=0.075, p=0.626) or Wexner-
incontinence scores (8 ± 5.8, r=0.185, p=0.223). 
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Figure 5.1: Scatter plot showing quadratic correlation between EDSS and Rectal 
compliance. 
5.5.2 Rectal Compliance 
There was a statistically significant difference in rectal compliance between the four 
groups (p<0.001) (Figure 5.2).  
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Figure 5.2: Comparison of rectal compliance between the 4 groups 
In summary, rectal compliance was higher in patients with SCI and MS-major 
disability group than in the other two groups. Bonferroni correction data are shown 
in Tables 5.2 and 5.3.  
Table 5.2: Comparison of rectal compliance of symptomatic groups vs. normal 
controls  
 
Rectal compliance 
mls/mmHg 
Mean 
difference 
p-value 
Confidence 
interval 
MS-minor disability 
vs. 
Normal controls 
10.5 ± 4.3 
vs. 
11 ± 3.1 
-0.5 1 -4.1 / 3.1 
MS-major disability 
vs. 
Normal controls 
15.4 ± 5.6 
vs. 
11 ± 3.1 
4.3 0.018 0.5 / 8.1 
Supraconal-SCI 
vs. 
Normal controls 
18 ± 5.8 
vs. 
11 ± 3.1 
7 <0.0001 3.1 / 10.8 
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Table 5.3: Comparison of rectal compliance between symptomatic groups 
 
Rectal compliance 
mls/mmHg 
Mean 
difference 
p-value 
Confidence 
interval 
MS-minor disability 
vs. 
MS-major 
10.5 ± 4.3 
vs. 
15.4 ± 5.6 
-4.8 0.006 -8.6 /-1 
MS-minor disability 
vs. 
Supraconal-SCI 
10.5 ± 4.3 
vs. 
18 ± 5.8 
-7.5 <0.0001 -11.3 / -3.6 
MS-major disability 
vs. 
Supraconal-SCI 
15.4 ± 5.6 
vs. 
18 ± 5.8 
-2.65 0.499 -6.7 / 1.43 
 
Rectal compliance was similar between normal controls and MS-minor disability 
patients, and was also similar between MS-major disability and the SCI groups. 
Rectal compliance was higher in the latter two groups than the normal controls and 
the MS-minor group. In summary: MS-major = SCI > MS-minor and Normal controls. 
5.5.3 Wexner-Constipation and Incontinence Scores 
A one-way Anova test comparing the Wexner-constipation score amongst the 
symptomatic groups was statistically significant with a p= 0.020 (Figure 5.3). 
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Figure 5.3: Comparison of Wexner-Constipation scores 
Results of the Bonferroni’s test are shown in Table 5.4.  
Table 5.4: Comparison of Wexner-constipation scores 
 
Wexner 
Constipation 
Mean 
difference 
p value 
Confidence 
interval 
MS-minor disability 
vs. 
MS-major 
10.8 ± 5.3 
vs. 
11.3±4.3 
-0.460 1 -4.5 / 3.6 
MS-minor disability 
vs. 
Supraconal-SCI 
10.8 ± 5.3 
vs. 
15.4 ± 5.8 
-4.5 0.027 -8.65 / -0.41 
MS-major disability 
vs. 
Supraconal-SCI 
11.3±4.3 
vs. 
15.4 ± 5.8 
-4 0.073 -8.41 / 0.27 
 
SCI patients had higher Wexner-constipation scores compared to MS-minor 
disability patients, but similar to MS-major disability patients. However, there was 
no difference between the two MS groups. 
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A one-way Anova test comparing Wexner-incontinence scores amongst the 
symptomatic groups also showed statistically significant differences amongst the 
three groups with a p= 0.048 (Figure 5.4), but the Bonferroni’s test showed no 
significant differences in the coupled comparisons (Table 5.5).  
In summary, there was no difference in symptom burden between the two MS 
groups. 
 
Figure 5.4: Comparison of Wexner-incontinence scores 
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Table 5.5: Comparison of Wexner-incontinence scores 
 
Wexner 
Incontinence 
Mean 
difference 
p value 
Confidence 
interval 
MS-minor disability 
vs. 
MS-major disability 
6.12 ± 4.72 
vs. 
9.8 ± 6.4 
-3.3 0.195 -7.7 / 1 
MS-minor disability 
vs. 
Supraconal-SCI 
6.12 ± 4.72 
vs. 
18 ± 5.8 
-4.217 0.067 -0.8 / 0.2 
MS-major disability 
vs. 
Supraconal-SCI 
9.8 ± 6.4 
vs. 
18 ± 5.8 
-0.887 1 -5.55 / 3.77 
 
5.5.3 Comparison of baseline ano-rectal physiology between MS groups 
The t-test was used to compare baseline ARP tests between the two MS groups 
(Table 5.6), and it showed that urge volume of rectal sensation was higher and anal 
electro-sensitivity was reduced in the MS-major disability group.  
Table 5.6: Comparison of ano-rectal physiology tests MS-minor vs. MS-major 
disability 
 
MS 
minor disability 
MS 
major disability 
p-value 
Resting Pressure 
mmHg 
67 ± 23 59 ± 27 0.259 
Squeeze Pressure 
mmHg 
86 ± 74 60 ± 47 0.155 
Threshold volume 
mls 
79 ±75 118±101 0.146 
Urge Volume 
mls 
127 ± 62 194 ± 102 0.015 
Maximum Tolerated 
Volume 
mls 
208 ± 71 249 ± 81 0.083 
Anal-
electrosensitivity 
mAmp 
24.6 ± 10.9 27.0 ± 15.5 0.028 
Rectal-
electrosensitivity 
mAmp 
10.5 ± 4.2 15.3 ± 5.6 0.555 
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5.6  Discussion 
Our hypothesis of a correlation between spinal cord disease, measured as disability 
(EDSS), and rectal compliance is confirmed by our findings. Evaluation of the rectal 
properties showed that rectal compliance is higher in patients with SCI above T5 
and those MS patients with severe disability than in either MS patients with minor 
disability or healthy volunteers. These findings though were not reflected in 
differences in bowel symptoms, as MS patients with minor and major disabilities 
had similar constipation and incontinence symptom burden. This is at least partly 
explained by the multifactorial nature of bowel dysfunction in MS.  
Comparison of baseline ARP revealed that MS patients with a major disability have 
higher urge volumes for sensitivity to rectal distension and higher threshold for anal 
electrosensitivity, even though the differences measured are small and probably 
not clinically relevant. This suggests mixed somatic and autonomic dysfunction, and 
also that the observed changes in rectal compliance are independent from sensory 
deficit. 
5.6.1 Strengths 
 This is a controlled study that was adequately powered to test our 
hypothesis. 
 Findings add to our theoretical knowledge of rectal physiology and to the 
understanding of MS-related bowel dysfunction. 
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5.6.2 Limitations 
 We employed a surrogate of spinal cord disease, EDSS, and our threshold to 
divide patients as MS-minor or MS-major disability has never been 
employed before. Nevertheless our choice takes into account the well-
described observation that EDSS correlates well with degree of spinal cord 
atrophy (Kidd et al, 1996; Kidd et al, 1993; Losseff et al, 1996); for an EDSS 
of less than 5 the degree of spinal cord atrophy is negligible, whilst for an 
EDSS of above 5 it is considerable. (Kurtzke, 1983). 
MS causes a progressive accumulation of cord lesions scattered at different levels, 
as opposed to the clearly defined level in SCI patients. However the acquisition of 
accurate MRI imaging of the entire spinal cord, to quantify MS lesions, is technically 
challenging and potentially highly inaccurate. We therefore used a surrogate clinical 
parameter of spinal cord involvement by MS (EDSS) that quantified extent, rather 
than level of disease. Most of the cord anatomically lies above T5, and therefore it 
can be assumed that patients with extensive spinal cord disease (EDSS≥5) have 
disease above T5. This explains our choice of a symptomatic control group. As the 
rectum is not under influence of the vagus nerve, the observed alterations of rectal 
compliance are likely to represent the result of loss of supra-spinal modulation of 
the spinal cord reflex activity, and the effect of un-opposed sympathetic outflow 
from the thoraco-lumbar segment. This could be a parallel phenomenon that leads 
to slow colonic transit, commonly observed in MS patients. 
  A limitation of motility studies is usually the lack of reproducibility. Three 
main factors we believe make our measurement reproducible and reliable. 
  Chapter 5: Autonomic Rectal Alterations 
121 
Firstly we employed polyethylene bags with infinite compliance (Krogh et al, 
2001b), an electronic barostat was used for measurements (Diamant et al, 
1999), and our distension protocol has been shown to obtain a reproducible 
measurement of rectal compliance (Bharucha et al, 2004; Fox et al, 2006; 
Hammer et al, 1998).  
 MS patients without bowel symptoms would have constituted an ideal 
control group, but we employed healthy controls for two reasons. One was 
ethical, as we had this data already available questioning whether it would 
have been reasonable to put gut-asymptomatic MS patients through these 
tests. Secondly, given the high prevalence of bowel symptoms in MS, it 
would have been difficult to recruit an asymptomatic MS group.  
5.6.3 Rectal Compliance in Health and Disease 
The importance of coordination of the anal and rectal components of bowel 
evacuation and continence has been demonstrated in healthy subjects (Fox et al, 
2011). It is established that alteration of rectal compliance can play a role in both 
constipation and incontinence in functional bowel disorders. In idiopathic faecal 
incontinence there is reduced rectal compliance that can result in hypersensitivity 
and faecal urgency, which in the presence of a weak anal sphincter can precipitate 
faecal incontinence (Steens et al, 2002). This can be corrected with pharmacological 
manipulation with clonidine, where increasing rectal compliance results in 
amelioration of symptoms (Bharucha et al, 2010).  
In idiopathic constipation there is increased rectal compliance, hyposensitivity to 
rectal filling and hence difficulty with evacuation (Gladman et al, 2006). However 
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some studies in patients with obstructed defecation have shown normal rectal 
compliance (Gosselink et al, 2001). 
Rectal alterations can also occur as the result of primary anatomical damage, and 
rectal compliance is correlated with disease activity in ulcerative colitis (Farthing & 
Lennard-jones, 1978; Rao et al, 1987) and radiation proctitis (Varma et al, 1985). 
After anterior resection of the rectum for cancer, reduced rectal compliance is 
correlated with faecal incontinence, regardless of sphincter function (anterior 
resection syndrome) (Rasmussen et al, 2003). Whilst these changes in rectal 
properties are the consequence of a mechanical damage (radiation, inflammation 
or surgery), in neurological patients, such as those with MS, changes in rectal 
compliance are the result of changes in the tone of the smooth muscle as a 
consequence of altered autonomic function. This has been shown in SCI 
patients,(Craggs et al, 2006; Trivedi P, 2009) though with conflicting results, but 
inconsistencies might have been related to sample size, heterogeneous patient’s 
cohort or methodology of measurement. 
However MS patients present unique features, such as the alternating and 
fluctuating patterns of bowel symptoms. So it is not surprising that in our cohort we 
observed increased rectal compliance in the presence of both constipation and 
faecal incontinence.  
Although ano-rectal alterations are associated with the presence of bowel 
symptoms, we could not demonstrate any specific symptom relationship. It should 
be observed that this study did not address other aspects of gut motility, and has 
been powered to look primarily at rectal properties.  
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Bowel symptoms in MS are likely multi-factorial in aetiology. Disability itself can 
limit the ability to access the toilet and cause behavioural modifications. So patients 
could either ‘learn’ to be constipated (Klauser et al, 1990), to avoid a trip to the 
lavatory, or might be unable to access the toilet in time, hence manifesting faecal 
incontinence (particularly in the presence of a full rectum). This might explain why 
trans-anal irrigation is effective in patients with high disability (Preziosi et al, 2012). 
The proof that behavioural factors come into play is demonstrated, indirectly, by 
improvement with biofeedback (Preziosi et al, 2011), even though pelvic floor 
incoordination might be a primary neurological symptom (Chia et al, 1996). 
Polypharmacy certainly has a role; antimuscarinic and anti-spasticity drugs in 
particular are powerful constipating agents. The latter were discontinued prior to 
testing of rectal compliance, but there is no evidence available to suggest that they 
might have contributed to compliance alterations. 
5.6.4 Future Studies and Wider Implications of our Findings 
What this study showed is that the observed alteration in rectal wall properties in 
MS patients is likely to be the consequence of spinal cord involvement, such that 
severe disability is associated with greater rectal compliance. Further confirmation 
might come from studies that correlate degree of spinal cord atrophy on MRI scans 
with ARP. Adequately powered studies, comparing patients with MS and bowel 
symptoms with a group of MS patients without bowel symptoms, extracted from 
the general MS population, could evaluate the significance of alterations in rectal 
compliance to determine bowel symptoms. 
Our findings also have wider implications. It is accepted that standard tests of ARP 
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(testing of ano-rectal sensation and sphincter pressures) are not specific, and their 
alteration cannot identify a specific underlying neurological abnormality (Diamant 
et al, 1999). This study shows that rectal compliance is a surrogate of reflex activity 
of the spinal cord regulating rectal function. Residual spinal cord function 
represents a potential treatment target, and the usefulness of our finding is that 
this can be clinically assessed with EDSS and measured with rectal compliance. 
Whilst the role of altered rectal compliance in determining bowel symptoms needs 
further evaluation, future studies should assess efficacy of physiotherapy or 
neuromodulation, and whether their effects are associated with modification of 
rectal compliance. Pharmacological modulation of compliance, and hence 
symptoms, could also represent an innovative treatment strategy.  
5.7 Conclusions  
In conclusion, we have shown that ano-rectal properties in MS patients with bowel 
symptoms are altered in predictable fashion, according to degree of disability. 
Symptom burden was very high in both MS groups, suggesting the presence of 
multiple causative factors. 
5.8 Summary of Main Findings 
With this study we have shown that: 
 Rectal compliance correlates positively with the extent of spinal cord 
disease  
 Patients with higher disability have greater threshold for urge sensation at 
rectal balloon distension and reduced ano-rectal electrosensitivity. 
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 Symptoms burden is very high in both MS groups, suggesting the presence 
of multiple causative factors including medications and behavioral factors. 
This has wider implications: 
 With the development of techniques of nerve stimulation, residual spinal 
cord function might represent a target for treatment, and rectal compliance 
might represent a predictive factor of response. 
 Pharmacological modulation of rectal compliance could be a therapeutic 
strategy for the treatment of constipation and incontinence.  
 Furthermore this study has shown that rectal compliance is a good 
surrogate measure of altered reflex activity secondary to spinal cord 
disease.  
In summary, I have discussed so far: 
 Potential pathophysiology of bowel dysfunction in MS. 
 Tested my primary hypothesis with a prevalence and a physiology study. 
I am now going to test my secondary hypothesis, which is that residual spinal cord 
function can be a target of treatment for bowel symptoms in MS. In the next 
chapter I will evaluate bowel biofeedback treatment in patients with MS and bowel 
dysfunction.  
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CHAPTER 6: BOWEL BIOFEEDBACK TREATMENT IN 
PATIENTS WITH MULTIPLE SCLEROSIS AND BOWEL 
SYMPTOMS 
Bowel biofeedback treatment for patients with multiple sclerosis and bowel 
symptoms.  
G.Preziosi, D. Raptis, J. Storrie, A. Raeburn, C.J. Fowler, A. Emmanuel,  
Diseases of the Colon and Rectum 2011: 54(9), 1114–1121  
6.1 Chapter Layout 
Below I provide a summary of the next chapter in the form of an abstract. I then 
discuss in detail the biofeedback study. 
6.2 Abstract 
Background: Bowel biofeedback treatment has a well-established role in the 
treatment of functional constipation and faecal incontinence.  
Objective: This study aimed to identify the effect of biofeedback on bowel 
symptoms, mood and ARP in patients with MS. 
Hypothesis: My secondary hypothesis is that the treatment strategies should target 
residual spinal cord function. The effect of bowel biofeedback treatment is thought 
be mediated by the extrinsic autonomic nervous system, with spinal efferents 
playing a key part. This biofeedback-induced modulation of gut autonomic function 
may be impeded by the underlying neural dysfunction secondary to MS. If this was 
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the case, then successful biofeedback could depend on secondary behavioural 
alterations and/or residual spinal cord function (lower disability).  
Design: This is a prospective observational study: we compared and analysed the 
amount of change between pre- and post-treatment values of outcome measures. 
Responders were considered to be patients who demonstrated an improvement 
greater than or equal to the 25th percentile of the change in bowel score. We then 
compared baseline characteristics between responders and non-responders. 
Settings: Neurogastroenterology clinic, tertiary referrals centre.  
Patients: Thirty-nine patients with MS and constipation and/or faecal incontinence 
Intervention: Bowel biofeedback. 
Main Outcome Measures: Primary: Wexner-constipation and Wexner-incontinence 
scores. Secondary: HADS, ARP parameters. 
Results: Data are reported as median and interquartile ranges. After biofeedback 
there was significant improvement in Wexner-constipation [12(5-19) pre-treatment 
vs. 8(4-14) post-treatment, p=0.001], Wexner-incontinence [12(3-15) pre-treatment 
vs. 4(2-10) post-treatment, p<0.001)] and HADS [7(3-11) pre-treatment vs. 5(3-10) 
post-treatment, p=0.015)]. The 5-seconds-endurance squeeze pressure was also 
improved [21(11-54)mmHg pre-treatment vs. 43(26-59)mmHg post-treatment, 
p=0.001]. Post-treatment change of Wexner-Constipation was -2(-5/0), and of 
Wexner-Incontinence was -3(-9/0) (‘-’ indicates improvement). Therefore those 
patients who had a reduction of at least 5 points in Wexner-constipation and/or of 
at least 9 points in Wexner-incontinence scores were considered responders (18 
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patients, 46%). They showed a greater improvement of only 5-seconds-endurance 
squeeze pressure [23.5(7.5/32.75)mmHg responders vs. 4(-6/20)mmHg non-
responders, p=0.008]; comparing baseline variables with non-responders no 
difference was observed. Significant negative relationship existed between change 
in Wexner-constipation [-2(-5/0)] and pre-treatment Wexner-constipation score 
[12(5/19), β= -0.463, p<0.001)], and change in Wexner-incontinence [-3(-9/0)] with 
pre-treatment Wexner-incontinence score [12(3/15), β= -0.590, p<0.001). So the 
higher the initial bowel symptom score the greater the improvement. 
Limitations: Lack of a control group. 
Conclusions: Biofeedback improves bowel symptoms, depression and 5-seconds-
endurance squeeze pressure in patients with MS.  
6.3 Introduction 
Bowel biofeedback treatment has a well-established role in the treatment of 
functional constipation and faecal incontinence, improving bowel symptoms, pelvic 
floor coordination, ano-rectal sensation and transit time (Enck et al, 2009). 
As discussed in section 1.4, the pathophysiology of bowel dysfunction in MS is 
multifactorial and partly common to both constipation and faecal incontinence 
(Wiesel et al, 2001). Some of the alteration observed represents the potential 
target of bowel biofeedback behavioural treatment. More specifically pelvic floor 
dyssynergia and slow bowel transit, which have been observed in association with 
constipation (Chia et al, 1996; Nicoletti et al, 1992), and anal sphincter weakness 
and rectal hyposensitivity, frequently associated to faecal incontinence (Nordenbo 
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et al, 1996). Pelvic floor dyssynergia could be a behavioural phenomenon as in non-
neurological patients (Halligan et al, 1995) or neurological in origin and parallel to 
bladder neck dyssynergia in MS (Betts et al, 1993).  
In fact it has been proposed for MS patients with lower disability and lesser 
alterations in standard ARP tests (Munteis et al, 2008; Wiesel et al, 2000) (anal 
sphincter manometry and ano-rectal sensation). These studies were limited by the 
small number of patients (Wiesel et al, 2000) and of being retrospective (Munteis et 
al, 2008).  
In patients with bowel disorders, depression and anxiety are classically observed 
traits associated with symptom burden, although it is not known if bowel symptoms 
are the cause or the effect of this (Burnett C, 1998; Nehra et al, 2000). Either way 
they also appear to improve after biofeedback therapy (Mason et al, 2002). The 
role of anxiety and depression in MS related bowel dysfunction, and the effect of 
biofeedback on these, has not been addressed before.  
Along with mood improvement, in non-neurogenic patients biofeedback has been 
shown to induce gut-specific changes in autonomic outflow to the large bowel 
(Emmanuel & Kamm, 2001). These are thought to be mediated by the extrinsic 
autonomic nervous system, with spinal efferents playing a key part (Emmanuel & 
Kamm, 2001). This biofeedback-induced modulation of gut autonomic function may 
be impeded by the underlying neural dysfunction secondary to MS. If this was the 
case, then successful biofeedback could depend on secondary behavioural 
alterations and residual spinal cord function (lower disability).  
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ARP tests can measure anal sphincter pressure and ano-rectal sensation, which can 
both be abnormal in MS (Nordenbo et al, 1996), and it is unclear if these tests can 
provide information on which patients are suitable for biofeedback or if this would 
modify the physiological test outcomes. 
The aim of the study is to evaluate prospectively the effect of biofeedback on bowel 
symptoms, mood and ARP variables in MS and to identify specific characteristics of 
the patients who had greater improvement.  
6.4 Patients and Methods 
Forty-four consecutive patients with bowel dysfunction and MS, seen by a 
consultant (Dr Anton Emmanuel) or myself in a neurogastroenterology clinic at a 
specialist tertiary referral centre and referred for biofeedback, were recruited to 
the study and signed a consent form.  
Entry criteria were:  
 definite diagnosis of MS 
 failure to respond to changes in diet, lifestyle and at least two forms of 
maximal dose laxative therapy  
 bowel symptoms onset post-dating the diagnosis of MS. 
Exclusion criteria were:  
 complete lack of sensation and squeeze at ARP 
 concomitant primary bowel pathology, co-morbidities (i.e. diabetes, thyroid 
dysfunction, coeliac disease, etc.) 
  Chapter 6: Bowel Biofeedback Treatment 
131 
 sphincter injury  
These were excluded in all patients by means of a negative investigation 
(colonoscopy, radiological or laboratory test) as appropriate. Two patients with 
complete lack of sensation and anal squeeze pressure, two who had relapses of 
their MS and one patient lost to follow up, were all excluded from the study.  
Therefore 39 patients [30 females] with constipation and/or faecal incontinence 
were included for analysis. 
6.4.1 Disability 
Disability was measured with EDSS, as discussed in the section 3.5.1. 
6.4.2 Outcome Measures 
Primary outcome measures were the Wexner-constipation (Agachan et al, 1996) 
and Wexner-incontinence (Jorge & Wexner, 1993) scores (section 3.4.3), assessing 
bowel symptoms. Secondary outcome measures were assesses using the HADS 
(Zigmond & Snaith, 1983) (section 3.4.4) to ascertain psychological state, and ARP 
tests. I collected the questionnaires and performed the ARP tests. In order to be 
blinded to questionnaire outcomes, the scores were calculated after all the tests 
had been performed. 
6.4.3 Ano-Rectal Physiology Tests 
Measurements were performed according to standardised criteria, which were 
discussed in section 3.2. 
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In brief, we measured resting anal pressures (resting, squeeze and endurance 
squeeze pressure). Ano-rectal sensation was measured as rectal sensitivity to 
balloon distension (threshold volume of first sensation, urge volume at which urge 
to defecate is first perceived and maximum tolerated volume) and as anal and 
rectal electro-sensitivity. 
6.4.4 Biofeedback 
Biofeedback is based on the theory of operant conditioning behavioural therapy, 
and teaches patients to focus on conscious modification of organic function, hence 
altering behaviour more permanently. According to its original definition, 
information about a physiological process is converted into a simple visual or 
auditory signal to enable the patient to learn to control the disordered function 
(Engel et al, 1974). Since then the technique has been bedevilled by the absence of 
a general consensus on the protocol to be used (Enck et al, 2009; Norton et al, 
2003), and the use of an external device, to feed the physiological information back 
to the patient has also been questioned (Koutsomanis et al, 1995; Norton et al, 
2003; Solomon et al, 2003).  
Biofeedback offered at our Unit is not computer assisted, and has been described 
previously (Chiotakakou-Faliakou et al, 1998; Koutsomanis et al, 1995; Norton et al, 
2003). It is a ‘package of care’ including toileting advice, optimising use of laxatives 
and constipating agents, defecatory habit conditioning and pelvic floor retraining. 
At the first appointment the patient was fully assessed, and toileting advice given. 
At this stage the patient’s test results were explained and he or she was then 
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educated about normal gut function and correct toilet position through the use of 
standardised diagrams.  
Given the mixed nature of symptoms there was some overlap in biofeedback 
strategies, and manoeuvres aimed to improve recto-anal coordination, sensory 
training and improving evacuation were adopted in all patients. For constipation, 
with the patient lying on his or her side a rectal balloon was inserted, and pelvic 
floor dyssynergia was addressed with balloon assisted defecatory coordination 
(Koutsomanis et al, 1995). With the balloon inflated in the rectum, the nurse would 
encourage the patient to recognise progressively lower balloon distensions, to 
improve awareness of rectal content (Rao et al, 1997). The balloon was then 
removed and in the sitting position the patient was taught how to utilise 
diaphragmatic and abdominal musculature (‘brace technique’) to optimise 
evacuation, improving abdominal and pelvic floor coordination. 
If faecal incontinence was present, the difference from the above described 
protocol was that biofeedback strategies included techniques for delaying 
defecation: with the rectal balloon inflated, the patient was encouraged to 
recognise urgency, resist it (if faecal urgency was present) and coordinate rectal 
distension with sphincter contraction (Miner et al, 1990). If hyposensitivity was 
present, lowering distensions were performed for sensory training (Chiarioni et al, 
2002). At the second appointment sphincter exercises to improve voluntary anal 
squeeze were taught (Norton et al, 2003). Crucially treatment was focused, in all 
patients, on reducing the number of inappropriate visits to the toilet and 
maximising rectal emptying. 
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All patients entered in the analysis had completed their treatment, which continued 
over a median period of 11 weeks (range 8-16), and were encouraged to implement 
learned manoeuvres and toileting advice by integrating them into their routine. 
Sessions were spaced four weeks apart, and a median of three sessions (range 2-4) 
comprised the course of treatment, all undertaken by the same therapist (Mrs Julie 
Storrie). The number of sessions was determined by agreeing with the patient if 
maximum success was achieved or no further progress was possible (Chiotakakou-
Faliakou et al, 1998). Two weeks after the final direct visit, the therapist made 
telephone contact with the patient to check on progress and give advice.  
Because of the underlying neurological cause for bowel symptoms and 
polypharmacy, laxatives and constipating agents were not always discontinued, but 
instead reduced or optimised as appropriate. 
6.5 Study Design 
Given the presence of mixed symptoms and overlapping biofeedback strategies, all 
patients were considered as one cohort. Questionnaires and ARP tests were 
undertaken before and after treatment, and values were compared; the degree of 
change occurring in outcome measures was also analysed.  
We wished to identify as responders those patients who had the highest 
improvement in bowel symptoms. So the responders group was formed of patients 
who demonstrated a reduction greater than or equal to the 25th percentile of the 
change in Wexner-constipation and/or Wexner-incontinence scores. Patients 
whose improvement was less than these values formed the non-responders group. 
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The amount of change in secondary outcome measures (HADS and ARP values) 
after treatment was compared between responders and non-responders. To 
identify characteristics of responders we compared baseline variables between the 
two groups. Linear regression analysis was performed to identify what could predict 
successful treatment. 
6.5.1 Statistical Analysis 
Given that the data, based on the Kolmogorov-Smirnov test, were not normally 
distributed, we used non-parametric tests: the Wilcoxon test to compare pre- and 
post-treatment values, and the Mann-Whitney U test to compare values between 
responders and non-responders. Data are expressed as medians and interquartile 
ranges. All calculated p values were two-sided and p values ≤ 0.05 were considered 
statistically significant. Linear regression analysis (β = standardised partial 
regression coefficient) evaluated relationship between change in Wexner-
constipation and Wexner-incontinence scores as dependent variables with 
respectively pre-treatment Wexner-constipation and Wexner-incontinence scores, 
and EDSS, HADS-anxiety and HADS-depression. Statistical analysis was performed 
using the statistical software package SPSS statistics v19 for Mac.  
6.6 Results 
Patient’s characteristics are summarised in table 6.1. 
Table 6.1: Patients’ characteristics 
 
All cohort 
(n=39) 
MS-C1 
(n=14) 
MS-I2 
(n=12) 
MS-CI3 
(n=13) 
Age 38 (31-50) 38 (34-51) 34 (26-49) 38 (36-53) 
Disease Duration (in years) 9 (5-24) 7 (3-23) 11 (7-25) 8 (5-23) 
  Chapter 6: Bowel Biofeedback Treatment 
136 
1= MS Patients with prevalent constipation symptoms, 2=MS patients with prevalent 
incontinence symptoms, 3= MS patients with constipation and faecal incontinence,      
*= Hospital Anxiety and Depression Score. 
6.6.1 Wexner Scores  
After biofeedback there was a significant improvement in Wexner-constipation 
scores [12 (5-19) pre-treatment vs. 8 (4-14) post-treatment, p=0.001, Wilcoxon 
test] and Wexner-incontinence scores [12 (3-15) pre-treatment vs. 4 (2-10) post-
treatment, p<0.001, Wilcoxon test] (Figure 6.1). 
 
Figure 6.1: Pre and post-treatment Wexner-constipation (left) and Wexner-
incontinence (right) 
6.6.2 Hospital Anxiety and Depression Scores  
After treatment, HADS-anxiety remained unchanged [3 (2-7) pre-treatment vs. 3 (2-
6) post-treatment, p=0.067, Wilcoxon test], whilst HADS-depression scores 
significantly improved [median 7 (3-11) pre-treatment vs. 5 (3-10) post-treatment, 
p= 0.015, Wilcoxon test]. 
Expanded Disability Status Scale 5 (3-7) 4 (2-6) 5 (4-8) 4 (3-7) 
Wexner-Constipation score 12 (5-19) 14 (11-22) 3 (2-5) 18 (12-24) 
Wexner-Incontinence score 12 (3-15) 2 (1-4) 15 (13-18) 14 (12-16) 
HADS*-Anxiety 3 (2-7) 2 (1-4) 4 (2-5) 6 (3-11) 
HADS*-Depression 7 (3-11) 5 (2-10) 7 (3-12) 8 (5-15) 
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6.6.3 Ano-Rectal Physiology Tests 
The only physiological parameter to improve after biofeedback (Table 6.2) was the 
5-seconds-endurance squeeze pressure [21 (11-54) mmHg vs. 43 (26-59) mmHg, 
p=0.001, Wilcoxon test]. 
Table 6.2: ARP parameters 
 Pre-treatment Post-Treatment P-value 
Resting Pressure (mmHg) 53 (34-76) 57 (41-77) 0.525 
Squeeze Pressure (mmHg) 53 (35-76) 60 (45-85) 0.152 
5 seconds endurance pressure (mmHg) 21 (11-54) 43 (26-59) 0.001 
Threshold Volume (mls) 55 (40-85) 55 (40-75) 0.182 
Urge Volume (mls) 110 (80-170) 120 (90-150) 0.523 
Maximum Tolerated Volume 225 (150-295) 210 (145-290) 0.816 
Anal Electro-sensitivity (mAmp) 8.5 (6.5-12) 8.4 (6.3-10.9) 0.402 
Rectal Electro-sensitivity (mAmp) 24.4 (18.3-31) 24.0 (17.0-30.0) 0.701 
 
6.6.4 Responders vs. Non-Responders Analysis 
Changes after treatment in individual Wexner-constipation and Wexner-
incontinence are shown in Figure 6.2.  
 
Figure 6.2: Ladder plots of pre- and post-treatment Wexner-constipation (left) 
and Wexner-incontinence (right) 
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The median amount of change in Wexner-constipation was -2 (-5/0), and for 
Wexner-incontinence was -3 (-9/0) (‘-’ indicates improvement, i.e. reduction, while 
positive values a worsening score), so the 25th percentile of the change in Wexner-
constipation was -5 and for Wexner-incontinence was -9. Therefore the threshold 
to declare a patient as a responder was an improvement of at least 5 points in the 
Wexner-constipation score and/or of at least 9 points in the Wexner-incontinence 
score. According to this criterion 18 patients (46%) formed the responders group 
(Figure 6.3).  
 
Figure 6.3: Changes in Wexner scores 
 
Comparing the amount of change in secondary outcome measures with non-
responders, it appeared that responders had a significantly higher improvement in 
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5-seconds-endurance squeeze pressure [23.5 (7.5/32.75) mmHg responders vs. 4 (-
6/20) mmHg non-responders, p= 0.008, Mann-Witney U test] (Table 6.3).  
Table 6.3:Responders vs. non-responders following biofeedback 
 Responders Non-responders p-value 
Change in HADS*- Anxiety 0 (-3.25/0.25) 0 (-1.5/1) 0.269 
Change in HADS*- Depression -1 (-3.25/0) 0 (-2/0.5) 0.443 
Change in Resting Pressure (mmHg) 3 (-6 /13.25) -3 (-12/13.5) 0.321 
Change in Squeeze Pressure (mmHg) 12.5 (-5/29.25) 3 (-15.5/11.5) 0.60 
Change in 5 sec. endurance pressure 
(mmHg) 
23.5 (7.5/32.75) 4 (-6/20) 0.008 
Change in Threshold Volume (mls) -2.50 (-10/15) -10 (-17.5/2.5) 0.245 
Change in Urge Volume (mls) 7.5 (-6.25/21.25) 0 (-15/12.5) 0.460 
Change in Maximum Tolerated Volume 
(mls) 
-10 (-27.5/30) 10 (-20/40) 0.245 
Change in Anal Electro-sensitivity 
(mAmp) 
-1.3 (-2.45/0.725) 0.7 (-1.4/1.6) 0.223 
Change in Rectal Electro-sensitivity 
(mAmp) 
-1 (-4 /2.85) 1.5 (-1.65/3) 0.223 
 
Comparing baseline variables between responders and non-responders no 
difference was observed (Table 6.4). 
Table 6.4: Responders vs. non-responders baseline values 
 Responders Non-responders p-value 
Age 40.5 (33-53) 37 (30-47) 0.335 
EDSS 4 (3-5) 6 (3.5-8.0) 0.94 
Disease Duration 10.5 (4.8-24.8) 8 (4.5-19.0) 0.364 
HADS*- Anxiety 3 (1.8-5.5) 4 (2.5-8.5) 0.234 
HADS*- Depression 4.5 (2.7-8.3) 8 (4-13) 0.1 
Wexner Incontinence 12 (3.7-10) 12 (2-15) 0.512 
Wexner Constipation  12.5 (6-22) 11 (4.5-8.5) 0.530 
Resting Pressure (mmHg) 49 (40-73) 58 (33-82) 0.989 
Squeeze Pressure (mmHg) 55 (50-75) 53 (32-81) 0.707 
5 seconds endurance pressure (mmHg) 22 (15-51) 20 (6.5-6.3) 0.626 
Threshold Volume (mls) 52 (40-79) 60 (33-88) 0.945 
Urge Volume (mls) 105 (80-155) 120 (93-200) 0.364 
Maximum Tolerated Volume (mls) 170 (150-282) 250 (148-303) 0.379 
Anal Electro-sensitivity (mAmp) 7.6 (6.2-18.8) 9.4 (6.8-12.5) 0.512 
Rectal Electro-sensitivity (mAmp) 25.2 (18.8-30.4) 22.0 (15.5-32) 0.587 
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6.6.5 Linear Regression Analysis 
There was a significant negative relationship between the amount of change in 
Wexner-constipation score and pre-treatment Wexner-constipation score (β= -
0.463, p<0.001), but not with EDSS (β=0.316, p=0.537), pre-treatment HAD-anxiety 
(β=0.326, p=0.219) and HADS-depression score (β=-0.129, p= 0.613). 
Similarly, amount of change in Wexner-incontinence score showed a significant 
negative relationship with pre-treatment Wexner-incontinence score (β= -0.590, 
p<0.001), but not with EDSS (β=0.698, p=0.97), pre-treatment HAD-anxiety (β= -
0.48, p=0.819) or HAD-depression score (β=0.206, p=0.317). 
The value of change in Wexner scores is negative (indicating a symptom burden 
reduction) as well as the direction of the relationship with initial Wexner scores. So 
the higher the initial bowel symptom score the greater the improvement. 
6.7 Conclusions 
This study suggests that:  
 Biofeedback behavioural therapy can improve bowel symptoms, refractory 
to standard medical treatment, in patients with MS in the short term. 
 According to our definition, about half of the patients were responders. 
 Bowel scores improved as well as depression score, which suggests the 
presence of a psychological component associated with bowel symptoms 
that is reversible with biofeedback, as in non-neurological patients (Burnett 
C, 1998; Nehra et al, 2000). Nevertheless the amount of improvement was 
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similar in responders and non-responders.  
 Responders had a median EDSS of 4 (low level of spinal cord disease, 
mobility not compromised). 
 Non-responders had a median EDSS of 6 (high level of spinal cord disease, 
mobility severely restricted). 
 High score on the initial bowel symptoms questionnaires predicted a more 
successful treatment, suggesting that biofeedback is also suitable for the 
more symptomatic patients.  
 Incontinence scores had the greatest improvement. This might be the result 
of improved squeeze pressure, but also of better rectal emptying. 
The only physiological parameter that improved was 5-seconds-endurance squeeze 
pressure, and improvement was higher in responders; this suggests that 
amelioration of symptoms was more related to improved toilet-behaviour, 
including improvement of pelvic floor dyssynergia and improved evacuation 
technique, than to changes in physiological parameters. The overall lack of 
significant improvement in physiological variables might be related to the presence 
of a fixed underlying neurological deficit, and may also explain why these tests did 
not have a predictive value in identifying responders. Overall improvement of 
bowel symptoms might be related to secondary physiological changes that were 
not measured in this study. Improvement of 5-seconds-endurance squeeze 
pressure could have been also due to recruitment of residual spinal function, 
secondary to implemented behavioural changes. 
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Responders had a median EDSS of 4 of and non-responders of 6. EDSS values and 
individual changes in Wexner Scores are graphically represented in figure 6.4 and 
6.5. 
 
Figure 6.4: A line is drawn at -9, which was the cut-off to declare a patient a 
responder. 
Please note that 2 responders with EDSS of 5 and 2 with EDSS of 4 had the same 
change in Wexner-Incontinence scores (-12 and -9 respectively).  
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Figure 6.5: A line is drawn at -5, which was the cut-off to declare a patient a 
responder. 
 
It interesting to note that the EDSS of patients who had the most significant 
improvement in Wexner-Incontinence scores was 5 or less. These patients had less 
clinically significant spinal cord disease, and possibly their symptomatic 
improvement might have been related to their ability to improve anal sphincter 
function by recruiting residual spinal cord function. This pattern is not observed for 
changes in constipation scores. If we included also patients with no ano-rectal 
sensation and no anal squeeze, this difference in EDSS might have become 
significant as well as baseline ARP values, but we judged it unethical for patients 
with these characteristics to undergo biofeedback. 
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6.7.1 Strength 
This is the largest series in the literature and its results will assist in any power 
calculations necessary for future case-control or randomised studies.  
6.7.2 Limitations  
This is an observational study, without a control group with alternative treatment. 
Patients with constipation and incontinence were pooled in consideration that 
bowel dysfunction in MS is mixed (as reflected in our cohort) and multifactorial, 
and as a consequence, biofeedback strategies were largely overlapping. Whilst this 
might bring in confounding factors, it is the consequence of inherent characteristics 
of this patients group. 
Laxatives and constipating agents were not discontinued, given the presence of 
irreversible factors such as the underlying neurological condition, and the presence 
of polypharmacy in these patients. On the other hand biofeedback is a ‘package of 
care’ that includes advising patients on drug titration and optimisation by a 
dedicated nurse specialist. Whilst this might means that improvement was partly 
caused by a better use of drugs, this falls within the aims of biofeedback in these 
patients. 
These limitations in our study reflect the lack of - and need for- an agreed 
instrument to measure bowel symptoms, and their impact on quality of life, in 
patients with ano-rectal symptoms and MS.  
We excluded patients with a complete lack of ano-rectal sensation and anal 
squeeze pressure, and this clearly introduced a selection bias. This might explain 
  Chapter 6: Bowel Biofeedback Treatment 
145 
why we didn’t show a statistically significant difference in EDSS and baseline ARP 
tests, as we might have excluded patients with higher disability who were highly 
unlikely to respond. 
There is an important limitation of our definition of responders, which was based 
on the amount of change in symptoms scores. This might have been greater in 
patients with a higher initial score. However, some of the non-responders, with a 
lower initial score, still had a significant benefit from the treatment. 
It is clear that the patient-therapist interaction is a key factor in defining outcomes 
of biofeedback (Norton et al, 2003), and the cost implications of this form of 
intensive therapy restricts its wider availability (Enck et al, 2009). Identifying 
prognostic criteria could render the treatment more cost-efficient, and available. 
This study however does not reveal any characteristic useful to identify which MS 
patient is suitable for biofeedback. In fact there was no statistically significant 
difference between responders and non-responders, but this can be explained by 
the selection bias. 
Finally, a reason for a lack of treatment response might have been cognitive 
impairment that was not evaluated in this study 
In summary, we have shown that biofeedback is an effective option to treat bowel 
symptoms in patients with MS. Depression and 5-seconds endurance squeeze 
pressure can also be improved.  
The variety of biofeedback strategies on one hand, and the specific characteristics 
of MS patients on the other, makes comparison of our results with general 
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literature on biofeedback very difficult. With regards to the effect of biofeedback 
on mood, it appear that our results are in keeping with those observed in idiopathic 
patients (Mason et al, 2002). It is not clear if this is a consequence of symptoms 
improvement or if the mood improvement causes bowel symptoms to be better. 
Pelvic floor coordination, measured as the ability to expel a rectal balloon, improves 
in idiopathic patients (Rao et al, 2010), and it might be that the improved sphincter 
function we have observed is a surrogate of this. In our patients pelvic floor 
coordination was assessed subjectively only by the trainer, Julie Storrie. The 
improvement of colonic transit time (Rao et al, 2010) is probably also an 
epiphenomenon of improve rectal expulsion ability. Sphincter pressure has been 
observed to improve with biofeedback (Rao et al, 1996), but not consistently 
(Boselli et al, 2010), possibly reflecting different strategies of biofeedback. Rectal 
sensation can also be improved with exercises involving lowering distensions (Rao 
et al, 1996), but this was not the case in our cohort. 
Building on these observations future randomised controlled studies should clarify 
criteria for patient’s selection for this therapist-intensive treatment. Clearly 
patients who are refractory to standard treatment and fail to improve with 
biofeedback are left with a considerable symptom burden. I therefore wished also 
to study a mechanical means to achieving bowel emptying, and I discuss this in the 
next chapter. 
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CHAPTER 7: TRANSANAL IRRIGATION FOR BOWEL 
SYMPTOMS IN PATIENTS WITH MULTIPLE SCLEROSIS 
Peristeen transanal irrigation in patients with Multiple Sclerosis.  
G.Preziosi, J. Gosling, A. Raeburn, J. Storrie, J. Panicker, A.V. Emmanuel.  
Diseases of the Colon and Rectum 2012: 55(10), 1066-73 
 
7.1 Chapter Layout 
I have shown in the previous chapter that patients who fail to improve with 
laxatives and changes in lifestyle regimes might benefit from biofeedback (Munteis 
et al, 2008; Preziosi et al, 2011; Wiesel et al, 2000). This treatment though is not 
widely available and is not suitable for more disabled patients (Munteis et al, 2008; 
Preziosi et al, 2011; Wiesel et al, 2000) who are left with a considerable symptom 
burden. Furthermore, response to biofeedback may diminish in the long-term if MS 
progresses. Therefore for these patients a suitable option could be TAI. 
My findings are summarised in an abstract format, and then the study is discussed 
in detail. 
7.2 Abstract 
Background: Constipation and faecal incontinence affect 68% of patients with MS, 
but management is empirical. TAI has been employed successfully in patients with 
NBD. 
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Objective: To evaluate the effect of TAI on bowel symptoms and general health 
status in these patients, characteristics of those that had successful treatment, and 
to obtain data for power calculations necessary for future randomised-controlled 
studies. 
Hypothesis: My secondary hypothesis is that the treatment strategies should target 
residual spinal cord function, and this was evaluated by the biofeedback study. For 
patients that do respond to biofeedback or are too disabled for this treatment, 
mechanical bowel emptying should be considered as an option. 
Design: Prospective observational study: comparison between pre- and post-
treatment questionnaires (bowel symptoms and health status). Patients that 
received treatment had at least a 50% improvement in bowel symptoms were 
considered responders. Baseline variables including ARP tests and rectal 
compliance were compared between responders and non-responders. 
Settings: Specialist neurogastroenterology clinic, tertiary referrals centre. 
Patients: Thirty patients with MS and constipation, faecal incontinence or both.  
Intervention: TAI. 
Main Outcome Measures: Primary: Wexner-constipation and Wexner-incontinence 
scores. Secondary: SF-36 health survey. All recorded before and after 6 weeks of 
treatment 
Results: At 6 weeks post-treatment the Wexner-constipation score significantly 
improved [12(8.75/16) pre-treatment vs. 8(4/12.5) post-treatment, p=0.001] as 
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well as the Wexner-incontinence score [12(4.75/16) pre-treatment vs. 4(2/8) post-
treatment, p<0.001]. The SF-36 score did not improve significantly (51.3±7.8 pre-
treatment vs. 50.4±7.8 post-treatment, p= 0.051). Sixteen patients were 
responders, and had higher baseline Wexner-incontinence scores [14(11/20) 
responders vs. 9(4/15) non-responders, p= 0.038] and SF-36 (53.9±6.3 responders 
vs. 47.9±7.8 non-responders, p=0.027) as well as greater maximum tolerated 
volume to rectal balloon distension [310(220/320) ml responders vs. 168(108/305) 
ml non-responders, p= 0.017] and rectal compliance [15.2(14.5/17.2) ml/mmHg 
responders vs. 9.2(7.2/15.3) ml/mmHg non-responders, p=0.019].  
Limitations: Small sample size and lack of control group with alternative treatment. 
Conclusions: TAI is effective to treat bowel symptoms in patients with MS. 
Responders (53%) had higher baseline incontinence symptoms and better 
perception of their health as well as a more capacious and compliant rectum. 
7.3 Introduction 
TAI is a means to achieve mechanical bowel emptying and has been proved to be 
effective and safe in the treatment of NBD (Emmanuel, 2010). Its use has been 
extensively studied in adult patients with SCI, where it has been shown to be more 
effective than conservative bowel management. The time spent for bowel toileting 
and the incidence of urinary tract infections are reduced (Christensen et al, 2006) 
improving both symptoms (Christensen et al, 2008; Del Popolo et al, 2008) and 
quality of life (Del Popolo et al, 2008). Its long-term use does not alter parameters 
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of ano-rectal function (Faaborg et al, 2010); however no predictive factor of 
successful treatment has been identified (Christensen et al, 2008). 
While previous studies on TAI included patients with MS, and the largest had 25 
(Faaborg et al, 2009a), no study has evaluated its efficacy in a selected group of MS 
patients.  
I therefore wished to evaluate the effects of TAI on bowel symptoms and general 
health status in patients with MS. In addition, we investigated whether initial ARP 
tests could characterise patients who responded to treatment. 
7.4 Patients and Methods 
Patients recruited to the study were seen in a neurogastroenetrology clinic at a 
tertiary referral centre, and signed a consent form after verbal and written 
explanations were given. 
We offered TAI to: 
 Patients with a definite diagnosis of MS and bowel symptoms onset 
postdating the diagnosis of MS.  
 All patients who had failed bowel biofeedback, or that were considered too 
disabled (severely impaired mobility) to undergo biofeedback, and failed to 
respond to changes in diet, lifestyle and at least two forms of maximal dose 
laxatives.  
Exclusion criteria were: 
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 Concomitant primary bowel pathology and previous colorectal surgery, 
including haemorrhoidectomy, fistulotomy and sphincter injury. These 
were excluded in all patients by means of a negative investigation 
(colonoscopy, radiological or laboratory test) as appropriate and as part of 
their assessment.  
Over a period of 2 years between August 2008 and August 2010, we recruited 37 
MS patients with constipation and/or faecal incontinence. None of the patients met 
any exclusion criteria. 
7.4.1 Disability and Impact of MS 
Disability was measured with the EDSS (section 3.5.1)(Kurtzke, 1983) and impact of 
MS on patient’s life was recorded with the MSIS-29 questionnaire (section 3.5.2,) 
(Hobart et al, 2001), which evaluates both the physical and psychological impact of 
the disease (Hobart et al, 2005; Hoogervorst et al, 2004). The MSIS-29 scores range 
between 29 and 145 and indicate respectively ‘no impact at all’ and life ‘extremely 
affected’ by MS.  
7.4.2 Outcome Measures 
As in the Biofeedback study I employed the Wexner-constipation (Agachan et al, 
1996) and Wexner-incontinence (Jorge & Wexner, 1993) questionnaires (section 
3.4.3) as primary outcome measures. The secondary measure was general health 
status, as measured with the widely used 36-item short form health survey (SF-36, 
(section 3.4.5) (McHorney et al, 1993). The scores range between 0 and 100, and 
the higher the score the better the health status. 
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7.4.3 Ano-rectal Physiology Tests 
I performed baseline measurements of standard rectal compliance according to 
standardised criteria (sections 3.2 and 3.3).  
7.4.4 Transanal Irrigation 
There are two commercially available TAI systems: the Enema Continence Catheter 
(Cardiomed Supplies, Ontario, Canada) and Peristeen (Coloplast A/S, Humlebaek, 
Denmark). The latter was employed, as it was the only irrigation system reimbursed 
by the National Health Service at the time of the study. Peristeen is made of a 
rubber catheter with an inflatable cuff connected to a water bag and a dial switch 
with a hand-held pump. The bag is filled with lukewarm tap water. With the patient 
on the toilet the rubber catheter is inserted in the rectum, and is held in place by 
inflating the cuff with air. Water is then flushed with the pump from the bag in the 
bowel. When the catheter is removed the irrigation water and bowel content are 
voided.  
The patients were referred to a nurse specialist (Mrs Julie Storrie) to be trained in a 
one-to-one session in the use of the device. If the patient was unable to perform 
irrigation independently, the caregiver was trained in the presence of the patient. 
There is no standardised protocol to perform TAI. The frequency and volume of 
water used are established empirically through trial and error. We usually suggest 
starting with a volume of 500 ml, to be increased up to 1.5 lt. This is then titrated to 
obtain the best response with the least volume. Initially, the recommended 
frequency is every third day, and is adjusted according to response.  
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Laxatives and constipating agents were not discontinued. After the initial 
appointment, patients were given direct phone access to a nurse specialist (JS) for 
advice.  
7.4.5 Study Design 
This is a prospective observational study. Given the significant overlap of bowel 
symptoms in MS, patients were pooled into one cohort.  
We recorded baseline demographic data, disability, rectal compliance, and 
questionnaire scores. Wexner-constipation and Wexner-incontinence scores 
(primary end point) and the SF-36 questionnaire (secondary end point) were 
repeated 6 weeks after treatment had been commenced, as this is the time 
required to adapt to TAI (Christensen et al, 2008). The pre- and post-treatment 
values were compared. I collected the questionnaires to avoid treatment bias. 
Correlations were evaluated between rectal wall properties and changes in 
Wexner-constipation and Wexner-incontinence scores. 
Responders were considered to be those patients who had, after treatment, an 
improvement of at least 50% in Wexner-constipation and/or Wexner-incontinence 
scores. Baseline variables were compared between responders and non-
responders. 
A telephone interview was conducted with all patients after 3 months to ask if the 
treatment was still being carried out. Patients who were still performing irrigation 
at that point were then interviewed again at 6 months. 
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7.4.6 Statistical Analysis 
Data from the SF-36 questionnaires were normally distributed and analysed with 
the t-test. Other data were not-normally distributed and were analysed with the 
Wilcoxon or the Mann-Whitney U test. The Spearman test was used to evaluate 
correlations (r= correlation coefficient). Data are expressed as medians and 
interquartile ranges, except SF-36 data which is presented as mean and standard 
deviation. All calculated p values were two-sided and p values ≤ 0.05 were 
considered statistically significant. 
Statistical analysis was performed using the statistical software package SPSS 
statistics v19 for Mac.  
7.5 Results 
Four patients after the training session, did not wish to start treatment, and one 
had worsening of MS and discontinued rectal irrigation before follow-up was 
arranged. Two patients were lost to follow-up before training started. These 7 
patients were excluded from the analysis. 
Thirty patients were therefore entered in the study [27 females, age 49 (42/56) 
years]. MS duration was 8 (5/13) years, while bowel symptoms duration was 5 (2/9) 
years; EDSS was 5 (4/7) and MSIS-29 was 88 (104/75). Baseline bowel symptoms 
scores are shown in Figure 7.1.  
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Figure 7.1: Scatter plot distribution of baseline bowel symptoms scores.  
In the top-left quadrant (A) are patients who had prevalent constipation symptoms; the 
top-right (B) quadrant represents patients with mixed symptoms, and the bottom-right 
quadrant (C) those with prevalent symptoms of faecal incontinence. 
 
Patients who discontinued TAI before the assessment at 6 weeks (due to difficulty 
handling the device, lack of results or worsening of incontinence) were still included 
in order to make a valid comparison of pre- and post-treatment scores using the 
principle of ‘intention to treat’.  
7.5.1 Comparison of Pre- and Post-Treatment Questionnaires 
After treatment the Wexner-constipation score significantly improved [12 (8.75/16) 
pre-treatment vs. 8 (4/12.5) post-treatment, p=0.001 – Wilcoxon test] as well as the 
Wexner-incontinence score [12 (4.75/16) pre-treatment vs. 4 (2/8) post-treatment, 
p<0.001 – Wilcoxon test] (Figure 7.2).  
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Figure 7.2: Boxplots showing comparison between pre and post-treatment of 
Wexner-constipation (right) and Wexner-incontinence score (left).  
There was no significant change in the value of SF-36 (51.3±7.8 pre-treatment vs. 
50.4±7.8 post-treatment, p= 0.051– paired t-test). 
Median change in Wexner-constipation was 0 (-6/0) and for Wexner-incontinence 
was -3.5 (-10/0) (‘-’ indicates improvement, i.e. reduction, while positive values a 
worsening score, and ‘0’ indicates no change) (Figures 7.3 and 7.4). 
 
Figure 7.3: Ladder plots of individual changes in Wexner-constipation (right) and 
Wexner-incontience score (left). 
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Figure 7.4: Scatter plot of individual changes of Wexner-constipation (y axis) and 
Wexner-incontinence (x axis) after treatment.  
Responders are represented by the black dots, and non-responders are in grey. The 
numbers 7 and 2 indicate overlapping patients.  
7.5.2 Correlation Analysis 
Correlations are shown in Table 7.1. 
Table 7.1: Correlation between changes in Wexner scores and rectal properties 
 Change in 
Wexner-
Constipation 
Change in 
Wexner-
Incontinence 
Threshold volume r= -215, p= 0.254 r= -0.321, p= 0.254 
Urge Volume r= -0.176, p=0.351 r= -0.310, p= 0.095 
Maximum Tolerated Volume r= -0.318, p= 0.087 r= -0.536, p= 0.002 
Rectal Compliance r= -0.317, p= 0.088 r= -0.463, p= 0.010 
Change in Wexner-Constipation 1 r= 0.630, p< 0.001 
Change in Wexner-Incontinence r= 0.630, p< 0.001 1 
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7.5.3 Responders vs. Non-Responders Analysis 
At 6 weeks follow-up 16 patients (53%) were considered responders. A caregiver 
performed the irrigation for two of our patients, and one was a responder. Of the 
non-responders 7 had no change in either Wexner scores, 4 had an increase 
between 1 and 4 in the Wexner-incontinence and 3 had a reduction of between 2 
and 4 in the Wexner-incontinence score, with lesser changes in the Wexner-
constipation score. Responders had a reduction of at least 6 points in one of the 2 
Wexner scores (Figure 7.3). Comparison of baseline variables between responders 
and non-responders is shown in Table 7.2.  
Table 7.2: Comparison of baseline variables between responders and non-
responders 
 Responders 
(n=16) 
Non-responders 
(n=14) 
p-value 
 
Age (years) 48 (36/55) 53 (45/55) 0.423 
MS duration (years) 9 (4/15) 10 (6/17) 0.423 
Symptoms duration (years) 7 (2/10) 5 (4/17) 0.759 
Baseline Wexner-Constipation  12 (5/16) 12 (9/13) 0.697 
Baseline Wexner-Incontinence 14 (11/20) 9 (4/15) 0.038 
SF-36 53.9±6.3 47.9±7.8 0.027 
MSI-29 81 (71/123) 96 (80/105) 0.608 
EDSS 5 (4/7) 6 (3/7) 0.984 
Resting pressure (mmHg) 54 (47/70) 55 (37/78) 0.951 
Squeeze Pressure (mmHg) 43 (21/58) 30 (11/68) 0.552 
Threshold Volume (ml) 60 (55/120) 40 (32/171) 0.179 
Urge Volume (ml) 130 (100/285) 105 (60/290) 0.355 
Maximum tolerated volume (ml) 310 (220/320) 168 (108/305) 0.017 
Anal Electrosensitivity (mAmp) 10.1 (8/13.8) 7.7 (6.4/19.3) 0.208 
Rectal Electrosensitivity (mAmp) 22.0 (15.7/31.7) 17.3 (12.5/50.0) 0.697 
Rectal Compliance ml/mmHg 15.2 (14.5/17.2) 9 (7.2/15.3) 0.019 
Change in Wexner-Constipation -6 (-9/-1.25) 0 (0/0) n/a 
Change in Wexner-Incontinence -9(-15/-6) 0 (-5/1) n/a 
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All data, with the exception of the SF-36, are presented as median and 
interquartile range and the p value for the Mann-Whitney U test is given. Data of 
the SF-36 are presented as mean and standard deviation and the p value given 
is for the independent-samples t-test. 
7.5.4 Follow-up 
All of the responders were using the Peristeen at the 3 months. At 6 months follow-
up all except two responders were continuing to use the irrigation: one patient 
reported no more response, and the other had severe deterioration of MS. Three of 
the responders who were still using the irrigation at 6 months, would do so on 
average once a week (particularly when going out or attending a public occasion), 
while the rest required 2 to 7 irrigations per week.  
7.6 Conclusions 
The principal findings are: 
 Peristeen TAI is an effective option to treat bowel symptoms in patients 
with MS.  
 Greater tolerance to rectal balloon distension and rectal compliance 
correlated with greater improvement in symptoms of faecal incontinence, 
but not of constipation. Both symptoms improved in tandem.  
 Fifty-three percent of the patients in our study were considered 
responders. They were characterised, in comparison to non-responders, by 
higher initial incontinence scores, better perception of their health, greater 
tolerance to rectal balloon distension and greater rectal compliance. 
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7.6.1 Strengths 
This is the largest of the series in the literature of studies including patients with 
MS, and the only one to address this patient’s group separately. It is also the first 
study that showed factors that might predict response to Peristeen (more 
capacious rectum and better perception of own health). Expulsion of the catheter 
in response to inflation of the irrigation catheter cuff is a common cause of 
unsuccessful treatment, and may be related to reflex contraction of the rectum, a 
phenomenon that has been observed in patients with SCI (Krogh et al, 2002b). 
Therefore responders, given their rectal properties, might have been able to better 
tolerate the irrigation catheter with the cuff inflated. In patients complaining of 
catheter expulsion it might be helpful to regulate the amount of air inflated in the 
cuff. 
7.6.2 Limitations 
This study does have limitations, such as the absence of a control group with an 
alternative treatment and the small sample size, which might have lead to a type 2 
error.  
The threshold of 50% improvement of Wexner score to identify responders had an 
inherent potential pitfall. In fact a responder could have been a patient with low 
initial Wexner score and subsequent small change, or vice-versa, we could have 
identified as a non-responder a patient who had a big drop (but not halving) from a 
high initial score. This was not the case, as non-responders had no change, 
worsening or minimal reduction in Wexner scores. Responders instead had an 
improvement of at least 6 points in at least one of the 2 Wexner scores. 
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Furthermore, all but two responders were still using rectal irrigation after 6 months. 
Consequently, our chosen threshold was arbitrary, but effective. That said it is of 
note that some of the most recent studies of faecal incontinence outcomes with 
neuromodulation have used a 50% reduction in incontinence symptoms to define 
responders (Boyle et al, 2010; Govaert et al, 2010). 
Another limitation of this study is the lack of an optimal measure of quality of life, 
as the SF-36 questionnaire failed to demonstrate an improvement with treatment. 
It should be noted that MS is a complex disease, so the SF-36 may fail to address 
clinically important aspects of the impact of specific symptoms (Riazi et al, 2003). 
Responders had a better perception of their health, despite a similar high disability 
and impact of MS on their lives. We speculate that this, and an almost ‘all or 
nothing’ response observed, suggest that in at least some patients lack of 
motivation was a factor in failing to implement a bowel regime with TAI. A variety 
of factors such as manual dexterity, vision and cognition are also likely to influence 
compliance. Furthermore, it could be that TAI itself affects some MS symptoms 
(such as spasticity or mobility). These elements were not addressed in this study 
and require further evaluation. 
As in the biofeedback study, laxatives and constipating agents were not 
discontinued, and their optimisation could improve efficacy of TAI. 
7.6.3 Further Considerations 
Incontinence symptoms showed a greater improvement than constipation, and 
responders had higher baseline incontinence scores. This might reflect the inability 
of the water enema to reach and mobilise the stools in constipated patients 
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(Christensen et al, 2003). Another theoretical explanation could be that a bowel 
peristaltic wave, stimulated by irrigating water, is required to produce an effect. 
This mechanism of action could be less effective in patients with reduced colonic 
motility. This is in keeping with literature of employment of transanal irrigation in a 
range of disorders. An heterogeneous study, including patients with a diverse range 
of pathophysiological conditions, used multivariate regression analysis to show that 
patients with NBD or faecal incontinence did better than patients with idiopathic 
constipation or patients with sequelae to anorectal surgery (Christensen et al, 
2009). This study showed that ‘Low rectal volume at urge to defecate’ and ‘low 
maximal rectal capacity’ were significantly associated with a successful outcome. 
Our study suggests that increased rectal compliance is associated with better 
outcomes. Increased rectal compliance can be associated with a rectum that 
accumulates faeces in the absence of rectal sensation, and in this group of patients 
urge incontinence arises when the rectum is full, rather than in a rectum with 
reduced compliance, as in a rectum subjected to irradiation injury (Bajwa A., 2009). 
Another study on NBD patients found successful outcome to be related to male 
gender, mixed constipation and faecal incontinence symptoms, and prolonged 
colonic transit time (Faaborg et al, 2009b). 
Overall NBD patients seem to do better than those with functional disorders 
(Emmanuel et al, 2013). 
The worsening of faecal incontinence seen in four of the non-responders (Figure 
7.3, right) was related to an inability to eliminate all the irrigation water in one 
setting. Fine-tuning the amount of irrigation required and implementing 
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manoeuvres of manual abdominal compression while on the toilet can improve 
post-irrigation leakage. 
Frequency of irrigation varies; if the patient is occasionally having no result with 
irrigation we suggest reducing the frequency, if there are episodes of incontinence 
in-between irrigations, we advise increasing the frequency. 
During the study no adverse effect was recorded. The risk of perforation with TAI is 
very low (2 non-fatal bowel perforation reported for 110,000 irrigation) 
(Christensen et al, 2009), and this treatment modality has been employed in 
patients after low anterior resection (Koch et al, 2009) with no anastomotic leak 
reported. Nevertheless, we routinely perform a flexible sigmoidoscopy in patients 
who are above the age of 45 to rule out a potential risk factor for perforation such 
as diverticular disease. In the presence of previous colonic surgery or diverticulosis, 
the patient is counselled about a theoretical increased risk of bowel perforation, 
and if he or she wishes to go ahead, the irrigation is initiated with smaller volumes.  
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CHAPTER 8: CONCLUSIONS 
8.1 Main Findings 
My studies testing the primary hypothesis, that the involvement of the spinal cord 
by the disease is central to the development of bowel symptoms, have shown that: 
 Prevalence of bladder symptoms is higher than expected in patients with 
MS and bowel symptoms. 
 Patients with MS and clinically significant spinal cord disease have similar 
alterations of the rectal wall properties as measured by increased rectal 
compliance to patients with a SCI above T5.  
I have also concluded that: 
1. Patient-reported bowel symptoms quantify well bowel dysfunction, and are 
correlated with patient-reported bladder symptoms.  
2. The cause of bowel symptoms in MS is multifactorial. 
The secondary hypothesis, residual spinal cord function is a target for treatment of 
bowel symptoms, was tested with the biofeedback study which concluded that: 
 Biofeedback improves bowel symptoms, depression and 5-seconds-
endurance squeeze pressure in patients with MS. There was no significant 
difference between responders and non-responders, yet responders had a 
median EDSS of 4 and non-responders of 6. This is clinically relevant, 
particularly in the light of the compliance study. 
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Finally I showed that: 
 TAI is effective to treat bowel symptoms in patients with MS who fail to 
respond to biofeedback. Responders (53%) had higher baseline incontinence 
symptoms and a better perception of their health, as well as a more 
capacious and compliant rectum. Incidentally, we have shown in study 2 
that rectal compliance is higher in subjects with a higher disability. These 
are the patients that are less likely to respond to biofeedback, and this 
consideration allows a treatment algorithm to be constructed to rationalise 
bowel dysfunction in MS.  
These findings are interwoven and support our central hypothesis that bowel 
dysfunction in MS is secondary to spinal cord involvement by the disease.  
Therefore I conclude that: 
 While the cause of bowel symptoms in patients with MS is multifactorial, 
the extent of spinal cord disease is a critical factor. 
 The actual burden of bowel symptoms depends on the extent of spinal cord 
disease, and the natural history of bowel dysfunction follows disability. 
 That this can be measured clinically with the EDSS and with rectal 
compliance. 
This in turn has wider implications.  
 With rapid development of techniques of nerve stimulation, residual spinal 
cord function might represent a target of treatment, and rectal compliance 
might represent a predictive factor of response. 
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 Pharmacological modulation of rectal compliance could be a therapeutic 
strategy for the treatment of constipation and incontinence.  
 Furthermore this study has shown that rectal compliance is a good measure 
of altered reflex activity secondary to spinal cord disease, where other 
symptoms of autonomic dysfunction are absent. The initial study by Trivedi 
(Trivedi P, 2009) in patients with spinal cord injury showed that there is a 
pattern of compliance alterations depending on injury level.  This study 
confirms that rectal compliance, when measured according to a 
physiological protocol employing an electronic barostat, a polyethelene bag 
with infinite compliance and a standard distension protocol, is a reliable 
indicator of autonomic rectal dysfunction. This has implication beyond 
patients with neurological disorders, given that most tests of ARP are non-
specific for the underlying neurological dysfunction. 
8.2 Strengths 
The strengths of these studies are that: 
 They are hypothesis driven, and are tightly interconnected.  
 Study design was rigorous and reflected the research questions. 
 It is the first sequence of studies to address the subject of MS guts 
pathophysiology systematically. 
 The results demonstrate that we have made a significant contribution to the 
knowledge in this area of research and in the understanding of the natural 
history of bowel dysfunction in MS. 
 A potential new target of treatment has been identified. 
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 I have also tried to identify clearly what the challenges for future studies are 
and how to overcome some of them. Consequently, future studies of NBD 
will be of higher quality. 
8.3 Limitations 
There are limitations that I had to accept when designing the studies, some which 
emerged whilst carrying out the studies and other that became apparent at their 
conclusion. Some of them are inherent to the population studied, some are 
inherent to the test we employed, and some will aid better studies in the future. 
A major limitation is the absence of imaging regarding the brain and spinal cord 
lesions. We didn’t set out to obtain imaging at the start, and the imaging available 
was not sufficiently specific or most of the times not close enough temporally to 
when the physiological measurements were taken. Given that MS is a fluctuating 
and often progressive disease, it made any available imaging unreliable to draw any 
conclusion. I attach an appendix (appendix 5) with available imaging of 16 patients 
who were in the rectal compliance study (chapter 5). 
The cut off we used in the biofeedback and TAI studies, were empirical, but another 
study has used a percentage improvement of the Werner score reduction to 
measure response: good response= 90% of the pretreatment score or absence of 
fecal incontinence symptoms, partial response= reduction of 50– 89% of the 
pretreatment score), and no response= reduction of less than 50% of the 
pretreatment score or no alleviation of the symptoms (Boselli et al, 2010). 
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In the biofeedback study we were directed by the reviewers’ comments. Overall 
they do help to separate patients who had a good response from those who didn’t. 
We initially considered as responders for the biofeedback study all patients whose 
Wexner score had gone below 10, but it was pointed out by the reviewers of the 
biofeedback study that many patients with great improvement, but not to below 
10, would have erroneously considered non responders. On the base of this 
experience we decided to employ a percentage reduction in score for the TAI study. 
The different type of intervention employed dictated the different strategy in 
selecting responders. In fact in the majority of cases response to TAI was more of a 
dualistic nature: it either worked very well or it didn’t work at all. It should finally 
observed that our strategy to identify responders is rather unorthodox, as in the 
literature questionnaire based response is usually measured either by comparing 
pre- and post-treatment scores or in comparison to a control group (NICE, 2007). 
Limitations Inherent to an MS Population  
Patients with MS are a challenging group to study, as many confounding factors 
come into play: 
 Multiple neurological lesions in the CNS, not necessarily correlating to 
neurological symptoms. I have tried to overcome this using a clinical index 
of spinal cord disease, the EDSS. 
 Multiple neurological symptoms, compounding perception of bowel 
symptoms. To overcome this I employed two different questionnaires in the 
TAI study: the SF-36 and the MSI-29. 
 Potential presence of cognitive impairment. 
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 Significant psychosocial impairment. 
 Multiple bowel symptoms, which are alternating and fluctuating. 
 Polypharmacy. 
8.3.1 Limitations Related to the Tests Employed 
 There are no validated instruments that take into account the above-
mentioned specific traits to measure bowel symptoms in MS 
 It is difficult to ensure reproducibility in tests of gut motility (rectal 
compliance). I have tried to overcome this by employing an electronic 
barostat, polyethylene bags with infinite compliance and a tested distension 
protocol. 
 Current imaging modalities do not help to identify clinically significant 
disease. Again to this end I used a clinical indicator of spinal cord disease 
(the EDSS). 
8.3.2 Limitations of our Study 
 I didn’t evaluate cognitive function; this would have been highly relevant in 
the biofeedback study. 
 I didn’t perform tests of autonomic dysfunction, which might have helped to 
distinguish the cause of autonomic dysfunction (spinal cord vs. higher 
centres). This would have been highly relevant in the rectal compliance 
study. 
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 Treatment studies 3 and 4 did not have a control group. They were pilot 
studies and the results will be employed for the power calculations in future 
studies. 
 I didn’t employ any measure of bowel-related quality of life 
8.4 Future Studies 
Further evaluation of the physiological alteration might be of interest, and to this 
end in the future it would be helpful to try to correlate: 
1. Alterations of rectal compliance with MRI findings, comparing number, size 
and volume of sclerotic plaques above and below the T5 level. 
2. Rectal compliance with RAIR. It has been shown that specific alterations of 
the RAIR occur. It could be that modification of rectal wall properties might 
be responsible for these alterations, or it could be that alteration of the 
RAIR and of rectal compliance are both manifestations of altered reflex 
activity in the spinal cord. In the latter, there might be specific patterns of 
alterations of rectal compliance and of specific component of the RAIR. 
What we have found is that physiological bowel studies in patients with MS present 
significant challenges, the principal being the multiplicity of patterns affected.  
Certainly from the patient’s perspective, in the absence of a cure for the 
neurological disorder, symptoms relief is paramount, and we believe that future 
efforts should focus in this direction. 
1. Biofeedback vs. Transanal irrigation 
  Chapter 8: Conclusions 
171 
Biofeedback and TAI both better improve symptoms of incontinence than 
constipation. Even though they are completely different approaches to treat bowel 
symptoms, they might achieve this improvement through a common mechanism, 
which is to optimise rectal emptying. Biofeedback has the great limitation of not 
being widely available, and results are dependent strongly on the patient-therapist 
interaction. Instead, Peristeen is a mechanical means to achieve bowel emptying, 
and even if it requires training and encouragement, this might be achieved through 
a single training session, and a lot of issues related to its use can be dealt with over 
the phone. It might be that Peristeen is equally or more effective than biofeedback, 
even in the less disabled patient, and therefore might represent a better treatment 
if laxatives fail. In my studies both biofeedback and TAI have proved to be more 
effective for incontinence symptoms rather than constipation. Another 
consideration to take into account is that all our patients who had transanal 
irrigation had failed biofeedback in the past. Therefore a randomised controlled 
trial based on my data should compare biofeedback (group A) versus biofeedback 
and TAI in combination (group B). A sample size calculation was performed with the 
available data from our existing study. With a alpha of 0.05 and power of 0.80, a 
mean difference in the Wexner score of -3.95 for group A and standard deviation of 
3.56 and a mean difference in the Wexner score of -5.13 for group B and standard 
deviation of 6.45 using the Student t tests comparing the mean of difference 
between two dependent means (matched pairs), we would need to recruit 179 
patients for a well powered study. Other power calculations are reported in 
Appendix 6. 
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2. Prokinetic study 
As discussed above, we have shown that biofeedback and TAI treat more effectively 
incontinence symptoms. However, constipation, whilst less socially embarrassing 
than incontinence, is a more prevalent bowel symptom. Prucalopride is a highly 
selective 5-HT4 agonist that has a pro-peristaltic effect in the gut. Linaclotide is a 14 
amino-acid peptide that activates the guanylate-cyclase pathway in colonic and 
small intestine enterocytes, resulting in luminal chloride secretion, and hence acts 
as a prokinetic. In MS slow bowel transit is related to disturbances in the CNS, but 
the bowel itself is actually normal (with the exception of the effects of certain 
drugs).  
We therefore speculate that patient with MS might respond even better to one or 
other of these prokinetics, and therefore studies should compare the use of these 
drugs with a placebo and/or other treatment modality (laxatives, biofeedback, TAI). 
3. Surgery for constipation 
As discussed above, we still have difficulty treating constipation in patients with 
MS, and efforts should be made in this direction. The Malone procedure (antegrade 
enema) has been successfully employed in paediatric patients, and should certainly 
be evaluated in patients with MS. 
4. Nerve modulation 
We believe that there is enough evidence to suggest a central role of spinal cord 
disease in determining bowel symptoms, and therefore future studies should focus 
on how to target residual spinal cord function. This might be achieved with sacral 
nerve stimulation or PTNS.  
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 A randomised clinical trial of interventions (stratified by extent and site of 
nerve lesion) would help optimise the currently available modalities of 
bowel management. 
 Specific instruments, tailored to assess NBD, should be developed to help 
monitor progress with interventions, from both a clinical and a research 
standpoint. 
 Understanding of the gut pathophysiology of each individual patient may 
permit tailoring of a specific bowel regime. Specifically, tailored electrical 
or magnetic stimulation may influence the specific pathophysiology, and 
hence improve symptoms. 
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Appendix 1 – Supporting data for Chapter 4 
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f rr 48 2.5 3 slow 0 25 30 0 0 0 0 
f rr 63 0.5 11 slow 0 50 90 75 82 25 12 
f rr 57 1.5 6 slow 0 25 55 25 40 0 0 
f rr 10 3.5 7 slow 0 25 50 0 0 0 0 
f rr 29 3 15 slow 0 75 33 50 18 50 67 
f rr 36 4 8 slow 0 50 28 0 0 0 0 
f rr 144 3.5 6 slow 0 50 44 25 63 0 0 
f rr 69 5 20 slow 0 100 69 25 21 0 0 
f rr 168 1.5 7 slow 0 50 59 50 68 25 49 
f rr 192 3.5 19 slow 0 100 80 100 72 50 83 
f sp 67 0 4 slow 0 25 64 50 32 100 100 
f sp 120 2 13 slow 0 75 66 75 88 25 12 
f sp 96 2 12 slow 0 50 77 25 53 0 0 
f sp 31 4.5 17 slow 0 75 70 25 56 0 0 
f sp 89 3 11 slow 0 50 60 25 37 0 0 
f sp 94 6 22 slow 0 100 43 0 0 0 0 
f sp 112 0 5 slow 0 50 31 75 69 25 13 
f sp 27 5.5 2 slow 0 50 18 0 0 0 0 
f sp 85 4 6 slow 0 50 45 25 12 25 9 
f sp 44 5 21 slow 0 75 61 50 63 0 0 
f sp 58 0.5 1 slow 0 25 24 75 36 0 0 
f pp 41 0 3 slow 0 25 48 25 25 0 0 
f pp 110 2.5 7 slow 0 50 55 25 41 25 69 
f pp 146 0.5 5 slow 0 25 60 50 49 50 21 
f pp 31 4.5 20 slow 0 75 88 50 68 50 33 
f pp 152 3.5 8 slow 0 50 49 25 22 0 0 
f pp 20 0.5 8 slow 0 50 56 50 30 0 0 
m rr 30 1 6 slow 0 50 39 25 9 50 38 
m rr 74 3 8 slow 0 25 76 0 0 0 0 
m rr 180 3.5 5 slow 0 50 49 25 36 25 47 
m sp 42 4 5 slow 0 50 20 0 0 0 0 
m sp 80 1 4 slow 0 25 31 25 41 0 0 
m sp 76 1.5 11 slow 0 50 80 50 17 50 26 
m sp 132 5 10 slow 0 75 24 75 57 25 32 
m pp 100 2.5 6 slow 0 50 12 50 20 75 59 
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m pp 53 1.5 3 slow 0 25 11 0 0 25 20 
m pp 20 6 17 slow 1 75 89 25 46 25 32 
f rr 42 3.5 30 slow 1 100 96 100 71 50 33 
f rr 67 4 27 slow 1 75 92 50 35 0 0 
f rr 16 4 8 slow 1 50 83 25 76 0 0 
f rr 88 6 11 slow 1 75 52 50 86 25 69 
f rr 72 3.5 17 slow 1 75 58 100 43 0 0 
f sp 36 1.5 9 slow 1 50 87 25 92 25 16 
f sp 89 4.5 29 slow 1 100 89 100 59 100 89 
f sp 94 2.5 10 slow 1 50 92 50 79 0 0 
f sp 60 4.5 12 slow 1 75 75 50 53 25 88 
f sp 84 3.5 28 slow 1 100 70 100 62 25 90 
f sp 126 4.5 11 slow 1 50 64 25 62 0 0 
f pp 84 1.5 6 slow 1 25 80 50 41 0 0 
f pp 48 5 5 slow 1 50 49 0 0 0 0 
m rr 88 1.5 8 slow 1 50 69 75 82 75 36 
m sp 70 1 13 slow 1 50 95 25 13 75 88 
m sp 116 0.5 12 slow 1 50 72 100 93 100 100 
f rr 55 2 9 normal 1 50 26 50 18 0 0 
f rr 90 4 25 normal 1 100 69 100 80 0 0 
f rr 53 3.5 8 normal 1 50 38 25 44 0 0 
f rr 100 1 11 normal 1 75 63 100 58 25 90 
f sp 103 4 30 normal 1 100 86 100 73 50 67 
f sp 47 5.5 10 normal 1 75 59 25 60 25 33 
f sp 69 0.5 8 normal 1 50 57 75 68 0 0 
f sp 192 4 6 normal 1 50 33 25 16 0 0 
f sp 40 0.5 2 normal 1 25 24 25 39 50 90 
f sp 87 6 30 normal 1 75 80 0 0 0 0 
f pp 63 1 3 normal 1 25 30 50 72 25 86 
f pp 66 0.5 4 normal 1 25 21 50 47 25 79 
f pp 22 0.5 4 normal 1 25 59 50 7 0 0 
f pp 150 0 6 normal 1 50 62 75 89 0 0 
f pp 49 2 5 normal 1 25 44 25 30 25 64 
m rr 70 6 19 normal 1 75 38 50 14 25 80 
m rr 58 3 7 normal 1 50 29 25 16 0 0 
m sp 106 1.5 6 normal 1 50 26 75 33 50 22 
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Appendix 2a – Supporting data for Chapter 5  
MS patients 
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2 4 rr 4.5 16 17 71 52 50 110 270 10.2 23 9.4 
1 5 rr 2 8 7 69 66 30 90 150 7 31.8 7.74 
>20 1 pp 5 17 16 73 38 60 320 320 7.8 22 17.1 
3 6 rr 6 0 13 34 102 20 60 90 7.2 17 25.6 
3 7 pp 4 16 
 
70 0 120 160 320 7.4 35.5 18.02 
1 
 
?rr?sp 5 0 16 47 161 140 200 220 10.2 19.5 10.11 
3 5 rr 5 20 0 51 12 320 320 320 20 50 15.5 
13 16 sp 5.5 16 8 59 43 45 75 200 10.2 14 7.9 
3 33 rr 3 4 2 55 188 300 320 320 8.4 23 19.51 
1 25 sp 7 11 10 109 0 120 320 320 9.2 25 16.3 
5 6 pp 3 0 8 100 136 30 60 200 10.4 25.5 13.1 
3 15 pp 2 9 14 104 70 180 220 240 7.8 42.5 9.4 
4 4 rr 2 7 9 62 124 45 105 160 9.2 33.5 10.1 
3 6years rr 2 0 21 50 36 170 220 270 5.6 17.5 7.8 
3 5 sp 2 2 2 29 279 170 180 320 4.8 19.5 11.5 
1 21 sp 2 2 15 53 58 100 140 220 12.6 21 6.7 
3 4 rr 6 4 16 78 94 120 140 300 19 50 20.1 
1 9 rr 2 13 14 69 56 40 80 200 9 27 7.8 
4 31 rr 3 0 7 22 18 60 140 280 11.2 18.5 8.5 
4 15 rr 7 15 14 67 26 40 100 130 6.4 39 7.18 
1 7 rr 2 6 4 50 24 40 160 210 7.8 17 10 
5 14 rr 2 0 13 64 62 80 140 200 14.6 39 8.45 
1 1 rr 2 9 19 106 54 40 80 110 7.2 11.5 8.23 
2 17 rr 3 8 7 65 122 20 35 60 3.4 11.5 10.1 
1 16 sp 6 8 10 64 74 20 60 150 8.6 19.5 5.9 
2 20 rr/sp 2 11 11 53 42 40 90 140 6.8 41 14 
3 16 sp 8.5 4 18 76 0 55 110 130 14.2 32.5 15.2 
2 22 sp 8 15 11 20 0 320 320 320 20 50 26.1 
1 26 rr 5 20 15 31 106 200 320 320 9.4 6.5 19.7 
2 10 rr 6 12 7 109 93 150 240 320 7.6 12 14.3 
15 24 sp 5.5 0 13 26 85 160 230 320 10 50 8.1 
2 9 sp 3 5 6 97 34 50 110 160 7.2 15 6.2 
1 12 rr 3 0 17 72 285 80 104 180 3.7 10.8 8 
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1 11 rr 5.5 12 9 73 59 80 280 320 9.4 5.5 17.7 
1 12 atipical 8.5 10 12 86 43 320 320 320 20 50 18.42 
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3 17 sp 4.5 7 14 76 39 80 150 200 11.6 50 14.25 
1 11 sp 4.5 1 4 117 130 70 120 180 11 25.5 7.3 
1 15 sp 4.5 8 12 50 133 70 130 280 14 29 9 
2 6 sp 6 4 8 73 62 40 100 160 8.6 20 18.8 
4 5 rr 4 12 9 54 41 20 40 80 6.2 7.5 22.1 
1 16 rr 4 11 16 67 92 50 80 210 7.8 18 4.2 
2 36 rr 5.5 13 7 32 36 50 110 220 7.8 22.5 17.5 
7 15 pp 6 10 9 59 152 60 160 220 13 22.5 12.5 
1 7 pp 6.5 6 14 12 16 35 110 280 6.4 14 13.3 
4 8 rr 4 8 11 67 25 40 120 240 6.2 21.5 12 
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Appendix 2b– Supporting data for Chapter 5  
SCI patients 
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F T11 n 38 6 95 18 15 16.7 
M C3 n 54 1 109 3 12 9.7 
F C5 n 76 2 83 11 21 7.8 
M T3/T7 n 40 2 101 13 12 20.2 
M C2-C3 n 58 4 66 18 17 15 
M C2-T10 n 39 3 95 3 16 21.8 
M c5 y 48 7 114 18 23 12 
M T5 n 51 
 
90 16 5 22.5 
F C6 y 26 21 
 
1 22 19 
M T3 y 33 6 
 
13 12 17.8 
M T2 y 24 9 
 
3 20 29.7 
M C8 y 49 16 
 
2 23 13.6 
F C6 y 38 19 
 
17 16 24.5 
F C5 n 41 14 
 
13 8 8.9 
M T1 y 47 11 
 
2 24 18.7 
F T2 y 59 20 
 
8 21 22.5 
M C7 n 56 8 
 
17 2 24.9 
M T3 y 40 10 
 
12 19 20.2 
M T4 n 49 7 
 
16 4 16.8 
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Appendix 2c– Supporting data for Chapter 5 
Sex Age TV UV MTV Compliance 
f 45 25 55 115 8.7 
m 76 60 160 220 11.3 
m 63 35 100 175 11.5 
f 42 40 150 215 12.7 
f 37 50 95 170 7.3 
f 74 60 110 200 9 
m 69 35 70 115 15.4 
f 71 40 110 160 10.4 
m 79 40 75 130 9 
m 66 50 145 210 9.1 
m 46 60 180 240 16.5 
f 73 30 105 150 11.3 
f 58 50 90 135 7 
f 70 40 85 160 17.2 
f 63 55 100 180 13.3 
f 44 50 115 205 12.1 
f 37 25 75 180 10.7 
m 58 20 40 90 5.7 
m 22 45 70 210 14.6 
f 24 40 70 160 8.2 
m 39 35 80 155 10.4 
m 62 40 65 120 9.2 
f 41 60 120 220 15.8 
f 72 45 110 195 12.5 
m 21 65 115 200 7.3 
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Appendix 3– Supporting data for Chapter 6 
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FI f 26 2 8 5 3 15 2 70 48 41 12 20 80 150 9.8 22 0 3 1 2 64 63 57 47 35 90 135 9 21.5 
FI f 28 4 11 2 5 12 3 62 76 46 30 180 220 290 5.6 31.5 2 5 3 4 79 71 50 60 105 160 200 5 30 
FI f 26 5 10 3 2 18 1 32 52 46 21 55 80 150 3.8 24.5 2 4 6 1 68 47 72 38 60 80 140 4 22 
FI f 44 3 24 4 12 10 0 142 65 66 20 70 190 250 4.8 35.5 2 5 6 1 120 77 53 58 50 150 230 5.6 31 
FI f 51 5 40 0 4 20 7 45 51 26 11 45 50 110 18.6 28 1 4 8 7 41 58 47 52 55 90 160 16 20 
FI f 52 6 25 2 7 14 4 32 121 166 106 35 95 220 5.2 11.5 1 3 9 2 38 111 169 102 50 110 210 8 13 
FI f 40 4 4 1 2 18 3 44 52 40 23 35 80 155 6.7 18.3 1 2 4 3 39 63 62 50 50 90 120 9 19 
FI m 59 5 29 4 6 12 2 32 68 55 30 40 105 150 4 16 4 6 14 2 47 44 51 27 35 95 180 5 19.6 
FI f 31 9 10 16 19 14 5 27 30 49 0 20 100 145 6.5 33 16 19 11 7 15 37 45 7 45 115 130 7.5 35 
FI f 26 8 5 12 15 20 3 68 53 70 13 15 55 90 11 41 12 15 20 2 54 46 54 7 20 65 100 10 37 
FI f 28 7 7 3 11 17 6 59 44 47 0 30 50 65 12 27 3 11 17 4 62 55 63 0 20 50 75 14.8 30 
FI m 37 8 14 5 7 15 1 70 36 79 21 25 35 75 9.1 22 5 7 17 3 54 21 45 20 25 45 70 10.8 26 
C m 37 1 4 0 3 1 12 42 26 26 8 25 50 90 7 9 0 1 1 8 40 41 38 28 35 50 100 5.6 10.2 
C m 47 6 5 2 9 1 22 63 53 56 50 40 100 160 6.3 30 2 5 1 4 55 82 47 46 40 95 155 7.4 14.9 
C f 39 3 3 2 4 4 19 42 142 60 23 60 100 140 6.6 26 2 2 3 3 45 109 63 59 55 110 175 6.8 17 
C f 41 3 9 3 2 0 10 53 61 36 17 50 180 450 17.4 50 3 5 3 4 57 56 32 41 45 150 390 15 50 
C f 48 6 22 10 15 2 18 45 57 62 54 50 110 160 8.2 7.5 2 11 3 8 58 72 69 66 40 110 145 6.4 9.2 
C f 59 2 30 1 6 3 12 32 173 107 63 40 80 170 16.6 27.5 2 3 1 7 30 194 126 116 60 90 150 13.7 30 
C f 34 1 2 0 0 0 10 88 125 111 93 80 210 260 9.4 31 1 3 5 10 74 89 106 69 55 155 210 8 24 
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C f 61 7 24 2 7 5 25 96 79 48 20 95 120 300 10 27 2 4 2 10 90 71 46 47 60 140 350 8 25 
C f 36 2 2 0 2 4 11 33 59 40 21 85 160 300 14 21 1 5 4 15 40 50 43 13 60 135 280 10.9 30 
C f 64 6 32 8 11 0 13 89 43 33 16 90 100 250 7.8 18.9 8 10 1 10 77 44 46 32 85 105 320 5 23.1 
C f 27 4 6 2 5 1 10 122 76 80 72 75 90 350 4.6 24.4 6 4 0 11 134 60 75 45 65 90 410 6.3 22.3 
C f 33 4 8 3 3 2 14 106 85 35 75 60 110 225 13 12 5 4 0 17 100 96 41 100 50 120 275 17 13.4 
C f 29 6 3 4 2 4 26 76 142 110 68 55 135 305 10.5 21.7 3 4 3 24 65 159 98 43 55 130 250 11 24 
C m 34 8 10 5 12 2 23 58 128 108 57 85 155 295 16 39 7 14 3 23 74 112 103 51 70 135 245 12 42 
CFI m 35 5 4 5 4 15 16 94 16 44 16 90 120 170 7.6 16 3 0 4 7 88 46 52 39 80 120 145 5.3 14.2 
CFI f 64 2 19 3 0 12 28 71 72 74 70 50 90 120 7.4 19 0 0 2 10 74 85 65 76 30 115 150 8 13 
CFI f 56 1 31 5 6 15 12 31 20 76 20 50 120 200 16 15 2 2 10 9 28 49 58 40 40 130 220 9.3 11.7 
CFI f 50 3 27 3 8 16 10 44 51 31 38 55 115 245 6 18 4 5 3 6 53 86 42 60 75 120 240 9.2 24.2 
CFI f 38 4 19 7 9 10 22 97 19 26 18 120 170 270 4.9 20 2 5 0 6 78 67 48 50 110 150 235 9.7 25.5 
CFI f 25 2 3 1 3 11 10 80 75 44 70 60 180 290 7.6 23 3 3 0 8 96 114 39 59 50 170 290 4.2 26.9 
CFI f 59 4 33 10 8 13 13 21 14 37 0 40 80 220 9.6 32 6 9 4 10 35 26 51 8 55 110 210 5.1 28.6 
CFI f 27 6 1 6 14 14 18 52 35 26 11 45 140 255 7.7 28.7 4 12 7 15 47 61 42 18 65 160 310 8.4 30.4 
CFI f 44 4 7 3 9 10 11 61 68 34 5 100 260 300 8.5 19.9 5 9 13 14 87 47 34 28 75 260 280 7.6 21.4 
CFI f 37 8 8 9 17 15 19 24 16 47 0 95 255 315 9.4 33 7 16 12 16 42 19 35 6 80 280 335 10.9 31.8 
CFI f 36 7 5 16 15 16 27 34 75 60 10 75 150 280 12 41 14 13 11 22 47 45 38 0 90 190 310 9.8 50 
CFI m 50 7 6 17 8 12 21 50 27 14 22 150 310 400 13 25 12 7 10 23 39 35 31 26 120 260 420 14 26 
CFI m 38 8 10 11 18 17 26 42 33 31 3 145 285 350 10.4 12.7 11 15 14 24 58 40 27 28 135 310 450 11 15.3 
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Appendix 4– Supporting data for Chapter 7 
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f 55 22 14 pp 6 103 20 4 -16 16 8 -8 50 73 38 60 320 320 7.8 22 17.1 
f 61 2 1 pp 6.5 83 16 4 -12 16 6 -10 80 70 0 120 160 320 7.4 35.5 18.02 
f 54 25 12 sp 7 89 11 8 -3 10 10 0 85 109 0 120 320 320 9.2 25 16.3 
f 47 9 7 rr 4 101 13 2 -11 14 6 -8 130 69 56 40 80 200 9 27 10.7 
f 45 16 8 sp 8.5 94 4 2 -2 18 8 -10 103 76 0 55 110 130 14.2 32.5 15.2 
f 46 21 14 sp 2 95 2 2 0 15 6 -9 81 53 58 100 140 220 12.6 21 6.7 
f 33 5 2 rr 4 105 12 0 -12 9 4 -5 49 54 41 200 320 320 6.2 7.5 22.1 
m 30 12 7 sp 8.5 89 20 0 -20 13 12 -1 135 46 22 320 320 320 20 50 15.2 
f 53 4 3 sp 4 101 12 4 -8 4 4 0 69 62 58 60 120 200 9.4 14.6 15.2 
f 58 5 4 sp 7 99 18 8 -10 4 4 0 130 23 20 55 100 320 14.2 22.1 17.4 
f 60 12 11 pp 4 98 20 4 -16 8 4 -4 78 69 89 80 100 260 8.9 11.9 14.8 
f 31 2 1 rr 5 102 14 6 -8 3 3 0 90 52 43 45 90 220 10.1 19 14.5 
f 54 16 12 sp 4.5 105 14 8 -6 4 2 -2 55 48 58 45 80 240 11.8 24.6 16.4 
f 48 12 6 sp 7 84 20 4 -16 20 8 -12 130 18 13 320 320 320 20 50 17.2 
f 50 9 7 sp 5.5 89 6 0 -6 10 4 -6 80 54 56 120 160 320 10.2 29.3 16.2 
f 45 3 2 rr 4 101 12 8 -4 10 4 -6 76 34 42 60 120 320 7.8 14.3 14.7 
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f 40 5 4 rr 5 98 17 18 1 2 2 0 83 51 12 320 320 320 20 50 15.5 
f 46 4 3 rr 6 84 4 4 0 16 16 0 134 78 94 40 60 120 19 50 10.1 
m 31 15 6 rr 7 90 15 15 0 14 14 0 90 67 26 40 100 130 6.4 39 7.18 
f 65 22 13 sp 8 78 15 15 0 11 11 0 102 20 0 320 320 320 20 50 16.1 
f 43 9 4 sp 3 92 5 5 0 6 6 0 104 97 34 20 40 90 7.2 15 6.2 
f 50 11 2 rr 3 90 12 10 -2 9 9 0 102 73 59 80 280 320 9.4 5.5 7.7 
f 52 7 7 pp 6.5 98 6 8 2 14 14 0 86 12 16 35 110 280 6.4 14 12.3 
f 53 11 4 sp 7 86 16 12 -4 12 10 -2 106 38 7 20 60 95 6.4 17 7.2 
f 21 5 2 rr 6 102 11 4 -7 20 18 -2 103 80 56 60 180 300 10.6 20 4.8 
f 54 34 20 sp 7 92 0 0 0 18 18 0 104 32 201 22 94 237 20 50 20.8 
f 55 12 8 sp 7.5 95 11 11 0 9 9 0 106 46 22 175 175 175 6.3 
 
5.8 
f 45 6 5 rr 2 85 0 0 0 21 21 0 50 50 36 170 220 270 5.6 17.5 7.8 
f 67 7 3 rr 2 75 2 4 2 12 12 0 68 59 39 40 60 110 8.2 12.5 8.9 
m 55 5 4 rr 2 110 4 8 4 20 20 0 49 78 189 40 60 100 6.9 12.5 9.2 
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Appendix 5 – Available Radiology data 
 
ARP Date MRI Date Neuroradiology Report Lesion 
No. 
Cord Atrophy 
6/7/2008 23/12/2008   C1-2: Large central ventral lesion 
involving grey and white matter, 
sparing the dorsal columns, tapering 
and fading away to mid C2 
 Craniocaudal distance: 11mm 
 No significant cord atrophy at this level 
 
 C4-5: Small right lateral lesion (possibly) 
 
 C5-6 lesion most likely due to cord 
compression 
 
 April 2009 – no change 
 
2 No significant 
atrophy 
17/9/2008 11/1/2010  C2: Large central dorsal lesion 
  Craniocaudal distance: 29mm 
 Cord atrophy at this level (mild) 
 
 C4: Small central dorsal lesion 
 
 T1-2: Left lateral dorsal lesion 
 Craniocaudal distance: 10mm 
 Local mild atrophy at this level 
 
 Lesions do not enhance with 
gadolinium  
3 Mild cord 
atrophy at the 
segmental 
level of the 
lesions  
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 12/11/2010 No change 
 
 March 2012 – Cord 
 Conus looks normal 
 No enhancement 
21/10/2008 8/3/2010  C2-3: Right lateral lesion 
 Craniocaudal distance: 10mm 
 
 C2-3: Left paramedian dorsal lesion 
 Craniocaudal distance: 7-8mm 
 
 C2-3: Left lateral lesion 
 
 All the above C2-3 lesions are 
associated with mild volume loss of the 
cord 
 
 C3-4: Mild volume loss of the cord 
 
 C4-5: Left lateral lesion  
 C7: Dorsal 
 T1: Central diffuse lesion 
 
 The lesions from C3-C7 are small in size 
 
7  Mild volume 
loss (cord) at 
the segmental 
level of the 
lesions 
7/9/2009 19/1/2011 Jan 2008: 
 C4-5: Midline dorsal lesion 
 Craniocaudal distance: 14mm 
 No enhancement with contrast 
 
6/2008: 
1/2 No cord 
atrophy 
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 C4-5: Lesion (described above) much 
smaller, much less T2 hyperintense 
 Craniocaudal distance: 12mm 
 Normal conus region  
 
Jan 2011 
 C7-T1: Possible new lesion on axial 
slices, at edge of field of view 
 No cord atrophy 
11/12/2008 29/12/2009  C3: Left hemicord lesion 
 C4-5:  
 C5-6: Cord appears flattened (mild 
atrophy) 
 
 C6-7: Right ventral lesion 
 
2 Patchy mild 
cord atrophy 
29/10/2008 25/2/2009  Extensive patchy signal change in 
cervical spinal cord C1-7 
 C2: Bilateral signal changes – right and 
left lateral regions, also dorsolateral 
region (3 lesions) 
 
 C7: Large lesion 
 Craniocaudal distance: 17.5mm 
 
 T1-2: Hyperintense region (lesion) 
 
 T6-7: Small right lateral lesion and left 
anterolateral lesion 
 
 T8: Diffuse lesion 
 
8 Very mild 
atrophy of the 
cervical spinal 
cord 
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 T9-10 Signal change (lesion)  
ARP Date MRI Date Neuroradiology Report Lesion 
No. 
Cord Atrophy 
02/07/2008 05/04/2005  C4-5: ?thinning of cord, but at edge of field 
of view so difficult to be sure 
 
T11-12: lesion 
 
(Suggestion of two lesions) 
2 Segmental 
volume loss 
16/12/2008 02/07/2008 Spinal cord: 
C3: small left lateral lesion 
 
C3-4: right dorsolateral lesion, central lesion 
 Craniocaudal distance: 1.3 cm 
 No convincing volume loss 
 
C5: right lateral lesion 
C5: left lateral lesion 
C5-6: left lateral lesion 
  
(3 small lesions that coalesce) 
 
Brain: 
 Large lesion load >20 
 Supratentorial cerebral volume loss 
 Frontal lobe involvement; left 
paracentral lobule and precentral gyrus 
 Left cerebral hemisphere more affected 
  
5 No atrophy 
28/05/2008 22/05/2008 (Poor quality images) 
 
Spinal cord: 
2  
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 T10-11: possible lesion (no axial image, 
?truncation artefact) 
 L1/conus: 3 cm craniocaudal distance 
 
Brain: 
 Saggital T2 2002 
 Lesion load > 20 (all small in size)  
~35 
 No paracentral lobule involvement 
 Normal posterior fossa 
 No volume loss 
09/07/2008 01/07/2009 Brain 
 V. Atrophic, brainstem involvement 
 Extensive intracranial lesion load 
 4 (severe) brain volume loss 
 Significant frontal lobe involvement 
 Left paracentral lobule involvement 
 Right paracentral lobule involvement 
(less compared to left) 
  
19/11/2008 14/07/2008 Brain 
 Large discrete intracranial lesions 
 Lesion load 24 (20-30) 
 Frontal lobe involvement 
 No significant volume loss 
 Periventricular enhancing lesion in 
splenium of corpus callosum (1 active 
lesion – faint enhancement) 
  
19/11/2008 24/06/2008 Brain 
 Lesion load 20-30 
 Right precentral gyrus lesion – 
subcortical 
 Mild volume loss 
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 Large right frontal lobe lesion 
16/04/2008 12/06/2006 Spinal cord 
 C1-2: Suggestion of a lesion, volume 
loss 
 
Brain 
 Frontal periventricular lesions + smaller 
peripheral lesions 
  
27/08/2008 13/04/2006, 
19/07/2007 
Brain 
 2006: extensive pontine and midbrain 
involvement 
 No paracentral lobule involvement 
 Lesion load > 20 
 
 2007: Progession of brainstem disease 
 Supratentorial lesions unchanged 
 Cerebellar lesions unchanged 
  
17/09/2008 3/2009 Brain 
 Right paracentral lobule – cortical and 
subcortical 
 Left frontal meningioma 
 Faintly enhancing lesions: 
Right trigone, right centrum semiovale 
(frontal) 
 Volume loss mild 
 Brainstem and pontine involvement 
 
11/2010 
 Lesion load – 19 (cerebral 
hemispheres), 1 pons, 1 cerebellar 
 
2012 
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 Enhancement even fainter 
07/09/2009 19/1/2011 Brain 
18/1/2008 
 2 large frontal lesions 
 No volume loss, posterior fossa normal 
(no contrast given) 
 
5/6/2008 
 Frontal lesions smaller, but new 
periventricular lesion superiorly 
 3 lesions in 2008 
 No paracentral lobule involvement 
 
19/1/2011 
 8 lesions in total  
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Appendix 6 – Power Calculations 
 
 
Sample Size Calculation – Biofeedback vs. Transanal Irrigation - Constipation 
 
Available data 
 
A. Non-paired: 
 
Biofeedback: 
Δ Wexner Constipation -3.41 (sd 5.95) 
Δ Wexner Incontinence -3.95 (sd 3.56) 
  
Transanal irrigation 
Δ Wexner Constipation -2.83 (sd 3.88) 
Δ Wexner Incontinence -5.13 (sd 6.45) 
 
B. Paired:  
 
Biofeebdack: 
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Descriptive 
Statistics 
 
N Minimum Maximum Mean 
Std. 
Deviation 
preWex-i 39 0 20 10.00 6.517 
preWex-c 39 0 28 12.69 8.339 
postWex-i 39 0 20 6.05 5.448 
postWex-c 39 1 24 9.28 6.875 
Valid N 
(listwise) 
39 
    
 
 
Transanal irrigation 
 
Descriptive 
Statistics 
 
N Minimum Maximum Mean 
Std. 
Deviation 
PreWexInc 30 .00 20.00 11.0667 6.30781 
PostWexInc 30 .00 18.00 5.9333 4.79895 
PreWexnConst 30 2.00 21.00 11.9333 5.50820 
PostWexnConst 30 2.00 21.00 9.1000 5.48572 
Valid N (listwise) 30 
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A. Non-paired - Constipation: 
 
t tests - Means: Difference between two independent means (two groups) 
 
Analysis: A priori: Compute required sample size  
Input:  Tail(s)                        = Two 
   Effect size d                  = 0.1154736 
   α err prob                     = 0.05 
   Power (1-β err prob)           = 0.80 
   Allocation ratio N2/N1         = 1 
Output:  Noncentrality parameter δ      = 2.8036553 
   Critical t                     = 1.9609714 
   Df                             = 2356 
   Sample size group 1            = 1179 
   Sample size group 2            = 1179 
   Total sample size              = 2358 
   Actual power                   = 0.8002604 
 
 
Appendix 6 
210 
 
0.6 0.65 0.7 0.75 0.8 0.85 0.9 0.95
0
1000
2000
3000
4000
T
o
ta
l 
s
a
m
p
le
 s
iz
e
 = 0.115474
Effect size d
t  tests -  Means: Dif erence between two independent means (two groups)
Tail(s) =  Two. Allocation rat io N2/ N1 =  1. α  err prob =  0.05. Ef ect size d =  0.115474
Power (1-β err prob)
Appendix 6 
211 
B. Paired - Constipation: 
 
t tests - Means: Difference between two dependent means (matched pairs) 
 
Analysis: A priori: Compute required sample size  
Input:  Tail(s)                        = Two 
   Effect size dz                 = 0.113776 
   α err prob                     = 0.05 
   Power (1-β err prob)           = 0.80 
Output:  Noncentrality parameter δ      = 2.8077556 
   Critical t                     = 1.9638734 
   Df                             = 608 
   Total sample size              = 609 
   Actual power                   = 0.8004857 
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Appendix 6 
212 
C. Non-paired - Incontinence: 
 
 
t tests - Means: Difference between two independent means (two groups) 
 
Analysis: A priori: Compute required sample size  
Input:  Tail(s)                        = Two 
   Effect size d                  = 0.2265128 
   α err prob                     = 0.05 
   Power (1-β err prob)           = 0.8 
   Allocation ratio N2/N1         = 1 
Output:  Noncentrality parameter δ      = 2.8063830 
   Critical t                     = 1.9638478 
   Df                             = 612 
   Sample size group 1            = 307 
   Sample size group 2            = 307 
   Total sample size              = 614 
   Actual power                   = 0.8001105 
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D. Paired - Incontinence: 
 
t tests - Means: Difference between two dependent means (matched pairs) 
 
Analysis: A priori: Compute required sample size  
Input:  Tail(s)                        = Two 
   Effect size dz                 = 0.2108687 
   α err prob                     = 0.05 
   Power (1-β err prob)           = 0.8 
Output:  Noncentrality parameter δ      = 2.8212309 
   Critical t                     = 1.9733809 
   Df                             = 178 
   Total sample size              = 179 
   Actual power                   = 0.8012286 
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